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Abstract
X-Linked severe combined immunodeficiency (SCID-X1) is caused by mutations in 
the gene encoding the common cytokine receptor gamma chain, yc, resulting in 
profound defects in both cellular and humoral immunity. Although allogeneic bone 
marrow transplantation has proved highly successful, HLA-mismatched procedures are 
associated with significant morbidity and mortality. This disease is therefore a good 
candidate for gene therapy and sustained correction o f 19 SCID-X1 patients have been 
reported in two clinical trials. However, the occurrence o f severe adverse advents in 
one trial has highlighted the potential side-effects o f retroviral gene transfer and 
reinforced the need to develop safer gene therapy vectors. A series o f self-inactivating 
(SIN) gammaretroviral and lentiviral vectors for the treatment o f SCID-X1 have 
consequently been developed. To reduce the potential for insertional mutagenesis 
mediated by the duplicated viral LTR sequences, alternative internal regulatory 
elements have been incorporated into the vector backbone. These include both 
endogenous (human elongation factor la  -  EFS) and viral (spleen focus forming virus - 
SFFV) promoters. In vitro, the SIN retroviral vectors were able to regulate yc 
expression on the cell surface of SCID-X1 cell lines and restore the lymphoid 
differentiation potential of Il2rg"  haematopoietic progenitor cells. Functional 
correction o f the immunological defect in the SCID-X1 mouse model was also 
achieved at similar levels for the both the SIN retroviral vectors and the LTR-regulated 
clinical vector. To further improve upon safety, lentiviral vectors were developed 
incorporating the endogenous human 1L2RG promoter to regulate physiological 
expression o f yc. In vitro and in vivo analysis o f the promoter indicated a degree of 
haematopoietic tissue specificity and restoration o f functional yc-receptor complexes 
was achieved following transduction o f a SCTD-X1 T cell line with a lentiviral vector 
incorporating this promoter; however phenotypic correction o f the yc-deficient mouse 
was unsuccessful. These results demonstrate that SIN retroviral vectors for SCID-X1 
are effective in restoration o f the immune defect in the yc-deficient murine model. The 
SIN design together with an endogenous (EFS) promoter might provide a potentially 
less mutagenic but equally effective vector for gene therapy o f SCID-X1.
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Chapter One
Introduction
Chapter One
1. X-Linked Severe Combined Immunodeficiency
Severe combined immunodeficiencies (SCIDs) are a group o f inherited disorders 
characterised by a profound block in T cell differentiation. These diseases represent the 
most severe forms o f primary immunodeficiencies, affecting approximately 1 child in 
every 75,000 live births (Fischer et al., 1997). In the absence o f T cell-mediated 
immunity SCID patients are susceptible to opportunistic infections and fail to thrive; if 
left untreated these disorders are fatal within the first year o f life (Fischer et al., 2005). 
Despite similar clinical manifestations, the molecular causes resulting in SCID are 
diverse and can be categorised into four different groups (Fischer et al., 2005): the first 
results from mutations in the gene encoding adenosine deaminase (ADA) leading to 
lymphocyte apoptosis due to the accumulation o f toxic metabolites. The second group 
involves mutations in one o f three genes (IL2RG , JAK3 and IL7Ra) resulting in 
defective cytokine signalling, whilst defective rearrangement o f antigen receptor genes 
due to mutations in the genes encoding either RAG-1, RAG-2 or ARTEMIS proteins 
form the third group. The last group o f SCIDs result from mutations in the genes 
encoding CD45, CD36 or CD3s leading to defects in pre-TCR/TCR signalling.
X-linked SCID (SCID-X 1) is the most common form of SCID accounting for almost 
half o f all cases. SCID-X 1 results from mutations in the gene encoding the common 
cytokine receptor gamma chain, yc, a subunit o f the cytokine receptors for interleukins
2, 4, 7, 9, 15 and 21 (Noguchi et al., 1993c; Noguchi et al., 1993b; Russell et al., 1993; 
Russell et al., 1994; Giri et al., 1994; Asao et al., 2001). The gene encoding the yc 
protein, IL2RG , is located on the X chromosome and is expressed constitutively in all 
haematolymphoid cells (Takeshita et al., 1992a; Orlic et al., 1997). The absence of yc 
signalling results in a classical phenotype characterised by the absence o f T and Natural 
Killer (NK) cells, whilst B cells are present but poorly-functional (T 'B ^ K ' SCID) 
(White et al., 2000).
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1.1 Clinical Features of SCID-X1
The clinical presentation o f the disease is characterised by early onset o f infections, 
typically o f the gut and respiratory tract, correlating with the loss of maternal 
antibodies and leading to diagnosis at approximately six months of age (Buckley, 
2004). Due to mutations in the gene encoding yc, lymphocyte precursors are unable to 
respond to cytokine signals, leading to failure o f T and NK lymphocyte development, 
whilst B cells are present but defective. Common opportunistic organisms include 
Pneumocytis carinii and Aspergillus, as well as viruses such as cytomegalovirus and 
adenovirus; these pathogens can cause recurrent infections, chronic diarrhoea and 
failure to thrive. Without recognition and treatment the condition is uniformly fatal for 
patients with classical SCID-X 1, typically during the first year o f life.
Histologically, the thymi from SCID-X 1 patients resemble human fetal thymi at six to 
seven weeks gestation, prior to colonisation with T cell precursors. These thymi are 
markedly hypoplastic and lack cortex/medullar differentatiation; Hassall’s bodies are 
also undetectable (Hale et al., 2004). Peripheral lymphoid organs in these patients are 
also found to be hypoplastic (Fischer et al., 1997).
1.2 The Molecular Pathology of SCID-X1
1.2.1 SCID-X1 is Caused by Mutations in IL2RG
The IL2RG  gene, encoding the yc protein, was localised to the SCID-X 1 locus on 
chromosome X ql3 through genetic linkage analysis (Noguchi et al., 1993c). Analysis 
o f three unrelated SCID-X 1 patients established association between mutations in this 
gene with development o f the disease. Several studies have since analysed IL2RG  
mutations from numerous SCID-X1 males and their relatives (Clark et al., 1995; 
Hacein-Bey et al., 1996; Puck et al., 1997; Kumaki et al., 2000), and sequencing of this 
gene has been established as a diagnostic procedure for human SCID-X 1.
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IL2RG  mutations have been identified in all eight exons and include point mutations, 
splice mutations, insertions and deletions (including deletions o f complete exons and 
one deletion o f the entire gene) (Clark et al., 1995; Hacein-Bey et al., 1996; Puck et al., 
1997; Kumaki et al., 2000). These mutations abrogate yc function through 
destabilisation o f IL2RG  mRNA, disruption o f functional motifs such as the WSXWS 
m otif common to all members of the cytokine receptor superfamily, changes in protein 
conformation, premature protein truncation or alteration o f the cytoplasmic portion of 
yc critical for signal transduction.
Up to January 2007, 198 unique mutations in the IL2RG  gene resulting in SCID-X 1 
have been reported in the X-linked SCID mutation database 
(http://genome.nhgri.nih.gov/scid) with the highest proportion o f cases resulting from 
single base-pair substitutions (figure 1.1). Although recurrent mutations have been 
observed, the majority o f IL2RG  mutations appear to be unique to one patient or family 
(Puck, 1996; Puck et al., 1997). Mutations in IL2RG  are unevenly distributed, with five 
mutational 4hot spots’ identified. Over a quarter o f all mutations occur in exon 5, which 
contains the aforementioned WSXWS motif, upstream o f which lie six CpG 
dinucleotides representing the most prominent mutational hot spot in IL2RG  (Puck, 
1996). Additional mutational hot spots in regions containing CpG dinucleotides are 
also found in exons 6  and 7.
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IL2RG Mutations in X-Linked SCID
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Figure 1.1. IL2RG  Mutations in SCID-X1. (Figure from the X-Linked SCID Mutation Database, National Human Genome Research 
Institute, National Institutes of Health)
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1.2.2 The Common Cytokine Receptor Gamma Chain -  yc
The common cytokine receptor gamma chain (yc) was first identified as a component 
o f the interleukin 2 receptor (Takeshita et al., 1990; Takeshita et al., 1992b; Takeshita 
et al., 1992a). Molecular characterisation o f this receptor had previously identified two 
subunits; the a (IL-2Ra) and p chains (IL-2Rp) which bind interleukin 2 (IL-2) with 
low and intermediate affinities, respectively. IL-2Ra contains only 13 amino acids in its 
cytoplasmic domain and was found unable to transduce intracellular signals mediated 
by IL-2 (Leonard et al., 1984; Nikaido et al., 1984). The P chain was characterised as 
belonging to the cytokine receptor superfamily and as essential for intracellular signal 
transduction (Hatakeyama et al., 1989b; Hatakeyama et al., 1989a). The interleukin 2 
receptor was classified into three isoforms, the high-, intermediate- and low-affinity 
receptors (Hatakeyama et al., 1989b). Expression o f IL-2Ra and IL-2RP on lymphoid 
lines induced the functional high-affinity IL-2 receptor, whilst expression o f IL-2Rp 
alone induced the intermediate affinity receptor. The p chain however, was found non­
functional when expressed on fibroblast cells, suggesting either essential modification 
o f the p chain in lymphoid cells or the existence o f a third, lymphoid-specific 
component (Hatakeyama et al., 1989b; Hatakeyama et al., 1989a). The latter hypothesis 
was supported by a study investigating binding affinities o f IL-2 molecules with 
substitutions at residue G lnl41. These mutant cytokines were found to bind normally to 
transfected fibroblasts expressing the IL-2 receptor a and p chains, whilst they were 
unable to bind T cells expressing the high affinity IL-2 receptor (Zurawski et al., 1990). 
Analysis o f cancer patient NK cells subsequent to receiving in vivo IL-2 therapy further 
endorsed the likelihood o f the existence o f a third receptor subunit, since increased IL- 
2Rp expression on these cells was unaccompanied by a corresponding high level of 
intermediate affinity IL-2 binding sites (Voss et al., 1990).
Molecular identification o f yc was first achieved in lymphoid cells expressing the high 
affinity IL-2 receptor by co-precipitation o f a 64 kDa molecule, with the p chain, in the 
presence o f IL-2 (Takeshita et al., 1990; Takeshita et al., 1992b). Cloning and 
characterisation o f yc revealed a protein consisting o f 347 amino acid residues, with 
sequences typical o f the cytokine receptor superfamily proteins, such as IL-2Rp. Both
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the P and y chains contain two pairs o f conserved cysteines located within neighbouring 
exons, and the conserved WSXWS m otif in their extracellular domains (see figure 1.2) 
(Noguchi et al., 1993a). The cytoplasmic domain o f yc was determined to be 
considerably shorter than that o f IL-2Rp, however the presence o f two subdomains of 
the Src homology region 2 (SH2), which can bind phosphotyrosine residues o f some 
phosphoproteins, suggested a putative role in signal transduction.
1.2.3 The IL-2 Receptor System
IL-2 is a T cell-derived cytokine which, through binding to the IL-2 receptor, plays a 
pivotal role in immune responses by inducing lymphocyte proliferation and activation 
(Smith, 1989). The identification o f all three receptor subunits allowed definitive 
characterisation o f the IL-2 receptor complexes (figure 1.2). Combinations o f 
expression plasmids for IL-2Ra, IL-2RP and yc were stably transfected into a fibroblast 
cell line and the resultant clones analysed for binding o f IL-2 (Takeshita et al., 1992a). 
Expression o f the a subunit alone resulted in the low-affinity receptor (Kd = 10' 8 M), 
previously characterised as unable to transduce IL-2 mediated signals (Greene et al., 
1985); whilst the p or y chains alone were unable to bind IL-2 molecules. The 
intermediate-affinity receptor (Kd = 10’9 M), constitutively expressed on NK cells and 
a subset o f resting lymphocytes (Siegel et al., 1987; Tsudo et al., 1987), was found to 
consist o f IL-2RP and yc, whereas the high-affinity receptor (Kd = 10' 11 M) is formed 
by simultaneous expression o f all three subunits (Leonard, 1996). Both the 
intermediate- and high-affinity IL-2 receptors are capable o f transducing IL-2 signals.
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Figure 1.2. Schematic of the IL-2 receptor isoforms. The three isofoms o f the IL-
2  receptor: the low-affinity receptor (composed o f the a  chain), the high-affinity 
receptor (composed of the a, 0  and 7  chains) and the intermediate-affinity receptor 
(composed o f the /3 and 7  chains). Only the high- and intermediate-affinity receptors 
are able to transduce IL-2 signals. The two pairs o f conserved cysteine residues and 
WSXWS motif, both typical o f the cytokine receptor superfamily, are illustrated for 
the £ and 7  chains. The locations o f tyrosines (Y392 and Y510) required for docking 
and activation o f Signal transducer and activator (STAT) proteins on the 
cytoplasmic domain o f IL-2R/3 are indicated. (Figure adapted from Leonard, W.J. 
Annu. Rev. Med. 47:229-39 (1996))
27
Chapter One
1.2.4 The Sharing of yc by Multiple Cytokine Receptors
The genetic locus o f the defective gene in SCID-X1 was mapped by linkage analysis to 
the region X ql3  (De Saint et al., 1987). A separate line o f research identified and 
mapped the gene for the IL-2 receptor y chain to the same locus, leading to the eventual 
confirmation that mutations in yc were the cause o f SCID-X1 (Noguchi et al., 1993c). 
This finding was unexpected however, since mice and humans deficient in IL-2 were 
known to undergo normal T cell development (Schorle et al., 1991; Chatila et al.,
1990). The severe immunological defects in SCID-X1 prompted research into the 
possibility that yc may also be a component o f other cytokine receptors, in particular 
those important for T and B cell development, since patients have profound T cell 
defects and obligate carriers o f the disease exhibit non-random X chromosomal 
inactivation in B cells (Buckley et al., 1986; Conley et al., 1988). yc was initially 
shown to be shared by the receptors for IL-4, a major B cell growth factor, and IL-7, 
the major factor for thymocyte development (Kondo et al., 1993; Russell et al., 1993; 
Noguchi et al., 1993b; Kondo et al., 1994). Chemical cross-linking experiments 
demonstrated a physical association o f yc with the human interleukin receptors for IL- 
4 and IL-7 (Russell et al., 1993; Noguchi et al., 1993b), whilst a monoclonal antibody 
specific for yc was found to inhibit IL-4 induced growth o f murine lymphoid cell lines 
(Kondo et al., 1993). Subsequent research also identified yc as a critical component of 
the receptors for IL-9, IL-15 and IL-21, enabling further understanding of the 
molecular basis o f the severe SCID-X1 phenotype (Russell et al., 1994; Giri et al., 
1994; Asao et al., 2001).
1.2.5 The Biology of the yc-Dependent Cytokines - Causative 
Relationship between defective yc and SCID-X1
IL-2 was initially described as a potent T cell growth factor in vitro, however as 
previously discussed, lymphoid development is essentially normal in IL-2 deficient 
mice and humans (Schorle et al., 1991; Chatila et al., 1990). Ageing mice deficient in 
IL-2 develop autoimmune systems such as haemolytic anaemia and inflammatory
28
Chapter One
bowel disease (Sadlack et al., 1993; Sadlack et al., 1995), and recent research has 
indicated that the main, non-redundant role for IL-2 is in the production o f regulatory T 
cells (Treg) and maintenance o f peripheral tolerance (Malek and Bayer, 2004). 
Consequently, the lack o f T cell development in SCID-X1 seemed likely due to 
aberrant IL-7 signalling, since mice deficient in IL-7 or the IL-7 receptor exhibit 
defective T and B cell development (Peschon et al., 1994; von Freeden-Jeffry et al., 
1995). This was further supported by the identification o f SCID patients with defective 
IL-7Ra expression, exhibiting a T B +N K + phenotype (Puel et al., 1998).
The block in B lymphoid development observed in IL-7 or IL-7Ra deficient mice 
indicates a disparity between the crucial role o f this cytokine in mice and humans with 
regards to B cells. SCID-X1 patients have normal or elevated numbers o f B 
lymphocytes; these cells are however non-functional, resulting in low immunoglobulin 
levels. Whilst this may be partially explained by a lack o f T cell help, an intrinsic 
defect is indicated by non-random X chromosome inactivation in terminally 
differentiated B cells in SCID-X1 carrier females (Conley et al., 1988). Furthermore, a 
significant number o f patients continue to require immunoglobulin therapy, post-bone 
marrow transplant, after reconstitution o f their T cell compartments (Buckley et al.,
1999). IL-4 is an important cytokine for mature B cell function, essential for Ig class 
switching to IgGl and IgE (Paul, 1991). Similarly, the most recently identified yc- 
dependent cytokine, IL -21, is also implicated in B cell function; mice lacking the IL-21 
receptor were found to have impaired IgGl production and elevated levels o f IgE 
(Ozaki et al., 2002). Double knockout IL-4"  IL-21R"  mice exhibit a phenotype which 
closely resembles that o f B cells from SCID-X1 patients, leading to the conclusion that 
this defect might result from the combined loss of IL-4 and IL-21 mediated signalling 
(Ozaki et al., 2002).
The absence o f NK cell development in SCID-X1 is attributed to defective IL-15 
signalling. IL-15 was first identified as a T cell growth factor with similar biological 
properties to IL-2, owing to the shared use o f IL-2Rp and yc receptor subunits. 
Treatment o f mice with an antibody to IL2Rp resulted in the selective long-term 
elimination of NK cells, a defect not seen in IL-2 deficient animals, implicating IL-15 
in the development and/or differentiation o f these cells (Tanaka et al., 1993). An 
obligate role o f IL-15 in NK cell development was confirmed following observations
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that this lymphoid lineage is completely absent in IL-15 and IL-15Ra deficient mice 
(Kennedy et al., 2000; Lodolce et al., 1998). Analysis o f these mice also revealed a role 
for IL-15 in homeostasis o f naive and memory CD8 + T cell populations.
The exact contribution o f defective IL-9 signalling in the development o f SCID-X1 
remains unclear. IL-9 is active on a variety o f haematopoietic cell types, including T 
lymphocytes, and in particular is a potent mast cell growth factor (Hultner et al., 1990; 
Townsend et al., 2000). Mice deficient in this cytokine undergo normal T cell 
development, however they exhibit excessive mucus production and mast cell 
proliferation, abnormalities not observed in patients with SCID-X1 (Townsend et al., 
2000). Dysregulation o f IL-9 has also been implicated in the development o f cancers; 
mice over-expressing IL-9 develop thymic lymphomas, underlining the ability of 
thymocytes to respond to this cytokine (Renauld et al., 1994; Lauder et al., 2004). The 
creation o f double-knockout mice deficient in IL-9 and a second yc-dependent cytokine 
might elucidate a redundant role for this cytokine in T cell development.
1.2.6 yc-Dependent Cytokine Signalling
As discussed above, signals mediated by the yc-dependent cytokines and their receptors 
are critical in the development and regulation o f the haematopoietic system. There are 
several major signalling pathways implicated to be activated by these cytokines, one of 
the most important being the Janus-activated kinase (JAK)/ Signal transducer and 
activator o f transcription (STAT) pathway.
Cytokine receptor molecules lack intrinsic kinase activity and therefore signal via the 
JAK family o f cytoplasmic tyrosine kinases. Four different JAK kinases have been 
identified -  JAK1, JAK2, JAK3 and TYK2, they constitutively associate with cytokine 
receptors and all, except JAK3, are ubiquitously expressed (Leonard and O'Shea, 
1998). JAKs associate with cytokine receptors through binding to regions termed Boxl 
and Box2, located in the membrane proximal cytoplasmic region (Murakami et al.,
1991). Deleting these domains abolishes cytokine signalling and mutations within this 
region in human 1L2RG result in SCID-X1 (Miyazaki et al., 1994). The cytokine-
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specific receptor subunits (such as IL-2Rp and IL-4Ra) associate with JAK1, whilst yc 
associates with JAK3, an inducible kinase whose expression is restricted to 
haematopoietic cells (Miyazaki et al., 1994). The discovery o f the specific association 
between yc and JAK3 prompted the hypothesis that mutations in the gene encoding this 
kinase would result in immunodeficiency analogous to SCID-X1. Patients with SCID 
due to mutations in JAK3 were subsequently identified and approximately 7% of all 
SCID cases result from JAK3 deficiency (Buckley, 2004).
Seven mammalian STAT proteins have been identified - STAT1, STAT2, STAT3, 
STAT4, STAT5a, STAT5b and STAT6 . They act as cytoplasmic latent transcription 
factors and serve as substrates for phosphorylation by JAK proteins (Leonard and 
O'Shea, 1998). In particular STAT5a and STAT5b are postulated to play an important 
role in T lymphocyte proliferation, and these proteins are activated by all o f the yc- 
dependent cytokines except IL-4 (see table 1.1) (Yao et al., 2006).
The JAK/STAT pathway is one o f the most rapid cytoplasm-to-nucleus signalling 
mechanisms (figure 1.3) (Puel et al., 1998). Cytokine binding on the cell surface brings 
together receptor subunits and their associated JAKs, leading to JAK activation and 
phosphorylation o f key tyrosine residues in the receptor-specific chains. The 
phosphorylated tyrosines serve as docking sites for STAT proteins, which bind via SH2 
domains in their C-termini, and are in turn phosphorylated at a conserved tyrosine 
leading to homo- or heterodimerisation. Dimerised STAT molecules translocate to the 
nucleus where they regulate transcription o f target genes, either through direct 
interaction with semi-palindromic motifs (known as GAS motifs), or in combination 
with other transcriptional co-activators (Imada and Leonard, 2000).
Other signalling pathways known to be activated by the yc-dependent cytokines are the 
phosphoinositide 3-kinase (PI3K)/Akt pathway, implicated in IL-2, IL-4 and IL-7- 
mediated signalling, and the RAS-mitogen-activated protein kinase (MAPK) pathway 
(Kovanen and Leonard, 2004).
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Figure 1.3. IL-2 signalling via the JAK/STAT pathway. Binding o f IL-2 induces 
the high-affinity IL-2 receptor, leading to activation of JAK1 and JAK3. The 
activated JAK molecules phosphorylate key tyrosine residues on the cytoplasmic 
region o f IL-2R# allowing docking of STAT proteins. The recruited STAT proteins 
are in turn phosphorylated enabling dimerisation, translocation to the nucleus and 
DNA-binding. STAT proteins may initiate transcription in the presence o f accessory 
transcription factors (TF). The TATA box enables binding of the basal transcription 
machinery. (JAK -  janus-activated kinase; STAT -  signal transducer and activator 
o f transcription; GAS -  7 -interferon activated sequences). (Figure adapted from 
Leonard, W.J. Nat. Rev. Immunol. 1:200-208 (2001))
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Cytokine Receptor Jak- and STAT-signalling 
m olecules
Biological Function
IL-2 IL-2R<x, IL2-Rp,yc Jak1, Jak3 Stat3, Stat5a, Stat5b Regulation of T cell growth and 
peripheral tolerance, increasing 
cytolytic activity of NK cells; Th2 
differentiation of T cells(Cote-Sierra et 
al., 2004)
IL-4 IL-4Ra, yC Jak1, Jak3 Stat6 B cell differentiation, Th2 differentiation
IL-7 IL-7Ra, yC Jak1,Jak3 Stat3, Stat5a, Stat5b T cell development and homeostasis
IL-9 IL-9Ra, yC Jak1, Jak3 Stat3, Stat5a, Stat5b Airway mucus production, mast cell 
proliferation
IL-15 IL-15Ra, IL2R(3,yC Jak1, Jak3 Stat3, Stat5a, Stat5b NK cell development, CD8+ T cell 
homeostasis
IL-21 IL-21Ra, yC Jak1,Jak3 Statl, Stat3, Stat5a, 
Stat5b
B cell differentiation, potential effects 
on T and NK cells
Table 1.1.The 7c-dependent cytokines - their receptors, signalling molecules and biological functions. (Table adapted from 
Leonard, W.J. Immunol. Rev. 202:67-83 (2004))
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1.3 Conventional Treatment of SCID-X1 - Haematopoietic 
Stem Cell Transplantation
In 1968 the first successful allogeneic bone marrow transplantation for SCID-X1 was 
reported (Gatti et al., 1968). Many patients with SCID-X1 have since been treated by 
haematopoietic stem cell transplantation (HSCT) with long-term survival rates of 
greater than 90% for transplants from genotypically-matched family donors 
(Cavazzana-Calvo et al., 2005; Antoine et al., 2003). This high success rate is due in 
part to the lack o f T and NK cells in patients with SCID-X1, allowing engraftment of 
donor cells in the absence o f myelosuppressive conditioning. The majority o f patients 
however lack an HLA-identical related donor and consequently haploidentical HSCT 
or transplants from matched unrelated donors (MUD) are their only alternative. Similar 
mean three-year survival rates within a cohort of patients receiving either MUD or 
genotypically-matched HLA-identical transplants have been achieved, however the 
survival rates following haploidentical HSCT have been lower (Antoine et al., 2003). 
These transplants have been performed since 1981, when techniques to deplete human 
marrow of T cells became available (Reisner et al., 1983). The overall success rate for 
haploidentical transplants is lower than that for HLA-matched procedures, with mean 
three-year survival rates o f approximately 75% (Haddad et al., 1998; Buckley et al., 
1999; Antoine et al., 2003). Recipients o f haploidentical transplants are susceptible to 
infections during the time required for mature, functional T cells to develop 
(approximately three to four months) and mortality is also associated with toxicity of 
the conditioning regime used to enhance engraftment o f donor stem cells.
One frequent limitation o f HSCT is persistence o f B cell deficiency. A significant 
proportion o f patients fail to develop donor-derived B lymphocytes and hence continue 
to require immunoglobulin (Ig) replacement therapy post-transplant (Haddad et al., 
1998; Buckley et al., 1999).
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1.4 Gene Therapy
Gene therapy aims to treat a disease through restoring, modifying or replacing a 
defective gene. Translation of this technology to success in the clinic was initially 
disappointing, with many clinical gene therapy trials conducted throughout the 1990s 
with only limited success (Scollay, 2001); major obstacles being inadequate gene 
delivery systems, poor transgene expression and induction o f an immune response to 
the gene-modified cells or vector (Nathwani et al., 2005).
The first approved clinical gene therapy trial was initiated in 1990 to treat adenosine 
deaminase deficiency (ADA), a form of SCID resulting from a defective enzyme 
critical in the salvage pathway for purine biosynthesis (Anderson, 1992). Clinical 
improvement was observed in patients following intravenous infusion o f gene- 
corrected autologous T lymphocytes, however, due to only transient transgene 
expression, regular infusions o f gene-modified cells continue to be required. A major 
setback to the field occurred in 1999 following the death o f a patient suffering from 
partial ornithine transcarbamylase deficiency (OTC) enrolled in a pilot safety gene 
therapy study. The patient suffered a fatal inflammatory response following systemic 
delivery o f an adenoviral vector to the liver; representing the first death directly 
attributable to gene therapy (Raper et al., 2003).
Since 1989 over eleven hundred gene therapy clinical trials have been initiated 
worldwide (Journal o f Gene Medicine clinical trials database), with therapies being 
developed to treat many diseases including haemophilia, cardiovascular disease, cystic 
fibrosis and cancer (Young et al., 2006). Almost 70% o f all gene therapy trials target a 
form of cancer and in 2004, the use o f an adenoviral vector was licensed in China as a 
routine treatment for head and neck squamous cell carcinoma (Peng, 2005).
The morbidity and mortality associated with haploidentical bone marrow transplants 
together with the high incidence o f failure o f donor B cell engraftment created a need 
for an alternative treatment for SCID-X1 patients for whom no genotypically-matched 
family donor is available, and led to the application o f gene therapy for this disease. 
The SCID-X1 clinical trials (detailed below) represent the first major success achieved
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using this form of treatment and highlight its potential as a long-term or even 
permanent cure o f a hereditary disease. Similarly encouraging results have since also 
been achieved in gene therapy clinical trials to treat adenosine deaminase deficient- 
SCID and chronic granulomatous disease (CGD) (Aiuti et al., 2002; Gaspar et al., 
2006; Ott et al., 2006).
1.5 Gene Therapy for SCID-X1
Several features o f SCID-X1 make the disease an ideal candidate for gene therapy. 
Firstly, it is a monogenic disorder and well-characterised at the molecular level. 
Secondly, correction o f the gene-defect in haematopoietic precursors should confer a 
strong growth and survival advantage which obviates the need for pre-conditioning. 
This concept is supported by partial immunological reconstitution observed in a patient 
following a spontaneous mutation reversion in a single T lymphocyte precursor 
(Stephan et al., 1996), demonstrating that the correction o f even a small number of 
lymphoid precursors may confer significant therapeutic benefit. Furthermore, an in vivo 
competitive study between normal and yc-deficient bone marrow cells in mice provides 
evidence o f selective repopulation o f lymphoid lineages from normal yc-expressing 
bone marrow cells (Otsu et al., 2000b).
Efficacy o f gene therapy for SCID-X1 has been demonstrated both in vitro and in vivo. 
Using retroviral-mediated gene transfer, yc expression and function has been restored 
in patient B cell lines (Hacein-Bey et al., 1996). Gene-corrected SCID-X1 cord blood 
CD34+ cells and haematopoietic stem cells were also demonstrated to differentiate into 
NK and T lymphocytes respectively in appropriate culture conditions (Cavazzana- 
Calvo et al., 1996; Hacein-Bey et al., 1998). Reconstitution o f yc-deficient mice with 
gene-modified haematopoietic stem cells verified the feasibility o f in vivo correction of 
the immunodeficiency. Three groups independently reconstituted T, B and NK cell 
lineages in these animals; no indication o f toxic effects were observed and the corrected 
phenotype was stable for up to 11 months (Soudais et al., 2000; Lo et al., 1999; Otsu et 
al., 2 0 0 0 a).
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1.5.1 French Gene Therapy Trial
The first clinical gene therapy trial for SCID-X1 was initiated at the Necker Hospital in 
Paris (Cavazzana-Calvo et al., 2000; Cavazzana-Calvo et al., 2005). Ten SCID-X1 
infants under the age o f one were enrolled between March 1999 and May 2002, under 
the criteria that they lacked an HLA-identical donor. The protocol involved the ex vivo 
transduction o f patient’s CD34+-selected bone marrow cells. These cells were first pre­
stimulated with cytokines to induce proliferation, followed by three one-day cycles of 
transduction with an amphotrophic gammaretroviral vector. After completion o f the 
four-day procedure, the autologous cells were infused back into the patient 
intravenously in the absence o f myeloablative conditioning (Cavazzana-Calvo et al., 
2000). In all but one o f the patients, infusion o f yc-corrected CD34+ cells resulted in the 
emergence o f T and NK lymphocytes (Cavazzana-Calvo et al., 2000; Hacein-Bey- 
Abina et al., 2002; Cavazzana-Calvo et al., 2005). Mature T cells were detectable in the 
periphery at ten to twelve weeks post gene therapy, and T cell counts reached normal 
levels within three months in seven o f the patients. The remaining two patients received 
fewer transduced CD34+ cells per kilogram of body weight than the other participants 
in the trial and were found to have undergone only partial T cell reconstitution.
It w'as demonstrated that the reconstituted T cells were polyclonal and elicited antigen- 
specific proliferative responses in vitro following patient immunisation. Clearance of 
varicella zoster virus (VZV) infection in several patients established T cell functionality 
in vivo. Sustained active thymopoeisis is indicated by the persistence o f CD45RA+ 
naive T cells and detectable TCR excision circles, 3-5 years post-gene therapy. 
Ultrasonograms also revealed the development o f normal-sized thymi in these patients. 
Restored NK cell populations in the patients were found to be low in number but were 
nevertheless functional. Similarly only a low proportion o f yc-expressing B cells were 
detected, however enough immunoglobulin was produced to negate the requirement of 
Ig therapy in the majority o f patients.
Retroviral integration site analysis revealed common insertion sites shared by T and B 
lymphocytes as well as mature myeloid cells, confirming yc gene-correction o f multi- 
potent progenitor cells (Schmidt et al., 2005). Insertion sites characterised in
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differentiated leukocytes were also found in CD34+ cells obtained 8 months later, 
demonstrating the initial transduction of primitive progenitor cells with self-renewal 
capacity. These findings are promising with regards to long-term restoration o f T cell 
immunity following retroviral-mediated gene therapy in these patients.
The patient for whom gene therapy was unsuccessful underwent a splenectomy four 
months post-treatment, due to an enlarged spleen caused by a disseminated Bacille 
Calmette-Guerain infection (Hacein-Bey-Abina et al., 2002). Analysis of the removed 
organ revealed it to be likely that transduced cells accumulated in the spleen, thus 
impairing T cell differentiation in this patient (Fischer et al., 2005). Eight months post­
gene therapy the patient was given a bone marrow transplant from an unrelated donor 
which restored partial T cell immunity.
Overall gene therapy was concluded to be beneficial to most patients, enabling them to 
live normal lives and cope with environmental pathogens as a result o f a restored, 
functioning immune system. Given the problems related with haploidentical 
transplantation and the associated failure o f B cell immunity post-HSCT, treatment of 
SCID-X1 patients who lack a suitable genotypically-matched HLA-identical donor by 
gene therapy presents an effective, alternative treatment with superior immune 
reconstitution.
1.5.2 British Gene Therapy Trial
The second clinical gene therapy trial for SCID-X1 was initiated at Great Ormond 
Street Hospital in 2001. Four children with SCID-X1 without an HLA-identical sibling 
were initially enrolled in the study between July 2001 and December 2002. A similar 
protocol was used to that in the French trial; however the gammaretroviral vector was 
pseudotyped with a different envelope, that o f the gibbon ape leukaemia virus (GALV) 
whose receptor is more highly expressed on human HSCs than that for the amphotropic 
envelope (von et al., 1994), and slightly different culture conditions were used (serum- 
free media, no protamine sulphate and lower concentrations of IL-3) (Gaspar et al.,
2004).
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Restoration o f cellular and humoral immunity was achieved in all four treated patients; 
two patients had achieved normal T lymphocyte counts at 29 and 23 months follow-up 
respectively, with the third patient achieving only partial T cell reconstitution at 24 
months post-gene therapy. The fourth patient was significantly older than the other 
patients enlisted in the trial (33 months old at time o f treatment); this patient received 
the lowest dose o f cells per kilogram and showed slower kinetics of lymphocyte 
recovery than the first three treated patients. Reconstituted T lymphocytes had a 
polyclonal repertoire and exhibited normal proliferative responses to mitogens. As was 
observed in the French trial, numbers o f reconstituted NK lymphocytes remained low. 
At time o f publication two o f the patients had discontinued immunoglobulin 
replacement therapy; however detection of CD27+ antigen-expressing B cells in all four 
patients indicated immunological B-cell recovery. Integration site analysis revealed 
polyclonal contribution to the restored T lymphocyte populations and initial gene 
transfer into multi-potent CD34+ progenitor cells was indicated by persistence o f gene- 
marked granulocyte populations (Gaspar et al., 2004).
All four patients have returned to normal social environments and the clearance o f viral 
or opportunistic pathogens has demonstrated the therapeutic benefits of the gene 
therapy procedure (Gaspar et al., 2004).
In January 2003 the clinical gene therapy trial for SCID-X1 at Great Ormond Street 
Hospital was extended to include a further six patients under the identical criteria. 
Following gene therapy, all are alive and well and currently living at home (Thrasher, 
A.J. unpublished data). All patients enrolled in the trial have reached lymphocyte levels 
at normal ranges as compared to age-matched children and six patients have 
discontinued prophylaxis. These results suggest improved reconstitution and lower 
levels o f morbidity and mortality than with haploidentical bone marrow transplantation.
1.5.3 Gene Therapy of a SCID-X1 Infant in Australia
In March 2002 an infant with SCID-X1 was treated by gene therapy at The Children’s 
Hospital at Westmead, Sydney (Ginn et al., 2005). The nine month old infant had a less
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common variant o f SCID-X1 exhibiting an NK+ phenotype, the result o f a splice-site 
mutation within IL2RG , and no HLA-identical sibling donor available.
The patient was treated according to the protocol followed in the French trial and 
initially underwent partial immunological reconstitution with the appearance of T 
lymphocytes; however normal levels o f T cells were never reached. T cell 
responsiveness to mitogens remained impaired and the patient continued to require 
intravenous immunoglobulin. The patient received a relatively low dose of CD34+ cells 
per kilogram, similar to the French patients who also underwent partial T cell 
reconstitution, yc remained undetectable on the cell surface o f the patient’s B cells and 
only appeared on NK cells at 19 months post-gene therapy. It is hypothesised that the 
patients NK+ phenotype may have reduced the selective growth advantage o f gene- 
corrected haematopoietic precursors in the bone marrow (Ginn et al., 2005).
Initially clinical benefit was observed following the appearance o f T lymphocytes with 
the clearance o f a chronic rotavirus infection and weight gain. However the patient’s 
clinical condition deteriorated four months after treatment with the development of 
neurological complications, severe persistent diarrhoea and failure to thrive; a possible 
cause o f which was immune dysregulation. The patient received a bone marrow 
transplant from a matched-unrelated donor at 26 months post-gene therapy.
1.5.4 Failure of Gene Therapy for SCID-X1 in Older Patients
The results o f a clinical trial to treat older SCID-X1 patients with gene therapy were 
published in 2005 (Thrasher et al., 2005). Two male patients were enrolled in the trial 
conducted at Great Ormond Street Hospital in London and the Necker Hospital in 
Paris. The first was a twenty year old who had received an HLA-identical paternal bone 
marrow transplant at three weeks o f age, but whose immune status had deteriorated 
with time resulting in low T and B cell numbers and an absence o f NK cells. The 
second patient was fifteen years of age at the time of treatment and had an incomplete 
SCID-X1 phenotype with normal T, B and NK cell counts but severe CD4+
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lymphopenia. Both patients were enlisted in the trial under the criterion that no 
genoidentical or HLA-matched donors were available for HSCT.
Gene therapy was unsuccessful for both patients; whilst transduction rates o f CD34+ 
haematopoietic progenitor cells were comparable to those obtained for the successfully 
treated younger patients, no significant changes in immunity or clinical status were 
observed in either patient and patient two died of respiratory failure one and a half 
years post-gene therapy (Thrasher et al., 2005). These data indicate a potential time- 
dependency on the capacity to re-initiate thymopoiesis, the absence o f which results in 
disorganisation o f the thymic architecture and hypoplasia (Hale et al., 2004). This 
hypothesis is supported by observations that allogeneic HSCT performed in neonatal 
SCID patients results in superior thymic output as compared to patients receiving 
transplants later in life (Myers et al., 2002).
1.5.5 Severe Adverse Events in the French SCID-X1 Gene Therapy 
Trial
In October 2002, it was reported that one of the patients in the French SCID-X1 gene 
therapy trial had developed a monoclonal lymphoproliferative disease (AFSSAPS, 
2002; Hacein-Bey-Abina et al., 2003c). News o f a T cell leukaemia in a second patient 
from the same trial was made public in January 2003, increasing the likelihood that 
these severe adverse events were therapy induced. As a consequence, a temporary halt 
was imposed by the United States Food and Drug Administration (FDA) and French 
Health Product Safety Agency (AFSSAPS) on gene therapy trials using retroviral 
vectors to transduce haematopoietic stem cells (AFSSAPS, 2002; Hacein-Bey-Abina et 
al., 2003a). The French SCID-X1 trial was resumed in May 2004, however in January 
2005 it was reported that a third patient in the trial had developed symptoms of a 
lymphoproliferative disease, leading to a further suspension o f the clinical trial by the 
authorities (AFSSAPS, 2005).
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The characteristics o f the lymphoproliferative disease affecting the third patient are still 
under investigation, however in the first two affected patients, an uncontrolled, 
exponential proliferation o f clonal mature T lymphocytes was observed approximately 
three years after gene therapy. The patients were the two youngest in the trial, at one 
and three months old at the time o f treatment, and had received a high dose of corrected 
CD34+ cells per kg o f body-weight as compared to other patients. It was also noted that 
T cell development in these patients was especially rapid early after therapy; however 
prior to the time o f lymphoproliferation, both patients’ T cell characteristics were 
indistinguishable from those o f age-matched children (Hacein-Bey-Abina et al., 
2003b).
In the first patient (patient 4) a monoclonal y6  T cell proliferation was detected thirty 
months post-gene therapy. Following conventional treatment for T cell acute 
lymphoblastic leukaemia (T-ALL) the patient received a matched, unrelated bone 
marrow transplant. The second patient (patient 5) was also treated for T-ALL; the 
lymphoproliferative disease in this patient was attributed to three different ap T cell 
clones and was detected thirty-four months after gene therapy. Unfortunately in 
October 2004 it was reported that one o f the patients who had developed a 
lymphoproliferation had died (AFSSAPS, 2005).
Analysis o f T cell clones from both patients revealed retrovirus vector integration in 
proximity to the LM 02  (LIM domain only-2) proto-oncogene promoter, leading to 
aberrant transcription and translation o f the gene product (Hacein-Bey-Abina et al., 
2003b). The L M 02  gene is located on the short arm o f chromosome 11; translocations 
at this locus involving T cell receptor (TCR) genes result in aberrant expression of 
LM 02 and are implicated in childhood T-ALL (Boehm et al., 1991). LM 02 acts as a 
bridging molecule in transcription factor complexes (Rabbitts, 1998) and is thought to 
be necessary early on in haematopoiesis, since a null mutation of the lmo2 gene in mice 
leads to failure o f yolk sac erythropoeisis and eventual embryonic lethality (Warren et 
al., 1994). LM 02 is not expressed in mature myeloid or lymphoid cells (Warren et al., 
1994) and this down-regulation appears crucial in T lymphocytes, given that transgenic 
mice constitutively expressing lmo2 in all tissues develop only T cell tumours (Neale et 
al., 1995).
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The leukaemias in the French SCID-X1 gene therapy trial represent the first reports of 
gene therapy vector-induced insertional mutagenesis in humans. Thus far no other 
oncogenic events have developed in over forty clinical trials worldwide involving 
retroviral-mediated gene transfer to HSCs (Kohn et al., 2003). The risk o f insertional 
mutagenesis ultimately leading to malignancy in a gene therapy setting, although 
recognized, was considered low (Kohn et al., 2003). Until a sole report in 2002, no 
incidences o f insertional mutagenesis in extensive murine studies involving retroviral- 
mediated gene transfer to HSCs had been observed (Li et al., 2002). In the single study, 
mice with vector integrations near the proto-oncogene E vil developed acute myeloid 
leukaemia (AML).
The exact mechanism o f leukaemogenesis in the two SCID-X1 patients is unclear. One 
plausible cause o f oncogenesis might have been the presence o f replication-competent 
retrovirus leading to multiple integration events; however none was detected in both 
cases (Hacein-Bey-Abina et al., 2003b). The long latency preceeding leukaemia 
development in these patients suggests that insertional activation o f LM 02  alone is 
insufficient to cause malignancy and that secondary events are required. This 
hypothesis is consistent with the multi-step model o f tumourigenesis; aberrant 
expression o f LM 02 in progenitor cells may have resulted in increased cell expansion 
and concomitantly the opportunity to acquire further, transforming mutations (Wu and 
Pandolfi, 2001). At the time o f clinical manifestation, the leukaemic cell clones from 
both patients were found to contain chromosomal abnormalities; in the first patient a 
t(6 ; 13) translocation had occurred, whilst in the second a SIL-TAL1 fusion transcript 
and trisomy 10 were detected (Hacein-Bey-Abina et al., 2003b).
It is also possible that the immunodeficient setting in SCID-X1 and/or the yc transgene 
may have contributed to the onset o f leukaemia. Infants with SCID-X1 may accumulate 
higher numbers o f T lymphocyte precursors in the bone marrow due to the block in 
differentiation resulting from the inability to respond to cytokine signals. LM 02 is 
expressed in stem and progenitor cells and hence this may increase the likelihood of 
retroviral vector integrations at this locus, yc is widely expressed in haematopoietic 
cells and therefore constitutive expression under the control o f the viral long terminal 
repeat (LTR) was postulated to be safe. Moreover, signalling through yc requires the 
involvement o f additional, specific receptor subunits. However, one recent publication
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purports that IL2RG  itself is oncogenic; Woods et al. reported the development of 
thymic lymphomas in five out o f fifteen X-SCID mice that had received wild-type or 
X-SCID bone marrow transduced with lentivirus encoding 1L2RG (Woods et al., 2006). 
Conclusions drawn from this study may however be premature; as yet molecular data 
regarding insertion sites and clonality o f the murine tumours have not been published 
and furthermore, vector sequences were undetectable in one of the lymphomas. Also, 
insertional mutagenesis as a cause of lymphoma development cannot be excluded, 
since vector copy number was high and a strong, ubiquitous promoter was incorporated 
into the lentiviral vector backbone. Investigations into JAK3 activation in these 
lymphomas would also provide evidence as to the role o f yc itself in tumour 
development in these mice, since yc specifically associates with and signals through 
this tyrosine kinase (Miyazaki et al., 1994). In the French clinical trial, no over­
expression o f yc was seen on either o f the patients’ clones, neither was any constitutive 
activation o f JAK3 observed, indicating that yc was functioning normally (Hacein-Bey- 
Abina et al., 2003b). Furthermore, pre-clinical studies in sixty-eight mice (X-SCID and 
wild-type) reconstituted by gammaretroviral or lentiviral IL2RG  gene transfer resulted 
in only three cases o f lymphoma, one of which was transgene-negative (Thrasher et al., 
2006). Trangenic mice expressing the human yc from a CD2 promoter have also been 
tumour-free for over twelve months (Thrasher et al., 2006). However, a synergistic 
effect between yc and LM 02 over-expression could in theory have played a role in the 
lymphoproliferations (Hacein-Bey-Abina et al., 2003b). A retrospective analysis of 
retroviral integration sites inducing murine leukaemia has provided evidence that 
LM 02 and yc may cooperate to induce leukaemagenesis (Dave et al., 2004).
Other potential contributing factors are the young age at which the children were 
treated and the high number o f corrected CD34+ cells that these patients received. A 
potential genetic predisposition to cancer and a possible synergistic influence o f a 
varicella zoster virus (VZV) infection in one o f the patients, could also have 
contributed as secondary events in the emergence o f a malignant clone (Hacein-Bey- 
Abina et al., 2003b). Conversely however, the third patient was treated at an older age, 
nine months, and does not appear to have an insertion at LM 02  (Couzin and Kaiser,
2005). Further investigation is needed to discover whether these events are disease- 
specific, nonetheless they highlight the necessity o f further pre-clinical investigation to
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evaluate the risks associated with gene therapy; including development o f predictive 
animal models and improvements in vector technology and experimental design.
1.6 Gene Therapy for ADA-SCID and CGD
Efficacy o f gene therapy for the treatment o f ADA-SCID using a similar methodology 
as for SCID-X1 has been reported in two clinical trials (Aiuti et al., 2002; Gaspar et al., 
2006). In the first trial, Aiuti and colleagues in Milan, Italy, treated two ADA-SCID 
patients for whom enzyme-replacement therapy, conventionally used to treat this 
disorder, was unavailable. A gammaretroviral vector derived from the Moloney murine 
leukaemia virus, whereby expression on the ADA transgene is regulated by the viral 
LTR, was used to transuce autologous CD34+ cells which were infused back into the 
patients following a low-intensity, nonmyeloablative conditioning regime used to 
enhance engraftment o f transduced progenitors. In both patients, the sustained 
engraftment o f transduced HSCs and the differentiation o f these cells into multiple 
lineages resulted in increased lymphocyte counts, improved immune function and 
correction o f the metabolic defect of ADA-SCID leading to the reversal of clinical 
phenotype (Aiuti et al., 2002). Successful reconstitution o f immunity and systemic 
detoxification o f ADA metabolites was also observed following treatment o f an ADA- 
SCID patient by gene therapy at Great Ormond Street Hospital, London (Gaspar et al., 
2006). A similar protocol to that used by Aiuti and colleagues was performed, however 
a vector derived from the Spleen focus forming virus (SFFV) and a different 
conditioning agent (Melphalan as opposed to Busulfan) were used in this trial. To date, 
no severe adverse events have been observed in either gene therapy trial.
The outcome o f a gene therapy trial to treat two adults suffering from CGD, an 
immunodeficiency caused by a defect in the oxidative antimicrobial activity of 
phagocytes due to mutations in the gene encoding gp91phox, has recently been reported 
(Ott et al., 2006). As for the successfully treated ADA-SCID children, the CGD 
patients received non-myeloablative conditioning prior to the infusion of mobilised 
peripheral blood CD34+ cells transduced with an SFFV-based gammaretroviral vector.
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Therapeutic benefit was observed in both patients shortly after the procedure with the 
clearance o f existing bacterial or fungal infections refractory to conventional therapy 
alone. Four months post-treatment however, an increase in gene-modified myeloid cells 
was detected with the appearance o f multiple dominant clones approximately one 
month later. Analysis o f retroviral vector insertion sites in both patients revealed the 
dominant clones to result from transactivating insertions within or close to one o f three 
genes -  M D S l-E V l, PRDM  16 or SETBP1. The insertional activation of these genes by 
the enhancer sequences within the SFFV LTR initially appeared to contribute to 
therapeutic efficacy as a result o f the expansion o f gene-corrected myeloid cells; such a 
benefit was consequently negated however due to transgene silencing resulting from 
methylation o f the SFFV LTR promoter sequences leading to deterioration in the 
clinical status o f both patients and the subsequent death o f one patient due to severe 
sepsis two and a half years post-treatment (M.Grez personal communication). 
Interestingly and quite unexpectedly, although transgene silencing was associated with 
methylation o f the SFFV promoter, the enhancer component o f this viral regulatory 
element remained unmethylated and functional, resulting in the continual activation of 
the nearby M D S l-E V l, PRDM16 or SETBP1 promoters and therefore maintenance of 
myeloid cell numbers harbouring integration events at these loci (M.Grez personal 
communication).
1.7 Viral Vectors for Gene Therapy
Viral vectors have been used in 70% of gene therapy clinical trials (Journal o f Gene 
Medicine clinical trials database) and currently represent the most effective means of 
gene delivery. No single vector is suitable for all applications and the choice o f viral 
vector depends largely on the cell type to be targeted and duration o f expression 
required. Desirable properties o f all vectors however are the ability to be reproducibly 
propagated and purified to high titres, and to mediate transgene delivery and expression 
to the target cell without substantial toxicity. Many viruses have been exploited to 
produce gene therapy vectors; some of the most commonly used are derived from
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gammaretroviruses, lentiviruses, foamy viruses, adenoviruses, adeno-associated viruses 
(AAVs) and herpes simplex viruses (HSVs) (see table 1. 2).
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Gamma- Lertivirus Foamy virus Herpesvirus Adenovirus AAV Non-viral
retrovirus
Genetic
Material
RNA RNA RNA dsDNA ssONA ssDNA dsDNA
Packaging
Capacity
-9  Kb - 10 Kb - 12Kb >30 Kb -30 Kb <5 Kb Unlimited
Tropism Broad Broad Broad Strong for 
neurons
Broad Broad except 
for HSCs
Broad
integration 
into host 
genome
♦ + ♦ - - <10% Rare
Duration of
transgene
expression
Long Long Long Transient Transient Transient Transient
Transduction 
of non­
dividing cells
♦ ♦ + + ♦ ♦
Inflammatory
potential
L ow Low Low High Hi-Ti Low Low
Safety
Concerns
Insertional
mutagenesis
Insertional
mutagenesis
Insertional
mutagenesis
Inflammatory
response
Insertional
mutagenesis
Low nsK of 
insertional 
mutagenesis
‘
Table 1.2. The properties of commonly used gene transfer vectors. (Table adapted from Nathwani et a lBrJ.Haem.Rev.  128:3- 
17 (2004))
oo
Chapter 
O
ne
Chapter One
1.7.1 Retroviruses
Retroviruses are composed o f single-stranded RNA genomes encapsulated in a protein 
core and packaged into a lipid envelope. Following entry into a target cell, the viral 
genome is reverse-transcribed into linear double-stranded DNA that is subsequently 
integrated into the host cellular chromatin. This family o f viruses may be grouped into 
seven genera based on genome sequence and complexity and site of particle assembly; 
however, in terms o f the development o f vectors for gene therapy, the focus has almost 
exclusively been on the following three genera: the Gammaretroviruses, the 
Lentiviruses and the Spumaviruses (Baum et al., 2006).
All retroviral genomes are flanked by two long terminal repeat (LTR) sequences; at the 
5’ end these contain the viral promoter and enhancers responsible for initiation of 
transcription o f viral genes, whilst the polyadenylation signal is situated in the 3’ LTR. 
The LTRs and neighbouring sequences act in cis during reverse-transcription, 
integration, viral gene expression and packaging. Framed between the LTR sequences 
are the gag, pol and env genes required by all retroviruses, these encode the structural 
proteins, viral replication enzymes and envelope glycoprotein respectively, and the 
packaging signal (vy) required for the incorporation o f the RNA genomes into viral 
particles (figure 1.4). Lentiviruses have a more complex genome containing two 
additional regulatory genes, tat and rev, required for gene expression, together with a 
variable set o f accessory genes. The spumavirus genome also contains several 
accessory genes in addition to gag, po l and env, one o f which, bel-1, is essential for 
regulation o f gene expression (Lee et al., 1993).
1.7.2 Retroviral Vectors
Retroviral vectors are derivatives o f viruses that have been engineered to carry a 
therapeutic gene into target cells. There are several advantageous features o f gene 
therapy vectors derived from this family o f viruses; firstly, the proteins required for 
reverse transcription and integration are carried within the viral particle and thus all
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viral genes may be removed from vectors. Secondly, integration o f proviral DNA into 
the host cell genome results in stable transmission o f the transgene to subsequent cell 
generations and therefore offers a potential long-term cure for monogenic disorders. 
Finally, these vectors have only a low potential o f triggering a detrimental 
inflammatory immune response as compared to vectors derived from other viral species 
(table 1 .2 ).
To generate a retroviral vector, both coding genes and c/'s-acting sequences are 
required; however an important safety feature is that these sequences are separated so 
as to prevent the formation of replication-competent retrovirus (RCR). Consequently 
the trans-acting gag , pol and env genes are removed from the viral genome and instead 
provided either on heterologous plasmids or within the chromosomes o f a packaging 
cell line. The vector genome, consisting only o f the c/s-acting regions (sequences 
recognised by viral and cellular proteins during the replication cycle) and the 
therapeutic gene, can therefore be introduced into packaging cells or co-transfected 
with packaging plasmids to produce replication-defective vector particles (figure 1.4).
A key factor regarding the potential for insertional mutagenesis is the integration site 
preferences of retroviral vectors. Completion of the human genome sequence has made 
possible genome-wide studies of retroviral vector integration, a process initially 
thought to occur at random. Such studies have identified a bias of MLV-based vector 
integration within the proximity o f transcriptional start sites, whilst lentiviral vectors 
derived from HIV-1 or SIV target integration within transcriptional units, downstream 
of transcriptional start sites (Wu et al., 2003; Schroder et al., 2002; Mitchell et al.,
2004). These integration site preferences have also been confirmed in vivo, following 
transplantation o f HSCs transduced with an MLV or SIV vector into rhesus monkeys 
(Hematti et al., 2004). On the basis o f this data MLV-based vectors appear to harbour 
the greatest potential to exert enhancer effects on endogenous genes following proviral 
integration, a propensity demonstrated in one study utilising a promoter-trapping 
method and in the human SCID-X1 gene therapy trials, whilst lentiviral vectors may 
pose a risk o f gene disruption given their bias for integration within transcriptional 
units (De et al., 2005; Hacein-Bey-Abina et al., 2003b). Retroviral vectors derived from 
foamy viruses (FVs) or avian sarcoma-leukosis virus (ASLV) may pose a decreased 
risk with regards insertional mutagenesis; genome-mapping o f FV vector integration
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has revealed no bias for integration within active genes as compared to lentiviral 
vectors, however once integration has occurred into a transcribed region of the genome, 
FVs exhibit a modest preference for integration near transcription start sites (Trobridge 
et al., 2006; Nowrouzi et al., 2006). ASLV vectors showed only a weak bias for 
integration into actively-transcribed genes with no preference for integration near 
transcription start sites (Mitchell et al., 2004).
1.7.2.1 Gammaretroviral Vectors
Gammaretroviral vectors are most commonly based on the Moloney murine leukaemia 
virus (MLV) and have been widely used both in experimental studies and clinical trials. 
As mentioned previously, the main limitation is their inability to cross the nuclear 
membrane and consequently these vectors are only able to transduce dividing cells, 
limiting their application in gene therapy to ex vivo transduction.
Gammaretroviruses such as MLV have a simple genomic structure containing only the 
aforementioned three essential viral genes and c/s-acting sequences such as the 
packaging signal (\|/), primer binding site (PBS), polypurine tract (PPT), splice donor 
and splice acceptor sites (figure 1.4A). The PBS and PPT act to position the tRNA 
primers during reverse transcription, whilst the packaging signal interacts with viral 
proteins to accomplish specific packaging o f viral RNA. The splice donor and splice 
acceptor sites are located 5’ and 3’ to the packaging signal respectively; translation of 
spliced RNA transcripts (such as Env in the wild-type virus), in which the complex 
secondary structure o f the packaging signal has been removed, is thought to proceed 
more efficiently (Krall et al., 1996). In MLV-based vectors, transgenes are classically 
placed between the packaging signal and PPT and early generations o f these vectors 
currently used in clinical trials retain full-length LTR sequences and portions o f viral 
gag-pol coding sequence incorporating the splice acceptor site (figure 1.4B) 
(Cavazzana-Calvo et al., 2000; Gaspar et al., 2004). Expression o f the transgene in 
these vectors is therefore regulated by the viral enhancer and promoter sequences in the 
5’LTR and the portions o f gag-pol coding sequence are maintained in these vectors to 
allow splicing and thus enhanced mRNA stability functions (Krall et al., 1996).
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Figure 1.4. Retroviral vector production. (A) Genome o f a wild-type 
gammaretrovirus. (B) Retroviral vector genome in which the viral genes have been 
removed and replaced with the cDNA of a therapeutic gene (e.g. IL2RG). (C) 
Genome o f a self-inactivating (SIN) gammaretroviral vector in which the transgene 
is regulated by an internal promoter (e.g. EFla). A Woodchuck hepatititis virus 
post-transcriptional regulatory element (WPRE) is positioned after the transgene to 
enhance its expression and viral titre. (D & E) A plasmid encoding the retroviral 
vector is transfected into a packaging cell line (D) or is co-transfected with 
packaging plasmids into producer cells (E), resulting in the production of 
replication-defective retroviral vector particles. (\p - packaging signal)
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A variety o f stable packaging cell lines for the production o f retroviral vector particles 
have been engineered from cell lines such as NIH3T3 (murine fibroblasts), 293 (human 
embryonic kidney cells), and HT1080 (human sarcoma cells). These cells lines 
constitutively express the viral gag , pol and env genes from separate, integrated 
constructs, thus decreasing the likelihood o f RCR generation through recombinagenic 
events. Stable, high-titre producer clones can be generated through integration of vector 
plasmid DNA into packaging cell lines; producer clones offer the advantage o f 
production o f viral supernatant o f consistent and known titre and are amenable to 
industrial scale-up for the production o f clinical grade vector particles.
The duplication o f the LTR promoter-enhancer regions following reverse transcription 
of these vectors may increase the risk o f insertional mutagenesis and these concerns 
have been reinforced by the leukaemic complications observed in the French SCID-X1 
trial (Hacein-Bey-Abina et al., 2003b). Another safety concern associated with LTR- 
regulated vectors is the generation o f replication competent retrovirus through 
homologous recombination, either during vector production or in the host cell, due to 
the presence o f residual viral sequences in the vector backbone. Enhanced safety may 
be achieved with use o f self-inactivating (SIN) vectors; deletions in the U3 region of 
the 3’LTR leads to inactivation o f the enhancer-promoter elements in both LTRs after 
reverse transcription and the transgene is regulated instead by a promoter placed 
internally, downstream of the packaging signal (figure 1.4C) (Yu et al., 1986). A 
further element o f regulation that these vectors offer is therefore the possibility of 
restricting transgene expression to required cell types through the use o f tissue-specific 
promoters. Whilst initial vector titres were disappointing, modifications to the 5’LTR 
and 3’ untranslated regions (3’UTRs) have enabled the production of SIN vector titres 
equivalent to those achieved for their LTR-regulated counterparts (Kraunus et al., 2004; 
Schambach et al., 2006b). These modifications include the incorporation o f a post- 
transcriptional regulatory element (PRE) o f the woodchuck hepatitis virus into the 3' 
UTR to improve RNA export and hence transgene expression and viral titre (Zufferey 
et al., 1999; Kraunus et al., 2004) and the removal o f aberrant translational start codons 
within the untranslated region 5’ o f the internal expression cassette (Hildinger et al., 
1999; Kraunus et al., 2004).
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A major limiting factor for successful gene transfer is efficient binding o f viral vector 
particles to the host cell. The viral envelope glycoprotein dictates the vector host range 
and substitution o f the envelope protein for one from a different virus (a process 
referred to as pseudotyping) can broaden vector tropism. The majority of clinical gene 
therapy trials targeting HSCs have used gammaretroviral vectors pseudotyped with 
either the MLV amphotropic envelope or with the Gibbon ape leukaemia virus 
envelope (GALV). Amphotrophic retrovirus binds to Pit-2, a sodium-dependent 
phosphate transporter protein, expressed at relatively low levels on both human and 
murine HSCs (Orlic et al., 1996). The receptor for the GALV envelope is the closely 
related phosphate transporter protein Pit-1, that appears to be more highly expressed on 
human HSCs than the amphotropic receptor resulting in improved transduction 
efficiency o f these cells by GALV pseudotyped vectors (von et al., 1994). Pit-1 is not 
expressed on murine HSCs, however efficient transduction of these cells may be 
achieved using the murine ecotropic envelope (Suzuki et al., 2001; Li et al., 2003), 
which targets a basic amino-acid transporter ubiquitously expressed in murine cells 
(Wang et al., 1991). Another envelope frequently used for transduction of 
haemtopoietic cells is that o f the Endogenous feline type C virus RD 114, an advantage 
of which is that vectors pseudotyped with this envelope are able to withstand 
concentration by ultracentrifugation (Kelly et al., 2001).
1.7.2.2 Lentiviral Vectors
Lentiviruses rely on active transport o f the preintegration complex through the nuclear 
membrane and hence vectors derived from these viruses offer the advantage o f being 
able to transduce and stably integrate into the genome o f non-dividing cells (Sherman 
and Greene, 2002). This ability is particularly advantageous in HSC gene therapy since 
cells may be transduced without prestimulation, thus avoiding prolonged ex vivo 
culture that may result in loss o f pluripotency and engraftment ability.
The first lentiviral vectors to be developed were derived from HIV-1 and these vectors 
have been used extensively in gene transfer studies (figure 1.5) (Vigna and Naldini,
2000). As previously mentioned, HIV-1 is a complex retrovirus that requires two
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additional regulatory genes, tat and rev, and a set o f accessory proteins. Initial 
packaging constructs for these vectors maintained the accessory genes; however these 
proteins were shown to be dispensible for efficient transduction and integration of 
lentiviral vectors and were therefore deleted in second generation packaging constructs 
(Zufferey et al., 1997). The deletion of accessory genes also increased the biosafety of 
these vectors, since any RCR generated during vector production would lack the 
essential factors for HIV-1 virulence in vivo. A further safety measure was achieved by 
the production o f third generation packaging constructs in which the rev gene was 
placed on a separate plasmid to that o f the gag-pol genes and the tat gene was removed 
altogether (Dull et al., 1998). The viral tat protein acts as a potent transcriptional 
transactivator o f the HIV-1 LTR and is therefore required for high titre virus production 
(Cullen, 1998). High vector titre in the absence o f tat was found to be possible however 
by replacement o f the U3 region in the 5’LTR with a constitutively active heterologous 
promoter such as that from the Rous sarcoma virus (RSV) (Dull et al., 1998). The viral 
rev gene product functions as a nuclear export factor; the protein binds to an RNA 
motif, the Rev-response element (RRE), and promotes cytoplasmic export o f unspliced 
and spliced transcripts and hence must be provided during vector production (Cullen, 
1998).
Considering the pathogenicity o f the parental virus there are several safety concerns 
surrounding HIV-1 derived lentiviral vectors that must be addressed before clinical 
application. Among these concerns is the possibility o f vector mobilisation in 
individuals who are or become infected with wild-type virus. The development o f self- 
inactivating lentiviral vectors has significantly increased their biosafety (figure 1.5). 
These vectors have been demonstrated to retain the in vitro and in vivo properties of 
lentiviral vectors retaining wild-type LTRs, whilst they are unable to interact with or be 
mobilised by wild-type HIV-1 (Zufferey et al., 1998; Bukovsky et al., 1999). Early 
lentiviral vectors containing intact, wild-type LTR sequences, required transgene 
expression to be regulated by an internal promoter (as opposed to MLV LTR-regulated 
vectors) due to the weak basal transcriptional activity o f the 5’LTR. Consequently, a 
further attribute o f the self-inactivating design is that promoter interference between the 
5’LTR and internal promoter is abolished (Zufferey et al., 1998). Modifications to 
lentiviral SIN vectors to enhance vector potency and transgene expression include 
reintroduction o f a central polypurine tract (cPPT) and insertion o f a WPRE into the
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vector backbone (figure 1.5) (Follenzi et al., 2000; Zufferey et al., 1999). Lentiviral 
vectors have also been derived from non-human lentiviruses (e.g. Equine infectious 
anaemia virus) on the rationale that they might be more acceptable to clinical 
application due to their parental viruses not being infectious to humans (Olsen, 1998).
The glycoprotein o f the Vesicular stomatitis virus (VSV-G) is most commonly used to 
pseudotype lentiviral vectors and expands vector tropism since the receptor for VSV-G, 
although still undetermined, appears to be ubiquitous in all cell types (Carneiro et al.,
2006). Furthermore, VSV-G pseudotyped vectors can be efficiently concentrated by 
ultracentrifugation, enabling the production o f serum-free, high-titre vector particles 
(Akkina et al., 1996). However, VSV-G is associated with cytotoxicity limiting the 
concentrations o f vector which can be used without reducing target cell viability. This 
toxicity has also hindered the creation o f packaging cell lines for production o f VSV-G 
pseudotyped lentivirus, however progress has been reported using inducible expression 
o f the envelope protein (Farson et al., 2001). Efficient pseudotyping of lentivirus has 
been achieved with R D 114, amphotropic MLV envelope and GALV, with particularly 
high transduction levels o f human CD34+ cells achieved using RD 114 (Relander et al.,
2005). As for gammaretroviral vectors, efficient transduction o f murine cells, including 
HSCs, has been demonstrated using lentivirus pseudotyped with murine ecotropic 
envelope (Schambach et al., 2006c).
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Figure 1.5. Lentiviral vector genomes and packaging constructs. (A) Genome o f 
a wild-type HIV-1. (B) Wild-type LTR lentiviral vector genome in which the cDNA 
of a therapeutic gene is regulated by an internal promoter (e.g. EFla). (C) Genome 
of a self-inactivating (SIN) lentiviral vector containing a modified 5’LTR in which 
the U3 region has been replaced by the constitutive RSV promoter. The vector 
contains a cPPT and WPRE to enhance vector potency and transgene expression. (D, 
E and F) First-, second- and third generation packaging constructs containing 
sequences from HIV-1 and the VSV-G envelope, used in conjunction with A, B orC. 
(\p - packaging signal)
57
Chapter One
1.8 Self-Inactivating Retroviral Vectors for Gene Therapy 
of SCID-XI
Pursuant with advances in vector technology, a novel series o f retroviral vectors 
encoding the yc cDNA have been developed, with the aim o f providing a potentially 
safer alternative gene therapy vector for the treatment o f SCID-XI. These vectors, 
derived from both murine leukaemia virus and HIV-1, differ from the vector currently 
used in clinical trials since they have deleted LTRs (SIN vectors), thus transcription of 
the IL2RG  cDNA is regulated instead by a series o f internal promoters. Alterations 
have also been made to the vector backbone to eliminate residual viral sequences and 
reduce the likelihood for viral recombination, and hence reduce the risk o f vector 
mobilisation, whilst maintaining efficient transgene expression and high vector titre.
1.8.1 Self-Inactivating Gammaretroviral Vectors
A series o f vectors termed SRS II derived from the Murine Embryonic Stem Cell virus 
(MESV) have been developed. These vectors have a chimeric 5’LTR containing the U3 
region o f RSV to enhance vector titre and a deleted U3 region in their 3’LTR, copied to 
the 5’LTR during reverse transcription, thus removing any viral promoter-enhancer 
activity (figure 1.6) (Schambach et al., 2006d). The internal architecture o f the vector 
series is designed so that all potentially recombinagenic viral coding sequences and 
aberrant AUG start codons have been removed (Hildinger et al., 1999; Kraunus et al., 
2004). Regulation o f the IL2RG  cDNA is therefore via an internal promoter placed 
downstream of this leader region and a modified WPRE, placed 3’ to the cDNA, is 
added to enhance transgene expression (Zufferey et al., 1999). Two different 
promoters, the U3 region o f the Spleen focus forming virus (SFFV promoter) and the 
short form (intron-deleted) o f the human elongation factor la  promoter (EFS), have 
been incorporated into the vector backbone to be evaluated for their potential efficacy 
in a clinical setting (see figure 1.7). Both promoters have been demonstrated to regulate 
high levels o f transgene expression in haematopoietic lineages, including human 
CD34+ cells, and consequently may represent suitable promoters for gene therapy of
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haematopoietic disorders (Baum et al., 1995; Demaison et al., 2002; Salmon et al., 
2000).
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Figure 1.6. Reverse transcription of self-inactivating retroviral vectors. (A) A
retrovirus-specific cellular tRNA hybridises with the primer binding site (PBS) on 
the vector RNA genome (black) and reverse transcriptase makes a DNA copy o f the 
U5 and R regions. (B) The vector U5 and R regions are removed by the RNase H 
activity o f reverse transcriptase. (C) The cDNA (blue) hybridises with the 
complementary R region at the 3’ end o f the vector RNA genome and the remainder 
o f the vector genome is copied into cDNA. (D) Most of the remaining vector RNA 
genome is removed by RNase H. A second cDNA strand is extended from the 
remaining viral RNA and the deleted U3 region of the 3’ LTR copied. (E) The tRNA 
and remaining vector RNA are removed by RNase H. The copied PBS region in the 
second DNA strand hybridises with the PBS region on the first strand and both 
strands are extended. (F) A double-stranded DNA copy o f the retroviral vector 
genome is produced with ‘self-inactivated’ LTR regions.
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1.8.2 Self-Inactivating Lentiviral Vectors
A series o f SIN lentiviral vectors has been produced with similar architecture to the 
SIN gammaretroviral vectors, whereby the IL2RG  cDNA is expressed from two 
differing internal promoter sequences (SFFV and EFS) with a modified WPRE placed 
downstream of the transgene to enhance expression (figure 1.7) (Zufferey et al., 1999). 
These vectors contain a cPPT, enabling the use o f second generation packaging 
plasmids during vector production, and a 400bp deletion in their 3’ LTR demonstrated 
to abolish promoter activity whilst maintaining high vector titre capability (Zufferey et 
al., 1998). As previously discussed, the SIN design increases the biosafety of these 
vectors by decreasing the likelihood o f producing replication-competent retrovirus in 
both the producer and target cells, and reducing the risk o f mobilisation by wild-type 
HIV in an infected host (Zufferey et al., 1998).
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A. SIN Gammaretroviral Vectors
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Figure 1.7. The gammaretroviral and lentiviral vectors used in this study. (A)
SIN gammaretroviral vectors including SRS II SF *yc and SRS II EFS 'yc, for the 
treatment o f SCID-XI, and SRS II SF eGFP encoding enhanced green fluorescent 
protein (eGFP) for use as a control vector. (B) LTR-regulated gammaretroviral 
vectors including MFG yc, currently used in the clinical gene therapy trial for SCID- 
X I, and SFFV-eGFP (with a chimeric 5’LTR containing the U3 from the 
Myeloproliferative sarcoma virus (MPSV) to improve vector titre) as a control 
vector. (C) SIN lentiviral vectors including SINLV SF yc and SINLV EFS 'yc, for 
gene therapy o f SCID-XI, and SINLV SF eGFP as a control.
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1.9 Haematopoietic Stem Cell Gene Therapy
1.9.1 Human Haematopoietic Stem Cells
Haematopoietic stem cells (HSC) have the potential for self-renewal and can 
differentiate into all blood lineages (figure 1.8). They can be derived from the bone 
marrow, mobilised peripheral blood or umbilical cord blood and present an attractive 
target for gene therapy since the cells are easily accessible and readily transplanted 
back into patients. Furthermore, their pluripotency offers the opportunity to correct 
defects in all haematopoietic lineages following gene transfer (see figure 1 .8 ).
One o f the first cell surface markers used to identify HSCs was CD34. Bone marrow 
cells enriched for this marker were demonstrated to be capable o f multi-lineage 
haematopoietic reconstitution o f lethally-irradiated baboons (Berenson et al., 1988) and 
consequently human CD34+ cells were used in both autologous and allogeneic bone 
marrow transplantation, resulting in rapid reconstitution o f all blood lineages (Link et 
al., 1996; Civin et al., 1996b). Engraftment and differentiation o f human CD34+ cells in 
chimeric sheep further supported the concept that this population contains HSC (Srour 
et al., 1993). Sub-division o f the CD34+ cell population led to the characterisation of a 
CD34+CD38' subset, devoid o f lineage (Lin) antigens, with a high capacity for long­
term multi-lineage haematopoietic engraftment. These cells comprise <0.1% of human 
bone marrow mononuclear cells and have been demonstrated capable o f sustained 
multi-lineage repopulation o f both chimeric sheep and non-obese diabetic/severe 
combined immunodeficient mice (NOD/SCID) (Civin et al., 1996a; Bhatia et al., 
1997).
Recent data suggests that the CD34 antigen is not expressed on all HSCs; human Lin' 
CD34'CD38' cells from cord blood were demonstrated capable o f restoring multi­
lineage haematopoiesis in the NOD/SCID mouse model (Bhatia et al., 1998). Long­
term engraftment o f human bone marrow-derived CD34' cells in sheep chimeras also 
confirms that a significant number of HSCs are present in this cell population (Zanjani 
et al., 2003). Characterisation o f alternative cell surface markers for HSCs is therefore 
underway. One putative marker is AC 133 (or CD 133) which has been demonstrated to
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be expressed on both human CD34+ and a subset of CD34' cells with high repopulating 
ability (Gallacher et al., 2000). In the majority of gene therapy clinical trials to date 
however, cells have been enriched for the CD34+ fraction and clinical-grade devices are 
available for enrichment o f this cell population.
1.9.2 Murine Haematopoietic Stem Cells
Expression o f the CD34 antigen on murine HSCs declines with age; CD34+ HSCs are 
present in foetal and newborn mice, however in adult mice HSCs with long-term 
repopulating ability are CD34* (Matsuoka et al., 2001). Consequently cell surface 
markers other than CD34 are used to define murine HSCs and populations that are 
CD34‘Lin*c-kit+Sca-l+ have been demonstrated capable o f long-term haematopoietic 
reconstitution in irradiated mice (Osawa et al., 1996).
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Figure 1.8. Haematopoietic stem cell development. Self-renewing HSCs give rise to multipotent progenitor cells which may 
develop into common lymphoid progenitor cells (CLPs) and common myeloid progenitors (CMPs). CLPs may differentiate 
into B, T and NK cells; dendritic cells may be derived from both CLPs and CMPs. CMPs give rise to granulocyte/macrophage 
precursors (GMPs) and megakaryocyte/erythroid precursors which in turn give rise to all myeloid cell populations. (MkP - 
megakaryocyte precursor; ErP - erythroid precursor). (Figure adapted from Reya et al., Nature. 414:105-111 (2001))
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1.9.3 Requirements for HSC Gene Therapy
The basic requirements for haematopoietic stem cell gene therapy are that the vector is 
stably integrated into the host genome to allow long-lasting transgene expression and 
that efficacy o f gene transfer is high enough to affect disease phenotype. The majority 
o f preclinical and clinical HSC gene transfer studies have therefore used 
gammaretroviral vectors owing to their ability to stably integrate into host DNA and 
their low immunogenicity, due to being derived from viruses non-pathogenic to 
humans (table 1.2) (Nathwani et al., 2005). More recently, research has focused on 
lentiviral vectors derived from HIV type 1 (HIV-1) since they are able to transduce 
quiescent cells and thus appear to be more efficient at transduction o f human HSCs 
(table 1.2) (Case et al., 1999; Miyoshi et al., 1999).
Optimisation o f transduction conditions is critical in order to achieve high transduction 
efficiency and yet maintain the engraftment potential and pluripotency of HSCs. Co­
culture o f retroviral producer cells with murine HSCs has been shown to be an efficient 
method for gene transfer; however this protocol is unsuitable for clinical trial due to the 
risk of contaminating producer cells being infused back into patients following 
transduction. Retroviral transduction of HSCs maintained in suspension culture is 
inefficient and results in the loss o f long-term engraftment ability (Halene and Kohn, 
2000), consequently a recombinant fragment CH-296 (Retronectin, TaKaRa Bio Inc, 
Japan) o f the extracellular matrix protein fibronectin is commonly used to mimic a 
bone marrow stromal layer during the transduction protocol. Retronectin enhances co­
localisation o f cells and viral particles and has been demonstrated to significantly 
improve both retroviral transduction and maintenance o f regenerative potential of 
HSCs (Moritz et al., 1996; Dao et al., 1998).
Improvements in cytokine cocktails have also enhanced retroviral-mediated 
transduction efficiency o f HSCs. As haematopoietic stem cells are mostly quiescent 
this is particularly important for gammaretroviral vectors, which are only able to 
transduce cells undergoing active mitosis. Amongst the earliest cytokines demonstrated 
to have beneficial effects on stem cell survival in culture and retroviral transduction 
efficiency are interleukins 3 and 6  and stem cell factor (SCF) (Bodine et al., 1989;
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Luskey et al., 1992). The addition o f Flt-3 ligand, IL-11 and thrombopoietin has also 
been shown to improve stem cell cycling whilst maintaining self-renewal and 
repopulating ability of HSCs (Hennemann et al., 1999; Oostendorp et al., 2000). These 
studies and consequent clinical trials have therefore demonstrated the possibility to 
induce self-renewal of HSCs for optimal retroviral-mediated transduction without loss 
o f engraftment potential or pluripotency.
1.10 The Murine Model of SCID-XI
1.10.1 yc-Deflcient Mice
The yc-deficient mouse was created to investigate the in vivo role of yc in lymphoid 
development in addition to establishing a murine model of human SCID-XI (DiSanto 
et al., 1995; Cao et al., 1995; Ohbo et al., 1996). Mice in which the yc gene has been 
targeted by homologous recombination display multiple abnormalities o f the immune 
system; however the phenotype, although related, is somewhat different to that of the 
human disease.
In contrast to SCID-XI infants, mice deficient in yc develop a small percentage of T 
lymphocytes, indicating the existence o f yc-independent pathways in the murine model 
that enable T cell development. One candidate pathway is that involving the receptor 
tyrosine kinase c-kit, since mice lacking both yc and c-kit display an early and severe 
thymocyte-specific developmental block (Rodewald et al., 1997).
yc-deficient mice exhibit thymic hypoplasia and have almost undetectable levels of 
circulating lymphoid cells in the peripheral blood. In particular CD8 + T cells are absent 
from the periphery leading to an increased CD4:CD8 ratio; this is postulated to arise 
from the requirement of yc-dependent cytokine signals for antigen-induced 
proliferation o f CD8 + T lymphocytes (DiSanto et al., 1996). NK cells are completely 
absent in this model, as are intra-epithelial lymphocytes (IELs) and TCRy6 T cells, 
indicating that yc differentially effects the development of lymphoid sub-lineages in 
mice (DiSanto et al., 1995). Despite the presence o f some T cells in the SCID-XI
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mouse model, these animals are functionally immunodeficient; the yc-deficient 
lymphocytes are unable to proliferate in response to mitogens in vitro (DiSanto et al., 
1995) or clear intracellular pathogens such as Listeria monocytogenes and Toxoplasma 
gondii in vivo (Andersson et al., 1998; Scharton-Kersten et al., 1998). Consequently 
these mice must be maintained in a pathogen-free environment.
Histological analysis o f spleens from three week old yc-deficient mice revealed severe 
lymphocyte hypoplasia, however an age-related increase in CD4+ T cells in the spleen 
was observed with no concomitant increase in thymic size, resulting in splenomegaly 
and colitis in these animals (Cao et al., 1995; Sharara et al., 1997). The accumulated 
CD4+ splenic T cells display an activated/memory phenotype and undergo proliferation 
and apoptosis at augmented rates than seen for thymocytes (Nakajima et al., 1997). 
Since a high proportion o f yc-deficient animals develop inflammatory bowel disease it 
is plausible that these CD4+ T cells are activated in response to self-antigens (Nakajima 
et al., 1997; Andersson et al., 1998). yc-deficient mice also exhibit marked 
extramedullary haematopoiesis in the spleen thought to result from the increased 
number o f activated cytokine-producing CD4+ T cells in the bone marrow (Sharara et 
al., 1997). Thus yc-dependent signals appear essential for both T cell development and 
homeostatic regulatory mechanisms in vivo.
SCID-XI patients have normal numbers of non-functional B cells; however an 
incomplete block in the development of B cell progenitors in the bone marrow of yc- 
deficient mice results in only a small number o f B220+ IgM+ mature B lymphocytes 
developing (DiSanto et al., 1995). The diminished B cell numbers in the SCID-XI 
murine model most likely reflects the key role played by IL-7 as a pre-B cell growth 
factor in mice, but not in humans (Peschon et al., 1994; von Freeden-Jeffry et al., 
1995). Despite a significant decrease in the numbers o f surface IgM+ B cells in the 
spleen, bone marrow and periphery o f yc-deficient mice, levels o f IgM in the sera are 
normal (DiSanto et al., 1995; Cao et al., 1995; Ohbo et al., 1996). IgE is however 
undetectable in vivo and yc-deficient B cells fail to undergo class-switching in vitro 
demonstrating the effects o f defective IL-4 receptor function in these mice (DiSanto et 
al., 1995; Cao et al., 1995).
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The yc-deficient mouse therefore provides a model for human SCID-XI that 
recapitulates many features of the disease. This model is invaluable in evaluating the 
feasibility, efficacy and safety o f gene therapy approaches for the treatment o f SCID- 
XI in an in vivo setting.
1.10.2 m r g  -RagZ 'cS-'- Mice
The susceptibility o f yc-deficient mice to develop colitis makes this model unsuitable 
for long-term engraftment studies; in such cases a second recipient strain, such as U2rg 
’R ag2"c5"  mice, with a more stable phenotype is desirable.
Mice homozygous for a mutation in the Rag2 gene are viable but fail to produce mature 
B or T lymphocytes due to the inability to initiate V(D)J recombination (Shinkai et al., 
1992). A genetic cross with yc-deficient mice produced alymphoid mice with a stable 
phenotype, doubly homozygous for the mutant yc and Rag2 alleles (ll2 rg /'Rag2 ') 
(Goldman et al., 1998). These mice were developed as an immunodeficient model for 
human cell engraftment, useful for the study of therapies for conditions such as GvHD. 
To further enhance human cell engraftment in this model, a second genetic cross was 
performed with inbred A/J mice which are naturally deficient in complement {c5" )  
(Blundell, M.P. personal communication). Thus the ll2 rg 'R ag2 ' 'c5"  triple-knockout 
mouse, deficient in T, B and NK cells, provide an ideal background with which to 
examine the efficacy o f gene therapy vectors for immune reconstitution of SCID-XI. 
The alymphoid strain is therefore used as a recipient for gene-corrected yc-deficient 
haematopoietic stem cells in long-term engraftment studies.
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1.11 Project Aims
The severe adverse events recently observed in the French SCID-XI gene therapy trial 
underline the necessity of continued research into improving the safety o f retroviral 
vectors for gene therapy. The aims o f this project are therefore:
• To evaluate the novel series of self-inactivating gammaretroviral and lentiviral 
vectors encoding human IL2RG in vitro. Viral and endogenous promoters will 
be assessed for restoration of functional yc expression and compared to the 
LTR-regulated gammaretroviral vector currently used in the clinical gene 
therapy trial for SCID-XI.
• To evaluate restoration o f lymphopoiesis in the murine model o f SCID-XI 
following ex vivo transduction o f HSCs with the retroviral SIN vectors and 
clinical vector.
• To generate a lentiviral vector in which the eGFP transgene is regulated by the 
endogenous human common gamma chain promoter (ycP) and assess for 
promoter tissue-specificity and efficacy both in vitro and in vivo.
• To generate a lentiviral vector for the treatment o f SCID-XI incorporating the 
ycP and assess for efficacy in restoration o f yc expression both in vitro and in 
vivo using the SCID-XI murine model.
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2.1 Materials
Unless otherwise stated, all tissue culture reagents were supplied by Gibco BRL 
(Invitrogen), all general chemicals were supplied by Sigma and all cytokines were 
supplied by Peprotech.
General Reagents and Enzymes
lkb Plus DNA Ladder Invitrogen
Restriction Endonucleases Promega
Benzonase Nuclease Novagen
Calf intestinal alkaline phosphatase New England Biolabs
Proteinase K, PCR-grade Roche
Agarose Invitrogen
Agar MERCK
(methyl-3H) Thymidine 88.0Ci/mmol Amersham
Retronectin Takara
Red Cell Lysis Buffer EBioscience
MethoCult GF M3434 StemCell Technologies
Perm buffer III Pharmingen
Lyse/Fix buffer Pharm ingen
Ampicillin Stratagene
ELISA Duo-Set substrate reagent pack R&D Systems
Formaldehyde (methanol free) 16% Ultrapure Polysciences, Inc
Ficoll-Paque PLUS Amersham Biosciences
Cyclosporin A Sandimmune
Aciclovir DBL
Sucrose BDH
Magnesium Chloride Fisher Scientific
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Cell Lines
293T
HT1080
SC-1
C2C12
U937
Hep-G2
B95-8
Phoenix-gp 
SCID-XI LCL 
ED-7R
ED-7R-yc
OP9-eGFP
OP9-DL1
Human embryonic kidney cell line
Human fibrosarcoma cell line (ATCC# CCL-121)
Murine fibroblast cell line (ATCC# CRL-1404)
Murine myoblast cell line (ATCC# CRL-1772)
Human monocytic cell line (ATCC# CRL-1593.2)
Human hepatocellular carcinoma cell line (ATCC# HB-8065) 
Marmoset cell line (ATCC# CRL-1612) that releases high titres 
o f transforming EBV. Supernatant from this cell line was a kind 
gift from Persis Amrolia (Molecular Immunology Unit, Institute 
o f Child Health).
293-T cells stably transfected with a construct expressing MLV 
gag-pol proteins for the production o f retroviral particles. 
EBV-transformed peripheral blood mononuclear cells from a 
SCID-XI patient at Great Ormond Street Hospital 
A kind gift from Professor Ian Alexander at The Children’s 
Hospital, Westmead, Sydney, Australia. This cell line is derived 
from a yc-deficient T cell line ED40515' (Ishii et al., 1994) and 
is stably transduced with a retrovirus encoding the human IL- 
7Ra receptor cDNA.
These cells were also a gift from Professor Ian Alexander; they 
are derived from ED-7R cells and stably express human yc.
A kind gift from Dr. Juan Carlos Zuniga-Pfliicker, University of 
Toronto, Canada. This mouse stromal cell line is stably 
transduced with a retroviral vector expressing eGFP.
Also from Dr. Juan Carlos Zuniga-Pfliicker’s laboratory, this 
mouse stromal cell line is stably transduced with a retroviral 
vector expressing eGFP and the Delta-Like-1 notch ligand.
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Lin* cell isolation and culture
StemSep mouse progenitor enrichment cocktail StemCell Technologies
StemSep 0.6” negative selection columns StemCell Technologies
Stemspan SF expansion medium StemCell Technologies
Antibodies
Unless otherwise stated below all antibodies were supplied 
IgM-FITC
Goat anti-human IL2Ry 
Anti-goat IgG-HRP 
Monoclonal anti-p-actin
Polyclonal goat anti-mouse immunoglobulins-HRP 
Rabbit anti-mouse IgG 
Polyclonal rabbit f(ab ’)2 anti-mouse Ig biotin
PCR
Primers Invitrogen
Taq DNA polymerase, dNTPs, buffer Promega
DNA polymerase I large (Klenow) fragment Promega
PfuTurbo DNA polymerase, buffer Stratagene
Quantitative Real-Time PCR
Primers Invitrogen
Probes MWG
Platinum qPCR SuperMix-UDG with ROX Invitrogen
from BD Pharmingen. 
Jackson Immunoresearch 
R&D Systems 
R&D Systems 
Sigma
DakoCytomation
Serotec
DakoCytomation
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Kits
Calcium phosphate (CAPHOS) transfection kit Sigma
Plasmid megaprep/maxiprep kit Qiagen
QIAquick gel extraction kit Qiagen
QIAquick PCR purification kit Qiagen
HIV-1 p24 Antigen ELISA Beckman Coulter
Western Blotting
M-PER mammalian protein extraction reagent 
Halt protease inhibitor cocktail 
Laemmli sample buffer 
SeeBlue Plus2 pre-stained standard 
NuPAGE NOVEX Bis-Tris gels 
MOPS Buffer 
SDS PAGE running buffer 
ECL Western blotting substrate
Bacteria
Escherichia coli strains used:
DH5a Competent Cells Invitrogen
Used for all plasmid transformations.
Genotype: F- cp80/tfcZAM15 A(lacZYA-argF) U169 deoR recAX endAX hsdRXl 
( r f ’ m t+) phoA  supEAA X  thi-1 gyrA96 relA  1
ElectroMAX Stbl4 Invitrogen
Used for all cloning procedures.
Genotype: mcrA A(mrr-hsdRMS-mcrBC) recAX endAX gyr A96 gar thi-X supEAA X 
relAX A{lac-proAB)fB' proAB+ laclq /acZAM15 TnJO (TetR)
Pierce
Pierce
Sigma
Invitrogen
Invitrogen
Invitrogen
Invitrogen
Pierce
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Centrifuges
Microcentrifuge 
Tabletop centrifuge 
Superspeed centrifuge 
Ultracentrifuge
2.2 Methods
2.2.1 Bacterial Manipulation
2.2.1.1 Growth and Maintenance of E.coli
Escherichia coli (E.coli) were grown in liquid LB media at 37°C with agitation at 250 
rpm or streaked out on solid LB plates containing 1.5% bacto agar. E.coli transformed 
with plasmids was grown on the same media supplemented with ampicillin (50 pg/ml).
For long-term storage, bacterial cultures were stored in 15% volume for volume (v/v) 
glycerol at -70°C.
2.2.1.2 Production of Electro-competent E.coli
A 1 L flask o f LB media was inoculated 1:1000 from a fresh overnight culture o f E.coli 
DH5a or ElectroMAX Stbl4 cells. The culture was grown at 37°C with agitation until 
the optical density at 550 nm reached between 0.7-0.8. The cells were harvested by 
centrifugation at 5000 rpm in a superspeed centrifuge for 10 minutes, the supernatant 
discarded and the cell pellet resuspended in 1 L of cold sterile 10% glycerol. The spin 
was repeated, the supernatant discarded and the cell pellet was resuspended in a second
Heraeus Biofuge Fresco 
Sorvall Legend RT 
Sorvall Evolution RC 
Sorvall Discovery SE
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1 L of cold sterile 10% glycerol. The cells were centrifuged again for a final time, after 
which the supernatant was carefully discarded and the cells resuspended in the small 
remaining volume o f glycerol. The cells were transferred to a smaller centrifuge tube 
and spun at 7000 rpm for 10 minutes. The supernatant was removed and the cell pellet 
resuspended in 2 ml cold sterile 10% glycerol; 100 pi o f cells were transferred to 
microfuge tubes and snap-frozen in a dry ice-ethanol bath. The electro-competent cells 
were subsequently stored at -70°C.
2.2.1.3 Bacterial Transformation
E.coli were transformed by electroporation; 50pl o f electro-competent cells were 
thawed slowly on ice and mixed with 1-10 ng o f DNA. The cell/DNA mixture was then 
pipetted into pre-chilled disposable micro-electroporation cuvettes (0.2 cm) and 
electroporated at 2.5 kV, 200 Q, 25 pF using a Bio-Rad Gene Pulser. 1 ml o f room 
temperature LB media was added to the cuvette and the media/bacterial mixture was 
transferred to a 5 ml tube. The cells were shaken at 250 rpm at 37°C for 1 hour, after 
which they were diluted in LB media and spread on LB agar plates containing 
ampicillin (50 pg/ml). The plates were incubated overnight at 37°C, after which 
colonies were picked using sterile 20 pi pipette tips and grown overnight in 5 ml liquid 
cultures.
2.2.2 Plasmid DNA Preparation
DNA for the SRS II series of retroviral vectors and the SINLV lentiviral vector series, 
together with the relevant packaging plasmids were kindly provided by Dr A. 
Schambach, Hannover Medical School, Germany.
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2.2.2.1 Small-scale Plasmid DNA Preparation
Plasmid DNA was prepared using Qiagen Mini-Prep kits as per the manufacturer’s 
instructions from 5 ml overnight cultures.
2.2.2.2 Large-Scale Plasmid DNA Preparation
For large-scale plasmid DNA preparation 500 ml LB media containing ampicillin (50 
pg/ml) was inoculated with 500 pi o f a fresh 5 ml culture and incubated over night at 
37°C with agitation (250 rpm). Plasmid DNA was subsequently prepared using Qiagen 
Mega-Prep kits as per the manufacturer’s instructions.
2.2.3 Measurement of DNA Concentration
Plasmid DNA concentration was calculated by measuring the absorbance of light with 
a wavelength o f 260 nm (A260) using a NanoDrop ND-1000 spectrophotometer with a 
0.2 mm pathlength; at this wavelength 50 pg/ml of double-stranded DNA has an 
absorbance o f 1.
2.2.4 Cell Culture
2.2.4.1 Propagation of Adherent Cell Lines
All adherent cell lines were maintained in Dulbecco’s modified eagle medium 
(DMEM) containing GlutaMAX supplemented with 10% (v/v) foetal calf serum (FCS)
and 1% (v/v) penicillin/streptomycin (referred to as complete DMEM). Cells were
2 2 2 grown in 25 cm , 80 cm or 175 cm tissue culture flasks or in 10 cm tissue culture
dishes in 37°C incubators in a 5% CO2 atmosphere. Cells were passaged when 80-90%
confluent; the monolayers were first washed with Dulbecco’s phosphate buffered saline
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(lx ) (PBS) and then incubated for 5 minutes at 37°C with trypsin/EDTA. The cells 
were subsequently diluted 1:10 in fresh complete DMEM and transferred to new tissue 
culture flasks.
2.2.4.2 Propagation of Non-Adherent Cell Lines
Non-adherent cell lines were maintained in RPMI 1640 media containing GlutaMAX
supplemented with 10% (v/v) FCS and 1% (v/v) penicillin/streptomycin (referred to as
1 1  1
complete RPMI). Cells were grown in 25 cm , 80 cm or 175 cm tissue culture flasks 
(standing upright) in 37°C incubators in a 5% CO2 atmosphere. Cells were passaged 
following media colour-change; the cells were transferred to 15 ml centrifuge tubes and 
centrifuged at 1200 rpm in a tabletop centrifuge for 5 minutes, washed with PBS, 
diluted 1:10 or 1:20 in fresh complete RPMI and transferred to new tissue culture 
flasks.
2.2.4.3 Long Term Storage of Cell Lines
For long term storage of cell lines a 90% confluent monolayer from a 80 cm tissue 
culture flask or 2-5 x 106 cells were pelleted by centrifugation at 1200 rpm in a tabletop 
centrifuge for 5 minutes, resuspended in 1 ml freezing medium (90% FCS, 10% 
dimethylsulfoxide) and transferred to a cryovial. Cells were frozen slowly overnight to 
-70°C in an isopropanol freezing box and then transferred to liquid nitrogen.
To revive frozen cells - aliquots were thawed rapidly in a 37°C waterbath and slowly 
transferred to 9 ml cold growth medium. The cells were pelleted at 1200 rpm in a 
tabletop centrifuge to remove the dimethylsulfoxide and then resuspended in 5 ml 
growth medium and transferred to a 25 cm2 tissue culture flask.
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2.2.4.4 Generation of SCID-X1 LCLs
10 ml o f anticoagulant-treated peripheral blood from a male SCID-X1 infant at Great 
Ormond Street Hospital was diluted with 10 ml RPMI and layered onto 15 ml Ficoll- 
Paque PLUS in a 50ml falcon tube. The sample was centrifuged at 2300 rpm for 30 
minutes in a table-top centrifuge (with no brake) and the peripheral blood mononuclear 
cells subsequently aspirated from the ficoll-plasma interface and transferred to a clean 
falcon tube. The cells were washed twice with RPMI and then counted. 5 x 106 cells 
were centrifuged at 1200 rpm and resuspended in 200 pi Epstein Barr Virus (EBV) 
supernatant (produced from a B95-8 cell line) by gently flicking the base o f the falcon 
tube. 1.8 ml complete RPMI supplemented with cyclosporin A (1 pg/ml) was added 
and 200 pi o f the resuspended cells (5 x 105 cells) was aliquoted into five wells of a 96- 
well flat bottom tissue culture plate. A further 1 ml o f complete RPMI containing 
cyclosporin A was added to the remainder of the cells which were then aliquoted (2.5 x 
105 cells -  200 pl/well) into 10 wells o f the 96-well plate. The outer wells o f the plate 
were filled with sterile distilled water and the cells were incubated at 37°C/5% CO2. 1 
week later 100 pi of media was removed from each well and replaced with 100 pi fresh 
complete RPMI. After 2 weeks o f incubation the cells were beginning to expand and 
one of the 5 x 105 cell wells was combined with two of the 2.5 x 105 cell wells into a 
single well o f a 24-well tissue culture plate. After one week of incubation at 37°C/5% 
CO2 the expanded cells were transferred to a 25 cm vented tissue culture flask in 5 ml 
complete RPMI. The cells were treated with acyclovir for two weeks to remove any 
remaining EBV.
2.2.4.5 OP9 Stromal Layers
Early passage OP9-eGFP and OP9-DL1 stromal cells were grown to confluency in 10 
cm tissue culture dishes in Minimum essential media (MEM) alpha supplemented with 
20% (v/v) foetal calf serum and 5% (v/v) penicillin/streptomycin. 2 x 104 stromal cells 
per well were seeded in 24-well tissue culture plates and left to adhere overnight. The 
following day the media was removed from the plates and 6,500-10,000 lin' cells 
(transduced or untransduced) were seeded on top o f the stromal layers in 2 ml o f co-
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culture media (see below). Every four days 1 ml o f media was removed from the top of 
the plates so as not to disturb the differentiating lin" cells and 1 ml of fresh co-culture 
media added. On days six and thirteen the cells were removed from the plates by 
vigorous pipetting, strained through a 70 pm nylon cell strainer to remove the OP9 
stromal layers, stained with antibodies to lymphocyte cell surface markers and analysed 
by flow cytometry for lymphoid differentiation.
OP9-eGFP co-culture media
420 ml MEM alpha
60ml foetal calf serum
250 pi murine IL-7 (10 ng/ml)
250 pi murine Flt-3 (5 ng/ml)
10.5 ml PG2 solution
10.5 ml HSG solution 
PG2 Solution
5 ml Penecillin/Streptomycin 
5 ml Sodium Pyruvate (100 mM) 
0.5 ml 2-Mercaptoethanol (50 mM)
OP9-DL1 co-culture media
420 ml MEM alpha 
60 ml foetal calf serum 
25 pi murine IL-7 (10 ng/ml)
250 pi murine Flt-3 (5 ng/ml)
10.5 ml PG2 solution
10.5 ml HSG solution 
HSG Solution
5 ml HEPES (100 mM)
5 ml Sodium Pyruvate (100 mM) 
0.5 ml gentamicin (50 mg/ml)
2.2.4.6 Isolation and Culture of Murine Lin" Cells
Bone marrow cells were harvested from the femurs and tibias of Il2rg"  or C57/B16 
mice, pelleted by centrifugation at 1200 rpm in a table-top centrifuge and resuspended 
in PBS 1% BSA within the range o f 2-8 x 107 cells/ml. The lin’ cells were subsequently 
isolated using a StemSep mouse progenitor enrichment cocktail and negative selection 
columns as per the manufacturer’s instructions (StemCell Technologies). Murine lin' 
cells were cultured in StemSpan SFEM serum-free medium supplemented with 1% 
(v/v) penicillin/streptomycin and cytokines (100 ng/ml mSCF, 100 ng/ml mFlt-3, 100 
ng/ml hIL-11, 20 ng/ml mIL-3).
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2.2.4.7 Methylcellulose Colony Forming Unit Assay
1 x 104 transduced or untransduced murine lin' cells were washed in Dulbecco’s 
phosphate buffered saline (PBS), pelleted by centrifugation at 1200 rpm in a table-top 
centrifuge and resuspended in 450 pi RPMI. 50 pi of lOx benzonase buffer (100 mM 
MgCb) and 25 units (1 pi) of benzonase nuclease was added and the cells were 
incubated at 37°C for 20 minutes to remove any contaminating plasmid DNA. The cells 
were then pelleted by centrifugation at 1200 rpm and resuspended in 300 pi RPMI. 3 
ml of methocult was mixed with the cells and 1.5 ml seeded into 10 mm tissue culture 
dishes and incubated at 37°C for 14-21 days. Approximately 28 colonies per condition 
were picked using a P20 Gilson pipette, lysed immediately in 20 pi DNA lysis buffer 
(10 mM Tris 1 mM EDTA pH 8.0, 0.5% NP40, 0.5% Tween 20, 1.25 mg/ml Proteinase 
K) and stored at -20°C. Genomic DNA was subsequently isolated following the 
protocol outlined in 2.2.14.
2.2.5 Flow Cytometry
All samples were analysed using a CyAn ADP flow cytometry analyser and Summit 
version 4.1 software (DakoCytomation).
2.2.5.1 Staining of Primary Murine Cells
For analysis by flow cytometry, all primary murine cells (except thymocytes and 
purified lin' cells) were first treated with red cell lysis buffer for 5 minutes at room 
temperature with occasional shaking -  1 ml o f lysis buffer was added per 100 pi of 
peripheral blood, whilst pelleted splenocytes or bone marrow cells were resuspended in 
5 ml lysis buffer. The lysis reaction was stopped by dilution with 10 ml PBS and cells 
were pelleted by centrifugation at 1200 rpm for 5 minutes in a table-top centrifuge and 
resuspended in the appropriate volume o f FACS buffer (PBS, 0.5% (w/v) BSA, 0.05% 
(v/v) NaN3). All primary cells were treated with mouse Fc Block (anti-mouse
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CD16/CD32 (Fey III/II receptor)) to prevent high background staining; 2 pi Fc block 
(0.5 mg/ml) was added per 1 x 106 cells in 100 pi FACS buffer and cells were 
incubated on ice for 10 minutes. Cells were pelleted by centrifugation at 1200 rpm for 5 
minutes, resuspended in 100 pi FACS buffer containing a 1:100 (FITC-conjugated) or 
1:200 (APC- or PE-conjugated) dilution of the appropriate antibody and incubated on 
ice for 30 minutes in the dark. For analysis o f T lymphocyte reconstitution, cells were 
stained with the following anti-mouse antibodies: CD3e-FITC, CD8a-APC, and CD4- 
FITC. For analysis of B lymphocyte reconstitution cells were stained with the 
following anti-mouse antibodies: CD45R/B220-APC and IgM-FITC. For analysis of 
NK and myeloid populations, cells were stained with the following anti-mouse 
antibodies: NK1.1-APC and C D llb-PE . Cells cultured on OP9 stromal layers were 
stained with anti-mouse CD25-PE and CD44-APC for analysis o f T cell differentiation 
or with anti-mouse CD45R/B220-APC and CD-19 FITC for analysis of B cell 
differentiation. Following staining cells were washed once with 1 ml FACS buffer, 
pelleted by centrifugation and resuspended in 300 pi FACS buffer and transferred to 
FACS tubes. Cells were stored in the dark at 4°C and analysed by flow cytometry 
within 24 hours of staining.
2.2.5.2 Staining of Transduced Cell Lines for Human yc Expression
Transduced cells were removed from tissue culture plates and washed once with FACS 
buffer to remove any traces o f media. For analysis of surface human yc expression, 1 x 
106 cells were stained with 0.5 pi anti-human CD132-PE antibody in 100 pi FACS 
buffer on ice, in the dark for 30 minutes. Cells were subsequently washed with 1 ml 
FACS buffer, spun at 1200 rpm for 5 minutes and then resuspended in 300 pi fresh 
FACS buffer. Cells were stored in the dark at 4°C and analysed by flow cytometry 
within 24 hours of staining.
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2.2.6 Western Blotting
5 x 105 primary or cultured cells were washed in PBS and pelleted in 1.5 ml microfuge 
tubes by centrifugation at 1200 rpm for 5 minutes in a table-top centrifuge. Protein was 
harvested from cell pellets by resuspension in 100 pi M-PER mammalian protein 
extraction reagent supplemented with 1 pi HALT protease inhibitor cocktail and 
incubation on ice for 10 minutes with occasional shaking. The cell lysates were spun at 
13,000 rpm in a microfuge at 4°C for 15 minutes and the supernatants containing the 
nuclear and cytoplasmic protein transferred to fresh eppendorfs. The samples were 
diluted 1:1 with 100 pi 2 x Laemmli sample buffer and heated to 95°C for 5 minutes. 
30pl o f protein samples were loaded onto 4-12% Bis-Tris Novex pre-cast gels with 10 
pi o f SeeBlue Plus2 pre-stained standard loaded into the outer-most well. Protein 
samples were separated by polyacrylamide gel electrophoresis at 200 V for 50 minutes 
in an XCell SureLock Mini-Cell (Invitrogen) in 1 x NuPAGE MOPS SDS running 
buffer. The separated proteins were subsequently immunoblotted onto PVDF 
membrane using the XCell II blot module (Invitrogen) at 30 V for 1 hour. The PVDF 
membrane was washed with methanol for 30 seconds, rinsed in distilled water and then 
washed in 1 x NuPAGE transfer buffer prior to immunoblotting.
Following immunoblotting, PVDF membranes were incubated overnight with blocking 
buffer (PBS, 0.1% (v/v) Tween 20, 5% (w/v) milk powder) to prevent non-specific 
antibody staining. Membranes were subsequently washed five times in PBS-T (PBS, 
0.1% (v/v) Tween 20) and incubated with primary antibody in 3 ml blocking buffer for 
2 hours at room temperature with agitation. The membranes were washed a further five 
times in PBS-T and then incubated with an HRP-conjugated secondary antibody in 3 
ml blocking buffer for 45 minutes at room temperature with agitation. The membranes 
were washed for a final five times after which 1 ml of ECL Western blotting substrate 
was added directly to the membrane and incubated for 1 minute at room temperature. 
Protein bands were visualised using an UVIchemi (UVItec) chemiluminescence 
documentation system and UVIsoft (UVItec) software.
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2.2.7 pSTAT5 Assay
lxlO 5 transduced or mock-transduced ED-7R cells and untransduced ED-7R-yc control 
cells were incubated overnight in complete RPMI media. The following day the cells 
were washed once in PBS, pelleted by centrifugation in a table-top centrifuge at 1200 
rpm and resuspended in 200 pi of RPMI only. The cells were split between two capped 
FACS tubes (100 pi in each) and 6  pi human IL-2 (100 ng/pl) was added to one o f the 
tubes. The cells were incubated at 37°C/5% CO2 for 10 minutes, at which time 2 ml of 
pre-warmed (to 37°C) FACs lyse/fix buffer (1:5 dilution) was added to each tube. The 
cells were then incubated for a further 10 minutes at 37°C/5% CO2. The cells were 
pelleted by centrifugation, after which the supernatant was decanted and the cell pellets 
resuspended in the small volume o f remaining media at the bottom of the tubes. 1 ml of 
cold Perm Buffer III was then added to each tube and the cells incubated on ice for 30 
minutes. The cells were pelleted and washed once with 1 ml FACs buffer. The cells 
were then stained on ice for 30 minutes in the dark with 5 ul anti-pSTAT5-PE in 100 pi 
FACs buffer. The cells were subsequently washed twice with 1 ml FACs buffer and 
finally resuspended in FACS buffer supplemented with 1% (v/v) paraformaldehyde 
solution and analysed by flow cytometry.
2.2.8 Gammaretrovirus Preparation and Transductions
2.2.8.1 Gammaretrovirus Production
Phoenix-gp packaging cells were grown in complete DMEM; the day before 
transfection, 5 x 106 cells were seeded in 10 cm tissue culture dishes. Retroviral vector 
DNA (8  pg) and packaging plasmids were transfected using the calcium phosphate 
precipitation method. To generate ecotropic retroviral particles the packaging plasmids 
used were as follows, 10 pg M57 (gag/pol expression plasmid) and 2 pg K73 or 5 pg 
K37 (Ecotropic or RD114 envelope expression plasmids repectively). The DNA was 
added to sterile distilled water to make a total volume o f 450 pi to which 50 pi CaCh 
(2.5 M) was added. 15 ml sterile falcon tubes were pre-loaded with 500 pi 2 x HEPES
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buffered saline (HBS) and the solution was bubbled using an electronic pipettor and 
sterile 1 ml pipette whilst the DNA/CaCh solution was added drop by drop. The 
mixture was incubated for 2 0  minutes at room temperature during which time the 
complete DMEM was removed from the plates containing the phoenix-gp cells and 
replaced with 9 ml o f transfection medium (complete DMEM with 20 mM HEPES) 
supplemented with 25 pM chloroquine (to inhibit DNA degradation by lysosomes). 
The 1 ml transfection reaction was then added to the plates slowly whilst gently 
swirling the media to evenly distribute the calcium phosphate/DNA precipitate. After 6 
hours incubation at 37°C/5% CO2 the media was replaced with fresh transfection media 
without chloroquine. Supernatants containing the viral particles were collected at 24, 
36, 48 and 60 hours post-transfection, pooled and filtered through a 0.22 pm filter. 
Viral supernatant was concentrated by centrifugation at 18,500 g, overnight at 4°C for 
14-16 hours. Retroviral pellets were resuspended in DMEM supplemented with 20 mM 
HEPES and stored in aliquots at -70°C.
2.2.8.2 Titration of Gamma retroviral Supernatants
Ecotropic and RD114 pseudotyped gammaretroviral preparations were titrated on 
murine SC-1 fibroblast cells and human HT1080 fibrosarcoma cells respectively.
5 x 104 cells/well were seeded in 12-well tissue culture plates in complete DMEM and 
left to adhere overnight. The following day the media was removed and serial dilutions 
of concentrated gammaretroviral supernatant were added directly to the cells and 
topped up with 500 pi complete DMEM supplemented with protamine sulphate (4 
pg/ml). The plates were spun at 950 g for 1 hr in a table-top centrifuge and then 
incubated at 37°C/5% CO2 for 6  hours, after which the cells were topped up with 1.5 
ml complete DMEM. The plates were incubated for two days at 3 7 °C/5 %C0 2 , at which 
time the cells were harvested and analysed by flow cytometry. Viral titre (transducing 
units per ml o f supernatant) was determined by multiplication of the number of 
transgene-positive cells by the dilution.
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2.2.8.3 Transduction of SC-1 cells with Ecotropic Gammaretrovirus
5 x 104 SC-1 cells per well were seeded in 12-well plates in complete DMEM and left 
to adhere for three hours or overnight. The media was subsequently aspirated and the 
virus added directly to the cells, 500 pi complete DMEM supplemented with protamine 
sulphate (4 pg/ml) was added to each well and the plates were spun at 950 g for 1 hour 
in a tabletop centrifuge. The cells were then incubated at 37°C/5% CO2 for 6  hours 
after which time the cells were topped up with 1.5 ml complete DMEM. 48 hours later 
the cells were removed from the plates for analysis.
2.2.8.4 Transduction of SCID-X1 LCLs and ED-7R cells with RD114 
Pseudotyped Gammaretrovirus
24-well non-tissue culture treated plates were coated with retronectin (48 pg/ml) 
overnight at 4°C or for 2 hours at ambient temperature. The plates were washed twice 
with PBS 1% BSA and then once with PBS only. RD114 pseudotyped 
gammaretrovirus was then added to each well, together with 500 pi RPMI and plates 
were spun at 950 g in a table-top centrifuge at 4°C for 30 minutes. The media and 
gammaretroviral supernatant was then removed and the SCID-X1 LCLs or ED-7R cells 
were added to the virally pre-loaded wells in complete RPMI. The cells were removed 
for analysis 48 hours later.
2.2.8.5 Gammaretroviral Lin' Cell Transduction
Lin' cells were pre-stimulated for 48 hours in StemSpan SFEM serum-free medium 
supplemented with 1% (v/v) Penecillin/Streptomycin, mSCF (100 ng/ml), mFlt3 (100 
ng/ml), mIL-3 (20 ng/ml) and hIL-11 (100 ng/ml) at a density o f 0.5-1 x 106 cells/ml. 
Non tissue-culture 6 -well plates were coated with 2 ml retronectin (50 pg/ml) and 
incubated overnight at 4°C. The retronectin-coated plates were washed twice with PBS 
1% BSA and then once with PBS only and subsequently preloaded with 
gammaretroviral supernatant by centrifugation for 30 minutes at 950 g at 4°C.
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Following centrifugation the gammaretroviral supernatant was removed and the pre­
stimulated lin' cells transferred to the virally pre-loaded plates and incubated overnight 
at 37°C, 5% CO2. On day four gammaretrovirus was again pre-loaded onto retronectin- 
coated plates, the lin- cells were removed from the intial plates using enzyme-free cell 
dissociation buffer and transferred to the new plate for a second of transduction. The 
transduced cells were harvested on day five for intravenous injection into irradiated 
mice or for co-culture on OP9 stromal layers.
2.2.9 Lentivirus Preparation and Transductions
2.2.9.1 Lentivirus Production
7 71.2 x 10 293T cells grown in complete DMEM were seeded in 175 cm tissue culture 
flasks the day before transfection. Lentiviral vector DNA (40 pg) and packaging 
plasmids pMDG.2 (VSV-G) (10 pg) and pCMVA8.74 (gag-pol) (30 pg) were added to 
5 ml OPTI-MEM, filtered through a 0.22pm filter and combined with 5 ml filtered 
OPTI-MEM supplemented with 1 pi polyethylenimine (PEI) (10 mM) transfection 
reagent. The transfection reaction was incubated at room temperature for 20 minutes 
during which time the 293T cells were washed once with OPTI-MEM media. The 10 
ml DNA/PEI complexes were subsequently added to the cells and they were then 
incubated at 3 7 °C/5 %C0 2  for 4 hours, after which the media was replaced with 14 ml 
complete DMEM. Viral supernatant was harvested 48 and 72 hours post-transfection, 
filtered through a 0.22 pm filter and concentrated by ultracentrifugation at 98,000 g for 
2 hours. Retroviral pellets were resuspended in serum-free media (DMEM or Stem Span 
SFEM) and stored in aliquots at -70°C.
2.2.9.2 Titration of Lentiviral Supernatants - Infectious Titre
Viral titre was determined by the transduction o f SC-1, HT1080 or ED-7R cells 
(dependent upon the experiment to be performed with the specific lentiviral 
preparation). 5 x 104 cells/well were seeded in 12-well tissue culture plates and left to
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adhere for 3 hours (SC-1 and HT1080s only). The media was subsequently aspirated 
from the cells and serially diluted lentiviral supernatant added. Infectious viral titre was 
determined by the analysis of transgene-positive cells by flow cytometry 72 hours post­
transduction.
2.2.9.3 Titration of Lentiviral Supernatants - p24 Titre
The quantity o f p24 antigen in lentiviral supernatants was measured using a Coulter 
HIV-1 p24 antigen assay as per the manufacturer’s instructions. Supernatants were 
diluted 1:1 x 106, 1:5 x 106 and 1:1 x 107 and added to p24 antibody-coated wells 
together with diluted calibration standards. Samples were lysed, washed and then 
incubated with biotinylated anti-HIV-1. The samples were washed again and 
subsequently incubated with streptavidin-HRPO followed by the addition of 
tetramethybenzidine (TMB) and Coulter stop reagent (4N H2SO4). The absorbance of 
each plate was then read at 450 nm and the quantity o f p24 reagent calculated from a 
standard curve generated from the diluted calibration standards.
2.2.9.4 Lentiviral Cell Line Transduction
Cells were seeded at a density o f 5 x 104 cells/well in 12-well tissue culture plates in 
the appropriate growth medium and left to adhere (adherent cell lines only) for three 
hours or overnight at 37°C/5% CO2. Concentrated lentiviral supernatant was added 
directly to the growth media and the cells were incubated at 37°C/5% CO2 for 48 hours 
and subsequently analysed for transgene expression by flow cytometry.
2.2.9.5 Lentiviral Lin' Cell Transduction
Lin- cells were seeded at a density of 0.5-1 x 106 cells per ml in StemSpan SFEM 
serum-free media supplemented with 1% (v/v) penicillin/streptomycin and cytokines 
(mSCF (100 ng/ml), mFlt3 (100 ng/ml), mIL-3 (20 ng/ml), hIL-11 (100 ng/ml)). 
Concentrated lentiviral supernatant was added directly to the growth media and the
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cells were transduced overnight at 37°C/5% CO2. The following day the transduced 
cells were harvested for intravenous injection into irradiated mice or for co-culture on 
OP9 stromal layers.
2.2.10 Murine Reconstitution Experiments
Between 3-10 x 105 transduced lin" cells, resuspended in 300 pi RPMI, were 
intravenously injected into the tail veins of sublethally irradiated Il2rg~~Rag2~/'c5"  
mice using a 27 G bevel needle attached to a tuberculin syringe. Recipients were 
irradiated with a total of 6  Gy in a split dose over two days.
2.2.11 Murine Secondary Transplantations
1 x 1 0 8 whole bone marrow cells isolated from the femurs and tibias of primary 
transplant recipients were resuspended in 300 pi RPMI and intravenously injected into 
the tail veins of lethally irradiated Il2rg'/'Rag2~/'c5~/' mice using a 27 G bevel needle 
attached to a tuberculin syringe. Recipients were irradiated with a total o f 10 Gy in a 
split dose over two days.
2.2.12 Splenocyte Proliferation Assay
Splenocytes were plated at a density o f 2 x 105 cells/well, in triplicate, in 96-well plates 
in complete RPMI media. The cells were stimulated for 48 hours at 37°C/5% CO2 with 
and without 1 mg/ml Concanavalin A and/or IL-2 (20 ng/ml). The cells were then 
pulsed with 1 pCi/well o f methyl-3H-thymidine for 12 hours and uptake determined 
using a beta-counter (MicroBeta TAILUX, Wallac).
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2.2.13 Immunoglobulin ELISAs
Approximately 100 pi of peripheral blood was collected from the cardiac chambers of 
transplanted mice immediately following sacrifice and stored at room temperature for 
approximately one hour to allow coagulation. Samples were then centrifuged at 13,000 
rpm in a micro-centrifuge for 10  minutes and the serum transferred to fresh eppendorfs 
and stored at -20°C.
Maxisorp 96-well NUNC-Immuno ELISA plates (NUNC) were coated overnight with 
1 0 0  pl/well capture antibody (see table 2 . - diluted to the appropriate concentration in 
PBS), wrapped in cling film and stored overnight at 4°C. The coated plates were 
washed three times with wash buffer (100 pi PBS/0.05% (v/v) Tween 20) and blocked 
for 1 hour at room temperature in the appropriate blocking buffer (see table 2.1). The 
plates were washed a further three times and 1 0 0  pi of diluted serum added in triplicate. 
Plates were incubated at room temperature for 1 or 2 hours (see table 2.1), at which 
time they were washed three times. 1 0 0  pl/well of detection antibody (see table 2 .1) 
was added to each well and plates were incubated at room temperature for 1 hour (for 
the IgGl and IgG2a ELISAs in which the detection antibody is HRP conjugated this 
incubation was performed in the dark). The plates were subsequently washed three 
times; for the IgG ELISA, 100 pl/well o f Streptavidin-HRPO was added and the plates 
were incubated for 30 minutes at room temperature in the dark before a further three 
washes were performed. Substrates A and B from the ELISA Duo-set substrate reagent 
pack were mixed in equal quantities, 1 0 0  pi o f the mixed solutions was added to each 
well and the plates were incubated at room temperature in the dark for approximately 
10  minutes to allow colour change, at which time the reaction was stopped by adding 
50 pi stop solution/well (2N H2SO4). The absorbance o f each plate was then read at 405 
nm using a FLUOstar Optima plate reader (BMG LABTECH).
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ELISA Capture Blocking Serum Sample Detection Tertiary
antibody Buffer dilutions incubation
time
Antibody antibody
IgG Rabbit anti­ PBS/ 1:4000 - 1 hour Polyclonal Strep-
m ouse IgG 1% BSA/ 1:128000 rabbit F(ab’)2 HRPO
(1:500) 5%
Sucrose
anti-m ouse Ig- 
biotin (1 :5000)
(1:1000)
IgGl Rabbit anti­ PBS/ 1:750 - 1 hour HRP-rat anti­ -
m ouse IgG l 1%BSA 1:6000 m ouse IgG l
(2p g/m l) (2pg/m l)
IgG2a Rabbit anti­ PBS/ 1:750 - 1 hour HRP-rat anti­ -
m ouse IgG2a 1%BSA 1:6000 mouse IgG2a
(2p g/m l) (2pg/m l)
Table 2.1. The antibodies and conditions used for immunoglobulin ELISAs.
2.2.14 Genomic DNA Isolation
5 x 104 cells were pelleted by centrifugation at 13,000 rpm for 10 minutes in a micro­
centrifuge, resuspended in 20 pi DNA lysis buffer (10 mM Tris, 1 mM EDTA pH 8.0, 
0.5% NP40, 0.5% Tween 20, 1.25 mg/ml Proteinase K) and incubated at 56°C for 2 
hours. Lysed cell pellets were pulsed at 13,000 rpm, incubated at 95°C for 15 minutes 
and then pulsed again at 13,000 rpm. 180pl o f distilled DNase-free water was added, 
followed by centrifugation at 13,000 rpm for 5 minutes. The supernatant containing the 
genomic DNA was then transferred to sterile eppendorfs and kept at 4°C for short-term 
storage and transferred to -20°C for long-term storage.
2.2.15 PCR
PCR reactions were performed in a total volume of 25 pi containing 100 ng template 
DNA, forward and reverse primers at 0.5 pM, dNTPs, each dNTP at 200 pM and 2.5 U 
of Taq DNA polymerase in the appropriate buffer (Promega). The concentration of 
M gCb to be used was determined for each specific reaction (typically 1.5 mM
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however). Typically cycling conditions were as follows: 30 cycles of 96°C for 30 
seconds, 58°C for 1 minute, 72°C for 1 minute.
2.2.15.1 Calculation of Lin" Cell Transduction Efficiency by PCR from 
Methylcellulose Colonies
Retroviral transduction efficiency was calculated by PCR from DNA isolated from 
methylcellulose colonies using gammac-F and gammac-R primers specific for the 
IL2Rg cDNA. The reaction was performed at an annealing temperature o f 60°C and 
amplified a 459 bp DNA product from cells transduced with gammaretroviral or 
lentiviral vectors encoding the human IL2RG  transgene.
Forward primer -  gammac-F (exon 3): 5’ CTGGCTGTCAGTTGCAAAAA 3’
Reverse primer -  gammac-R (exon 8 ): 5’ GAGATAACCACGGCTTCCAA 3’
To confirm the presence o f genomic DNA from each picked colony and to determine 
transduction efficiency, a PCR was performed using HPRT-F and HPRT-R primers to 
exon 9 o f the murine housekeeping gene, Hprt. The reaction was performed at an 
annealing temperature o f 58°C and amplified a 324 bp product.
Forward primer -  HPRT-F: 5’ TCCCCAGACTTTTGATTTGC 3’
Reverse primer -  HPRT-R: 5’ GGAAAATACAGCCAACACTGC 3’
2.2.15.2 PCR of the IL2RG Promoter
The 1.24 kb promoter was amplified from human genomic DNA using a high fidelity 
PfuTurbo DNA polymerase and primers hIL2RG prom-XhoF and hIL2RG prom-BamR 
or hIL2RG prom-EcoF and hIL2RG prom-BamR incorporating restriction 
endonuclease recognition sequences at their 5’ ends. The PCR reactions were 
performed at an annealing temperature o f 61°C.
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Forward primers:
hIL2RG prom-XhoF: 5’ GTCCTCGAGCTATCCCCCTCTCCATCTT 3’ 
hIL2RG prom-EcoF: 5’ GCGAATTCCTATCCCCCTCTCCATCTTG 3’
Reverse primer:
hIL2RG prom-BamR: 5’ ATGGATCCGGCGCTTGCTCTTCATTC 3’
2.2.15.3 Purification of PCR Products
PCR products to be used for cloning procedures were purified using a QIAquick PCR 
purification kit as per the manufacturer’s instructions.
2.2.16 Quantitative Real-Time PCR for the Determination of Proviral 
Copy Number
Quantitative real-time PCR was used to determine proviral copy number in transduced 
murine lin' cells or primary cells from reconstituted mice. Genomic DNA was isolated 
as described in 2.2.14 and approximately 100 ng of DNA used as a template for each 
PCR. Reactions were performed in triplicate in a final volume o f 50 pi containing 
forward and reverse primers at 0.9 pM, a fluorescently-labelled probe at 0.2 pM and a 
pre-mixed mastermix (Platinum qPCR SuperMix-UDG with ROX) diluted to 1 x with 
sterile distilled water. DNA samples were analysed using primers and probe to the 
human yc cDNA (a gift from Elke Grassman, Cincinatti Children’s Hospital Medical 
Center, Cincinatti, USA) for detection of integrated proviral copies and using primers 
and probe to exon 5 o f the murine titin gene (Ttn) (a gift from A Galy, Genethon, Paris, 
France) to enable quantitation o f the number o f cells in each particular sample. 
Standard curves of diluted plasmids harbouring either the yc cDNA or murine titin gene 
(gifts from Dr Steven Howe and Dr Mike Blundell, Molecular Immunology Unit, ICH) 
were used to quantitate integrated viral copies and the number of copies o f the murine 
titin gene which was then normalised for cell number. Reactions were performed using
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an ABI Prism 7000 Sequence Detection System (Applied Biosystems) using the default 
cycling parameters -  1 cycle o f 50°C for 2 minutes, 1 cycle of 95°C for 10 minutes 
followed by 40 cycles o f 95°C for 15 seconds and 60°C for 1 minute.
Primers and probe for the detection on integrated provirus (yc cDNA):
Forward primer -  gamma chain US F I : 5’ TGCTAAAACTGCAGAATCTGGT 3’ 
Reverse primer -  gamma chain US R l: 5’ AGCTGGGATTCACTCAGTTTG 3’
Probe -  gamma chain US: 5’ FAM-CCTGGGCTCCAGAGAACCTAACA-TAMRA 3’
Primers and probe for the detection o f the murine Ttn gene:
Forward primer -  Titin M ex5 F: 5’ AAAACGAGCAGTGACGTGAGC 3’
Reverse primer -  Titin M ex5 R: 5’ TTCAGTCATGCTGCTAGCGC 3’
Probe -  Titin M ex5: 5’ FAM-TGCACGGAAGCGTCTCGTCTCAGTC-TAMRA 3’
2.2.17 DNA manipulation
2.2.17.1 Restriction Enzyme Digestion
Plasmid DNA (typicially 0.5-5 pg) was digested in a final volume of 25-50 pi of 10 x 
buffer (supplied by the manufacturer and diluted to 1 x with distilled water) and bovine 
serum albumin (0.1 mg/ml). The amount of enzyme used varied depending o f the 
concentration o f the enzyme stock and the amount of DNA, but never exceeded 10% 
(v/v) of the total reaction volume. The endonuclease reaction was carried out at the 
manufacturer’s recommended temperature for 1-2 hours and DNA digestion was 
verified by agarose gel electrophoresis. Double or triple digestions were performed 
either in compatible buffers or sequentially, following clean-up of DNA by ethanol 
precipitation.
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2.2.17.2 Ethanol Precipitation of DNA
The volume o f the DNA solution was estimated and one-tenth of the volume o f 3 M 
sodium acetate (pH 5.2) and two times the volume of 100% ethanol were added. The
solution was mixed by inversion and placed at -20°C for 1 hour. The precipitated DNA 
was subsequently pelleted by centrifugation at 13,000 rpm in a microfuge for 30 
minutes at 4°C. The supernatant was discarded and the pellet washed in 1 ml 70% 
ethanol, followed by centrifugation for 10  min under the same conditons as previously. 
The supernatant was again discarded and the DNA pellet briefly air dried and 
resuspended in an appropriate volume o f 1 x TE buffer (10 mM Tris-HCl pH 8.0, 1 
mM EDTA) or distilled water.
2.2.17.3 Agarose Gel Electrophoresis
DNA fragments were resolved by electrophoresis through 1% agarose gels in 1 x TAE 
buffer (40 mM Tris-acetate, 5 mM EDTA). To prepare the gels, agarose was dissolved 
in 1 x TAE buffer by boiling in a microwave, after cooling ethidium bromide was 
added at 0.5 pg/ml for visualisation of DNA. DNA samples were mixed with Orange G 
loading buffer (10 mM Tris pH 7.5, 50 mM EDTA, 10% Ficol 400, 0.4% Orange G) 
before loading onto agarose gels. A 1 kb plus DNA ladder was loaded onto each gel to 
enable size determination o f DNA fragments. Gels were electrophoresed using a 
voltage of 50-100 V (up to 150 mA) and the separated DNA fragments subsequently 
visualised by exposure to ultra-violet light using an UVIdoc gel documentation system.
2.2.17.4 Gel Purification of DNA
Following electrophoresis DNA fragments were excised from agarose gels using a 
clean scalpel blade under ultra-violet light. The DNA was then extracted from the 
agarose using a QIAquick gel extraction kit as per the manufacturer’s instructions.
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2.2.17.5 Dephosphorylation of Digested Plasmid DNA Ends
In cases where digested vector DNA ends had compatible termini, the digested plasmid 
DNA was treated with calf intestinal alkaline phosphatase (CIP) to dephosphorylate the 
DNA ends prior to ligation. Dephosphorylation reactions were perfomed directly in 
restriction endonuclease buffers; immediately following digestion, 10 units o f CIP 
enzyme was added to the reaction mixture and incubated at 37°C in a waterbath for 1 
hour. Dephosphorylated plasmid DNA was subsequently purified by ethanol 
precipitation.
2.2.17.6 Filling of 5 ’-Protruding Ends by Treatment with Klenow
DNA Polymerase I Large (Klenow) fragment was used to fill in the 5’ overhang 
created by digestion o f the vector with this restriction endonuclease and thus create a 
blunt end. Immediately following digestion with Xho\, five units of Klenow enzyme 
were added directly to the reaction mixture together with 40 pM of each dNTP and the 
reaction was incubated at room temperature for 10 minutes. The reaction was then 
stopped by heating to 75°C for 10 minutes. The blunt-ended DNA was subsequently 
purified by ethanol precipitation prior to ligation.
2.2.17.7 Ligation
Ligations were performed using vector to insert ratios o f 1:3 or 1:5 (100 ng vector 
DNA) in a final volume o f 10 pi o f 10 x T4 DNA ligase buffer (diluted to 1 x with 
distilled water) containing 1 unit o f T4 DNA ligase. Ligation reactions were incubated 
overnight (16 hours) at 15°C. The ligation reactions were either immediately 
transformed into electro-competent E.coli (2 pi) or stored at -20°C for later use.
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2.2.18 Neonatal Injections
This procedure was performed by Dr Simon Waddington. 1-day old neonatal mice were 
placed on ice slush until they no longer moved when touched. The heads were 
subsequently illuminated and 40 pi o f concentrated lentiviral supernatant injected into 
the superficial temporal vein (a prominent vessel located on either side of the head, 
visible just below the eye) using a 33 G Hamilton needle. Following the procedure, the 
mice were allowed to return to normal temperature on a warming mat before being 
returned to their mothers.
2.2.19 Statistical Analysis
Where applicable data was analysed using a two-tailed, unpaired t-test.
2.2.20 Bioinformatics
2.2.20.1 Human and Murine Genomic Sequences
Human and murine genomic sequenes were obtained from the UCSC Genome 
Bioinformatics Site (http://genome.ucsc.edu/) or from the Ensembl Genome Browser 
(http://www.ensembl.org/index.html).
2.2.20.1 Alignment of Human and Murine Sequences
Sequences were aligned using a multiple sequence local alignment and visualisation 
tool (Mulan, http://mulan.dcode.org).
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2.2.20.2 Analysis of Transcription Factor Binding Sites
Sequences were analysed for transcription factor binding sites using the online tool 
TFSEARCH tool (www.cbrc.jp). For analysis of transcription factor binding sites 
conserved in both the human and murine genomes, the MultiTF tool 
(http://multitf.dcode.org) was used.
2.2.20.3 Analysis of Putative CpG Islands
Sequences were analysed for the presence o f putative CpG islands using CpG plot 
(http ://www. ebi. ac.uk/emboss/cpgplot/).
2.2.20.4 Analysis of Alu Elements
Sequences were analysed for the presence o f Alu Ements using the online 
RepeatMasker program (www.repeatmasker.org).
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Self-Inactivating Gammaretroviral Vectors for
SCID-X1
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3.0 Aims
• To assess the performance of the SRS II series o f SIN gammaretroviral vectors
in vitro
• To compare the SRS II series of vectors to MFG yc for the ability to restore
the lymphoid differentiation potential of Il2rg f' lin' cells in vitro
• To assess the ability of the SRS II vector series to restore immunity in the
SCID-X1 murine model following ex vivo gene therapy
3.1 Introduction
The intact 5’ and 3’ Moloney murine leukaemia virus (MLV) LTRs within MFG yc 
contain potent, duplicated enhancer sequences and a promoter region that regulate 
high levels of transcription. The enhancer sequences consist o f two, approximately 75 
bp, direct repeats within which several transcription factor binding sites are located 
(figure 3.1 A). To reduce the potential for insertional mutagenesis, the SRS II series of 
self-inactivating gammaretroviral vectors have been developed that incorporate only a 
single internal regulatory element as opposed to the two LTR sequences present in 
MFG yc (see figure 1.7). The internal SFFV and EFS promoters were selected due to 
their ability to regulate high transgene expression in haematopoietic lineages.
The potent promoter activity o f the U3 region o f the SFFV LTR has been shown to 
efficiently express transgene in both haematopoietic progenitor cells and their multi­
lineage progeny in vivo, suggesting its potential as a promoter element in gene therapy 
vectors for haematological disorders (Demaison et al., 2002; Baum et al., 1995; 
Tumas et al., 1996). As for MLV, the U3 region of the SFFV LTR contains duplicated 
enhancer regions consisting o f several transcription factor binding sites, including the 
conserved LVb recognition site for the Ets family of transcription factors (figure 
3 .IB). In addition, a binding site for the ubiquitous Spl transcription factor is also 
present within the SFFV U3, located 5’ to the 42 bp enhancer repeat sequences (Baum 
et al., 1997). The Ets family o f transcription factors control expression of a large 
number of genes in haematopoietic cells, in particular during lymphoid development
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(Anderson et al., 1999), and consensus sequences for Spl and Ets factors are observed 
in several genes specifically expressed in haematopoietic lineages (as reviewd in 
(Baum et al., 1997).
The EFS promoter is derived from the regulatory sequences 5’ to the human 
elongation factor l a  gene, a housekeeping gene that encodes an enzyme which 
catalyses the binding o f aminoacyl-tRNA to ribosomes (Uetsuki et al., 1989). The 
promoter is described as the short form of the E F la  promoter (EFS) due to the 
deletion of the first intron, demonstrated to also contain promoter activity 
(Wakabayashi-Ito and Nagata, 1994), removed so as to avoid any problems associated 
with splicing. E F la  is abundantly expressed in most eukaryotic cells and the CpG rich 
promoter has been demonstrated to induce high levels o f trangene expression in 
human CD34+ cells, primary T cells and in vitro differentiated blood lineages, whilst 
remaining unaffected by the SIN design (Salmon et al., 2000; Dardalhon et al., 2001). 
Analysis of putative transcription factor binding sites located within this 242 bp 
promoter using the TFSEARCH tool (www.cbrc.jp) revealed the presence of several 
consensus sequences for haematopoietic-specific transcription factors, including the 
lymphoid restricted Ik-2, the myeloid zinc finger protein MZF1 and GATA-1, a 
transcription factor important in erythroid development (figure 3.1C). This promoter 
therefore presents an attractive alternative to viral regulatory sequences for 
incorporation into viral gene therapy vectors.
To assess vector performance in terms of transgene expression, the SIN 
gammaretroviral vectors encoding human yc were analysed both in vitro and in vivo 
and compared directly to the LTR-regulated vector, MFG yc.
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Figure 3.1. Comparison of the prom oter/enhancer sequences within the MLV 
LTR, the SFFV U3 region and the EFS prom oter. (A) The MLV LTRs contain 
duplicated enhancer regions containing several transcription factor binding sites and 
a promoter region containing CAAT and TATA motifs. (B) The SFFV U3 contains 
a Spl binding site upstream of the two enhancer direct repeat sequences and a 
promoter region also containing CAAT and TATA motifs. (C) The 242 bp EFS 
promoter contains several putative haematopoietic-specific transcription factor 
binding sites and a TATA box (analysed using the TFSEARCH tool). (D) A putative 
CpG island of 128 bp within the EFS promoter is identified following analysis with 
CpG plot (www.ebi.ac.uk/emboss/cpgplot/).
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3.2 In vitro Analysis of SIN Gammaretroviral Vectors
3.2.1 Transduction of the SC-1 Murine Fibroblast Cell Line
Replication incompetent retroviral vector encoding the human “yc cDNA was 
pseudotyped with murine ecotropic envelope and produced by transient transfection 
o f phoenix gag-pol packaging cells. The vector supernatant was subsequently 
concentrated by overnight centrifugation to produce high titre vector stocks.
To confirm the presence o f infectious virus and assess the ability o f the SIN vector 
series to transduce cells in vitro and express the yc transgene to detectable levels, the 
murine fibroblast cell line SC-1 was transduced with the SIN vectors and the LTR- 
regulated vector, MFG 'yc. Cells were transduced at a defined multiplicity o f infection 
(MOI) so as to obtain equal transgene dose. Cell surface expression o f human 'yc was 
determined by flow cytometry following staining with an anti-CD 132 (anti-'yc) 
antibody conjugated with phycoerythrin (PE). Both the SIN vector series and the 
LTR-regulated vector were able to efficiently transduce SC-1 cells, with the highest 
levels o f transgene expression being observed for the SIN vector SRS II SF 'yc 
containing the internal Spleen focus forming virus (SFFV) promoter (figure 3.2A - B). 
Western blot analysis o f transduced cell lysates revealed the presence o f a 64 kDa 
band representing human 'yc and two smaller bands that possibly represent 
underglycosylated or degraded forms o f the protein (figure 3.2C); similar isoforms 
have also been observed in 'yc-retrovirally transduced SCID-X1 B cell lines and 
following Western blot analysis o f a 'yc-expressing cell line (data not shown) 
(Kleiman et al., 1998).
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Figure 3.2. Hum an yc expression in transduced SC-1 cells. (A) Flow cytometric 
analysis o f SC-1 cells transduced with the SIN vector series and MFG *)€ at an MOI 
of 1. Plots are from a representative single transduction. (B) The mean fluorescent 
intensity (MFI) was compared for the transduced cells revealing that the highest 
expression levels o f human -yc were observed for SRS II SF 7 : (n = 1). (C) Western 
blot analysis of transduced SC-1 cell lysates. To confirm antibody specificity and as 
a vector control, SC-1 cells were also transduced with an LTR-regulated vector 
expressing enhanced green fluorescent protein (SFFV-eGFP). The blot was also 
probed with an antibody to the 41 kDa /3-actin protein (lower lane) to demonstrate 
equivalent loading in each lane.
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3.2.2 Restoration of 7c Expression in SCID-X1 Lymphoid Cell Lines
Human T and B cell lines deficient in yc were used to assess SEN vector performance 
in haematopoietic cells in which yc is normally expressed. A "yc-deficient 
lymphoblastoid B cell line was created by immortilisation of a SCID-X1 infant’s B 
cells using Epstein Barr Virus (EBV), whilst the 7 c-deficient ED-7R T lymphocyte 
cell line is derived from a human T cell leukaemia line (ED40515 ) naturally deficient 
in yc (Ishii et al., 1994). Gammaretroviral vectors pseudotyped with the feline 
endogenous virus envelope (RD114) have been demonstrated to transduce human 
lymphoid cells at high efficiency (Onodera et al., 1998) thus for this purpose, RD 114- 
pseudotyped retrovirus was produced by the same method used for the production of 
ecotropic viral particles.
The SCID-X1 B and T cell lines were transduced with both SRS II SF 7 c and SRS II 
EFS 73  at an MOI o f one and cell surface 7 c expression subsequently detected by flow 
cytometry following staining with an anti-CD 132-PE antibody. Low levels o f human 
yc expression were detected on B and T cell lines transduced with both SIN vectors as 
opposed to negligible levels on mock-transduced cells (figure 3.3A). Expression 
levels appear almost equivalent in the SCID-X1 B cell line for both the viral (SFFV) 
and endogenous promoter (EFS) whilst slightly higher levels o f expression in the T 
cell line were observed with the SFFV promoter (figure 3.3B). These data confirm 
that the SEN gammaretroviral vectors are capable o f restoring human 7 : expression on 
the cell surface o f  SCED-X1 lymphoid cell lines.
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Figure 3.3. Human yc expression in transduced SCID-X1 lymphoid cells.
(A) Flow cytometric analysis o f SCID-X1 T (ED-7R) and B (SCID-X1 LCL) cell 
lines transduced with SRS II SF yc and SRS II EFS 'yc at an MOI of 1. (B) The mean 
fluorescent intensity (MFI) o f transduced SCID-X1 B cells was similar for both 
promoters, whilst the SFFV promoter appeared to be more potent in ED-7R cells (n 
= 1).
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3.2.3 The OP9 System -  In Vitro Differentiation of Transduced 
Murine Haematopoietic Stem Cells
OP9 cells provide a convenient model for the induction of lymphopoiesis in vitro 
from haematopoietic progenitor cells. The OP9 stromal cell line was originally 
derived from the bone marrow o f mice deficient in macrophage colony-stimulating 
factor (MCSF) and was demonstrated to support haematopoiesis from both HSCs and 
embryonic stem cells (Kodama et al., 1994; Nakano et al., 1994). The lack of MCSF 
expression was found to contribute to the ability o f OP9 cells to support B cell 
lymphopoiesis by limiting the expansion of differentiated myeloid cells; subsequent 
refinements o f the co-culture protocol consequently enabled efficient generation o f B 
cells from embryonic stem cells using this method (Cho et al., 1999). To enable in 
vitro differentiation of T lymphocytes from haematopoietic progenitors, OP9 cells 
were retrovirally transduced to express the Notch ligand, Delta-Like-1 (DL-1) since 
notch signalling is thought to be crucial in the earliest stages of T cell commitment 
(Schmitt and Zuniga-Pflucker, 2002). The resultant OP9-DL1 cell line lost the ability 
to support B cell differentiation, however the stromal cells were found capable o f 
supporting normal T cell lymphopoiesis (figure 3.4) (Schmitt and Zuniga-Pflucker, 
2002).
THYMUS
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Figure 3.4. The different stages of T cell development in the murine thymus.
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0P9-eGFP (OP9 cells transduced with a retroviral vector expressing eGFP only) and 
OP9-DL1 stromal cell lines were therefore used to investigate the potential o f I l2 r g ' 
murine HSCs to undergo lymphoid differentiation in vitro following transduction with 
the SRS II gammaretroviral vector series. Murine HSCs were isolated using lineage 
negative selection o f whole bone marrow cells from Il2rg'A or C57/B16 mice (as a 
positive control). The Il2rg ~ lin" cells were prestimulated in serum-free media with 
cytokines for forty-eight hours and subsequently underwent two rounds o f retroviral 
transduction with either MFG 'yc, the SIN vectors expressing human 'yc or with the 
control vector, SFFV-eGFP, over two days, before seeding on OP9 stromal layers 
(figure 3.5A). The C57/B16 control lin' cells were maintained in serum-free media 
with cytokines for four days prior to seeding on the OP9 stromal layers. Cells were 
co-cultured with the OP9 stromal cell lines for thirteen days in the presence o f IL-7 
and Flt-3 to support lymphoid differentiation and analysed by light microscopy and 
flow cytometry.
Following five days o f co-culture on either the OP9-eGFP or OP9-DL1 stromal cell 
lines, densely-packed adherent ‘cobblestone colonies’ were visible for all cells, 
indicating early progenitor cell populations. Round, healthy-looking haematopoietic 
cells were also identifiable sitting on top o f the stromal cell layer (figure 3.5B). No 
differences were observed at this stage between the control C57/B16 HSCs and the 
l l2 r g '  HSCs that had been transduced with either the SIN vectors expressing /yc or 
with the control vector SFFV-eGFP; thus it appears that in the SCID-X1 murine 
model, 'yc is not crucial early on during haematopoietic differentiation. The presence 
o f early progenitor populations from the SFFV-eGFP transduced HSCs may also 
reflect the ability o f Il2 rg f~ mice to develop some lymphoid cells in the absence o f 'yc 
expression.
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Figure 3.5. Cobblestone colony formation following incubation of yc- 
retrovirally transduced //2rgv' lin' cells on OP9 strom al layers. (A) An outline of 
the experimental protocol used. (B) Cobblestone colonies representing early 
progenitor cell populations are visible after five days co-culture o f transduced HSCs 
on the OP9-GFP stromal cell line. For the control vector SFFV-eGFP these colonies 
appear bright green, indicating that they are formed from transduced Il2rg ~ donor 
cells. The fainter, eGFP-expressing OP9 stromal cells are also observed under the 
fluorescence microscope. Round, differentiated haematopoietic cells resting on top 
o f the stromal layer are also detected at this stage.
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3.2.3.1 Co-culture on OP9-eGFP Stromal Layers - B cell 
differentiation
Flow cytometric analysis o f the haematopoietic cell populations was performed after 6 
days o f co-culture (figure 3.6). Cells cultured on the OP9-eGFP stromal layer were 
stained with antibodies to NK1.1 for the detection o f NK cells, and to CD 19, which is 
expressed on pro-B cells and all subsequent stages of B cell development. 
Approximately 70% of the C57/B16 cells were found to express CD 19 by day six, 
with only 4% o f NK cells detected in the total population. The Il2 rg ' cells transduced 
with either the SIN vectors or MFG yc appeared to undergo differentiation more 
slowly than the control C57/B16 cells, since only 10-15% of CD19+ B cell progenitors 
were detected at this stage, a higher proportion of NK1.1+ cells were also present. The 
Il2rg ' cells transduced with the control vector, SFFV-eGFP, had only small fractions 
o f both populations present, with a large number o f eGFP+ cells detectable.
C57/BI6
67.26S
10* 10* 10C 10* 10*
MFG 7c SFFV-eGFP
10* 10* IOC
5.47%
CD19
Figure 3.6. Day six analysis of OP9-eGFP co-cultures. Cells were stained with 
antibodies to NK cell marker NK1.1 and B cell marker CD19 and analysed by flow 
cytometry. A large population o f CD19+ early B lymphocytes are observed for 
C57/B16 control cells, with smaller CD19+ populations present for the H2rg/' cells 
transduced with the SIN vectors or MFG *yc. A large eGFP+ population is present for 
the //2rg 7' cells transduced with SFFV-eGFP (ungated population on the far right o f 
the plot) with a small fraction o f eGFP'CD19+ cells detected.
SRS II SF yc SRS II EFS yc
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After ten days co-culture, large numbers o f round, differentiated haematopoietic cells 
were visible resting on top o f the OP9-eGFP stromal layers (figure 3.7A). 
Surprisingly, large numbers o f these cells were also present for the Il2rg~  HSCs 
transduced with SFFV-eGFP, however by day twelve almost all o f these cells were 
found to be dead, indicating the requirement o f yc for B cell differentiation and 
survival. The C57/B16 and 'yc-retrovirally transduced Il2rg cells were analysed by 
flow cytometry on day thirteen following antibody staining for B cell markers CD 19 
and B220. Almost 100% o f cells were characterised as CD19+B220+ B lymphocytes, 
with no differences observed between the wild-type C57/B16 cells and the 
retrovirally-transduced Il2rg ' cells (figure 3.7B). These results indicate that the SIN 
gammaretroviral vectors are capable o f efficiently transducing primitive Il2rg ' 
murine HSCs under the culture conditions used and expressing functional human 'yc 
on the cell surface at levels that enable B cell differentiation in vitro. Furthermore, B 
cell differentiation o f the transduced cells was identical to that seen for wild-type 'yc+ 
HSCs or for Il2rg A HSCs transduced with the LTR-regulated vector MFG 'yc.
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Figure 3.7. Analysis of OP9-eGFP co-cultures on days ten and thirteen. (A)
After ten days co-culture large numbers o f round haematopoietic cells are observed 
resting on top o f the OP9 stromal layers. (B.) Cells were analysed by flow cytometry 
after thirteen days o f co-culture following staining for B cell surface markers CD 19 
and B220. After thirteen days o f co-culture CD19+B220+ B lymphocytes are 
detected for both wild-type and retrovirally transduced Il2 rg ' HSCs.
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3.2.3.2 Co-culture on OP9-DL1 Stromal Layers - T cell 
differentiation
Intra-thymic murine T cell development proceeds via four stages characterised by the 
differential cell surface expression o f CD44 and CD25 within the double negative 
(DN) CD4 CD8 'population (figure 3.4) (Godfrey et al., 1993). Cells cultured on OP9- 
DL1 stromal layers were therefore analysed for their ability to undergo T cell 
differentiation in vitro by staining with antibodies to CD25 and CD44. By day six, 
approximately 90% of the C57/B16 wild-type cells were found to be at the 
CD44+CD25' DN1 stage, with the remaining 10% o f cells having proceeded to stage 
DN2. Similar results were observed for the 'yc-retrovirally transduced Il2rg~  cells 
with the majority o f the cell populations being at the DN1 stage; however these cells 
also appeared to be undergoing T cell differentiation at a higher rate than the control 
C57/B16 HSCs, with between 30 and 40% having already proceeded to the 
CD44+CD25+ DN2 stage (figure 3.8B). The apparent increased rate o f T cell 
differentiation seen for the transduced H2rg'A HSCs might be explained by the 
presence o f an increased pool o f committed T lymphoid progenitors in the bone 
marrow o f these mice. No differences in differentiation were observed at this time 
point between I l2 rg ' cells transduced with the SIN vectors and those transduced with 
the LTR-regulated vector MFG 'yc. SFFV-eGFP transduced Il2rg'A cells appeared 
arrested at the DN1 stage o f development with both CD44+eGFP+ and CD44+eGFP' 
populations observed, but no CD44+CD25+ DN2 stage cells detected. This block is 
most likely due to the inability o f the Il2rg~  cells to signal through the IL-7 receptor, 
since this cytokine plays an important role during early lymphocyte development (von 
Freeden-Jeffry et al., 1995; Puel et al., 1998). Furthermore, thymocyte development in 
mice treated with antibodies to IL-7 or in IL-7Ra-deficient mice is unable to proceed 
efficiently beyond the DN1 stage (Bhatia et al., 1995; He et al., 1997). However, 
Il2rg'A mice are able to develop some T cells in the absence o f 'yc, consequently it is 
likely that factors absent in this in vitro system are required for the 'yc-independent 
development o f T cells. C-kit, the cytokine receptor for SCF, has been postulated to 
partially compensate for the 'yc-deficiency, since thymocyte development is 
completely abrogated in mice doubly-deficient for both receptors (Rodewald et al., 
1997); OP9 cells have been demonstrated to produce SCF when cultured under
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similar conditions and hence it appears that this pathway is unable to rescue T 
lymphopoiesis beyond the DN1 stage in vitro (Cho et al., 1999).
As was observed for the cells cultured on the OP9-eGFP stromal layers, after ten days 
o f co-culture large numbers o f round, differentiated haematopoietic cells were visible 
(data not shown). These cells were again analysed by flow cytometry on day thirteen 
following staining with antibodies to CD25 and CD44. For both wild-type C57/B16 
cells and the yc-retrovirally transduced H2rg'A cells, the majority of the population 
was found to be at stage DN2, with fewer cells remaining at the DN1 pro-T cell stage 
(figure 3.8C). Cells were also detected at the later CD44'CD25+ DN3 and CD44' 
CD25' DN4 stages, indicating the occurrence o f ongoing T cell differentiation in vitro. 
No viable cells remained in the co-culture o f Il2 rg f' cells transduced with the SFFV- 
eGFP control vector by this stage o f the experiment. The SRS II series o f SIN 
gammaretroviral vectors are therefore able to efficiently transduce murine lin' cells 
and express the yc transgene at functional levels that permit T cell differentiation in 
vitro.
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Figure 3.8. Analysis of OP9-DL1 co-cultures. (A) Illustration of the four stages o f 
T cell development as characterised by flow cytometry following staining with 
antibodies to CD25 and CD44. (B) Cells were stained with antibodies to early T cell 
markers, CD44 and CD25, after six days co-culture on OP9-DL1 stromal layers and 
analysed by flow cytometry. Both the C57/B16 and Tc-retrovirally transduced cells 
appeared to be differentiating from the DNl to the DN2 stage of T cell development. 
Control SFFV-eGFP transduced cells appeared arrested at DNl. (C) After thirteen 
days o f co-culture the SFFV-eGFP transduced cells had all died whilst the wild-type 
C57/B16 and 'yc-retrovirally transduced cells appeared to be differentiating further 
towards DN4.
82.59%
SRS II SF yc SRS II EFS yc MFG yc
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3.3 In vivo Analysis of SIN Gammaretroviral Vectors -
Reconstitution of the SCID-X1 Murine Model
Data from the in vitro experiments demonstrated that the SRS II vector series were 
capable o f transducing both haematopoietic and non-haematopoietic cell lines and 
expressing the transgene on the cell surface to detectable levels. Furthermore, the SIN 
vectors efficiently transduced primary murine ll2 rg '  HSCs and expressed human yc 
to functional levels that enabled both T and B cell differentiation in vitro. It was 
therefore decided to directly compare these vectors to the LTR-regulated vector in an 
in vivo setting using the SCID-X1 murine model. It has been previously demonstrated 
that human 'yc is able to form part o f functional murine interleukin receptors in vivo 
and that immunological reconstitution o f this model can be achieved by gene therapy 
(Lo et al., 1999; Soudais et al., 2000; Otsu et al., 2000a).
A protocol involving five days ex vivo incubation was used as outlined in figure 3.9. 
Briefly, lin' cells were harvested from ')c-deficient mice and prestimulated for forty- 
eight hours in serum-free media plus cytokines. The cells subsequently underwent two 
rounds of transduction with ecotropic retroviral particles over forty-eight hours using 
a method adapted from Li et al. (Li et al., 2003). On day five the transduced cells 
were harvested and injected into sub-lethally irradiated recipient Il2rg/'Rag2'/~c5~/' 
mice. Transplanted animals were maintained in pathogen-free environments for 
between three to five months to allow engraflment and repopulation, experimental 
animals were subsequently sacrificed and analysed for immune reconstitution.
ll2rgv RagZ/ c5^
Figure 3.9. E x vivo lin' transduction protocol. A schematic o f the ex vivo 
transduction protocol. Lin' cells isolated from Il2rgA mice were prestimulated over 
forty-eight hours before undergoing two rounds of transduction with ecotropic 
retrovirus over two days using an MOI o f between 1 and 2. The transduced cells 
were intravenously injected into sub-lethally irradiated Il2rg/'R agl/ c5'/' mice on 
day five.
Lin* cell
Retroviral 6Gy
transduction  x2
*  isolation * *
48hrs pre- Intravenous
H2rg7 stim ulation injection
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3.3.1 Lin'Transduction levels
To assess pre-transplant lin' transduction levels, on day five a proportion o f 
transduced cells were seeded in semi-solid media supplemented with murine 
cytokines and incubated at 37°C for two weeks. During this time progenitors or 
colony-forming units (CFUs) proliferated to form discrete colonies o f cells which 
were subsequently isolated and lysed for genomic DNA extraction. Colonies were 
then analysed by polymerase chain reaction (PCR) for the presence o f integrated 
vector using primers specific for the 'yc transgene, enabling calculation o f the 
proportion of transduced progenitor cells that were injected into the recipient mice. 
For SFFV-eGFP transduced cells, transduction efficiency was assayed by flow 
cytometry to measure the proportion o f eGFP+ cells in the population. It was not 
possible to assay the 'yc-retrovirally transduced cells by this method as the anti- 
CD 132-PE antibody appears not to recognise human 'yc in primary murine cells 
(personal observations). This might be due to the presence o f altered glycosylation 
patterns in murine cells or that the antibody is unable to recognise human 'yc when 
forming part o f heterologous murine interleukin receptors. Analysis of CFUs by PCR 
confirmed that high transduction levels were achieved for both the SIN vectors and 
the LTR-regulated vector, MFG 'yc (figure 3.10).
MFGyC SRS II SFyC SRS II EFSyC
Figure 3.10. Lin' transduction efficiency. (A) Pre-transplant CFU transduction 
efficiencies o f a representative lin' cell transduction. (B) Transduction efficiency for 
SFFV-eGFP transduced lin' cells was assayed by flow cytometric analysis.
SFFV-eGFP
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3.3.2 Detection of Circulating Lymphoid Cells in the Peripheral 
Blood of Transplanted Il2rg/~Rag2 /' c f  ' Mice
Fifteen to eighteen weeks post-transplant, samples o f peripheral blood from 
repopulated Il2 rg /'Rag2'/'c 5 /' mice were analysed for the presence o f circulating 
lymphoid cells by staining with antibodies to B (B220) and T (CD3) cell markers and 
analysis by flow cytometry. Peripheral blood from mice that had received Il2 rg A lin" 
cells transduced with the control vector, SFFV-eGFP, were also analysed for eGFP 
expression.
Circulating T and B lymphocytes were detected in the peripheral blood o f eight out o f 
eight mice that had received Il2rg~  lin" cells transduced with SRS II SF yc and in all 
six SRS II EFS yc mice (figure 3.11). Six out o f seven mice repopulated with cells 
transduced with MFG yc also had CD3+ and B220+ cells present in the periphery. 
Peripheral blood mononuclear cells from all animals were also stained for cell surface 
human yc expression (data not shown) however none was detected by flow cytometry, 
further confirming previous observations that the anti-CD 132 antibody does not 
function in the murine setting. Recipient mice that had been injected with Il2 rg A lin” 
cells transduced with the control SFFV-eGFP vector had no detectable circulating B 
or T lymphocytes; eGFP+ cells were however detected in the periphery o f two out o f 
four animals (figure 3.11). eGFP+ H2rg'A lin" cells would have no selective 
proliferative advantage in this murine model and therefore, since recipient mice had 
received only sub-lethal doses o f irradiation prior to injection, these data are expected.
These results indicate that the reconstitution o f peripheral blood T and B lymphocytes 
in experimental animals results directly from the engraftment o f 'yc-retrovirally 
transduced lin" cells. It is possible that poor engraftment levels were achieved in the 
single lymphocyte-null MFG 7 c transplanted mouse and/or that this animal may have 
received lower doses o f corrected cells as a result o f unsuccessful intravenous 
injection. These preliminary results also suggest that the novel self-inactivating 
gammaretroviral vectors are able restore lymphopoiesis in a SCID-X1 animal model 
at similar levels to the older LTR-driven retroviral vector currently proven effective in 
human gene therapy clinical trials.
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Figure 3.11. Reconstitution of circulating T and B lymphocytes in engrafted 
animals. (A) Restoration o f circulating T and B lymphocytes in Il2rg/'Rag2'/'c5'/' 
mice transplanted with 'yc-retrovirally transduced U2rg~ lin* cells. Peripheral blood 
mononuclear cells were stained with antibodies to CD3 (T cell marker) and B220 (B 
cell marker) and analysed by flow cytometry. Plots from one representative animal 
from each group are shown. The C57/B16 cells are from an untransplanted control 
animal. (B) No B or T cells were detected in mice that had received cells transduced 
with control vector SFFV-eGFP, however eGFP+ cells were detected in the 
periphery o f two out o f four animals.
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3.3.3 Splenic Weights and Cellularity of Transplanted lU rg^ R agl^  
c 5~a  Mice
Experimental animals were sacrificed approximately five months post-transplant for 
analysis o f lymphoid reconstitution. Spleens from experimental and control animals 
were removed and weighed before further analysis. The splenic weights and 
cellularity o f animals repopulated with SFFV-eGFP transduced Il2rg'A lin' cells were 
uniformly low, likely representing the absence of lymphocyte populations in these 
mice. In contrast, the splenic weights o f mice transplanted with 'yc-retrovirally 
transduced cells were increased in size and cellularity following gene therapy. This 
difference in both the mean weight and cellularity was statistically significant for the 
SRS II EFS 'yc group (figure 3.12). Two o f the three spleens taken from Il2rg~  donor 
animals were found to be enlarged, a phenomenon previously described for this 
mouse strain due to accumulation o f CD4+ cells and extramedullary haematopoiesis 
(Cao et al., 1995; Sharara et al., 1997). Similarly, one or two cases o f splenomegally 
were observed in each o f the groups o f mice that had received 'yc-retrovirally 
transduced cells.
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Figure 3.12. Splenic weights and cellularity of transplanted Il2rg~/~Rag2~/~c5~A 
mice. (A) Splenic weights and (B) cellularity are increased for mice repopulated 
with 'yc-retrovirally transduced cells as opposed to those that received SFFV-eGFP 
transduced cells, most likely due to lymphoid reconstitution. Bars represent the 
mean values for each group. (*, P<0.05; **, P<0.01)
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3.3.4 Flow Cytometric Analysis of Lymphoid Populations in the 
Spleen and Bone Marrow
Cells harvested from the spleens and bone marrow of transplanted mice were analysed 
for restoration o f lymphopoiesis by staining for a variety o f lymphocyte cell surface 
markers and analysis by flow cytometry.
Four to five months post-transplant, T, B and NK cell populations were detected in 
the spleens and bone marrow o f all SRS II EFS yc and SRS II SF yc treated mice, with 
similar levels o f lymphoid reconstitution also detected in six out o f seven MFG yc 
transplanted mice (table 3.1 and figure 3.13A). The percentages of recovered CD4+ 
and CD8+ T cells in the spleens o f SIN vector transplanted animals were found to be 
within similar ranges as those detected in mice transplanted with MFG *yc-transduced 
cells (table 3.1) and comparable to the levels detected in wild-type C57/B16 mice. 
Furthermore, splenic T lymphocyte CD4/CD8 ratios in the SEN vector transplant 
recipients were comparable to those in wild-type mice, and considerably lower than 
for I l2 r g ‘ donor mice which have increased CD4+ T cell numbers (data not shown) 
(DiSanto et al., 1995; Cao et al., 1995).
The presence o f mature B220+IgM+ B cells in the spleens and bone marrow o f treated 
mice, in particular indicates lymphocyte reconstitution as a direct result o f 
engraftment o f retrovirally-transduced lin' cells, since the 'yc-deficient donor strain is 
almost completely devoid o f mature B lymphocytes. Furthermore, the small 
percentage o f NK cells detected indicates restoration o f lymphopoiesis due to 
functional 'yc-mediated signalling in the reconstituted animals, this lineage being 
entirely absent in Il2rg ~ mice. B cell reconstitution in the SIN vector treated mice 
was found to be as efficient as for those mice that had received cells transduced with 
the LTR-regulated gammaretroviral vector (table 3.1).
No aberrant increases in lymphocyte or myeloid populations were detected by flow 
cytometry in mice that were noted to have enlarged spleens.
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In accordance with peripheral blood analysis, one o f the MFG yc transplanted mice 
(MFG 'yc 3) failed to reconstitute lymphocytes o f any lineage (data not shown). As 
previously discussed, poor reconstitution in this animal might be attributable to low 
levels o f engraftment following transplantation or to a low dose o f 'yc-corrected lin' 
cells as a result o f unsuccessful intravenous injection.
Animals that had received SFFV-eGFP transduced Il2rg'A lin' cells failed to develop 
CD4+ or CD8+ T lymphocytes or NK cells populations in either the spleen or bone 
marrow; however some B220+ B cells were detected. In two o f the four transplanted 
mice, a small percentage o f eGFP+ cells were detected in both these tissues, a 
proportion o f which appeared potentially to co-stain with CD3 or B220 lymphoid 
markers (figure 3.13B), although no CD3+ T cells were detected in the two mice that 
failed to develop eGFP+ cell populations. The B lymphocytes detected in these mice 
appeared mostly to be immature B2201o cell populations with only a small percentage 
in the spleen expressing the more mature B220hi cell surface marker (figure 3.13). 
These cells represent engraftment o f both transduced and untransduced I l2 r g '  donor 
lin' cells and highlights the ability o f early B lineage development in 'yc-deficient 
mice, even in the absence o f yc signalling.
____________________________CD4 %_________ CD8 %_______ B220 lgM% NK1.1 %
C57/BI6 <n = 3) 15.75 ±  0.9S 10.17 + 0.27 58.53  ± 0.4G 2 .49  ± 0.84
MFG (n = 6) 18.55 ±  2.69 5.47 ± 0.58 16.72 ± 3.28 0 .36 ±  0 .09
SRS II SF yc (n =  7)* 26.9 ±  5.92 9.66 ±  3.27 18.13 ±  4.01 0 .65 ± 0 . 1 7
SRS II EFS yc (n = 7)+ 16.83 + 1.87 6.92 +  1.19 20.31 ±  3.31 1 . 3 6 +  1.12
Results are presented as the mean % + SEM
* n = 6 for NK1.1 
+ n = 6 for B220 IgM
Table 3.1. Lymphoid reconstitution in the spleens of transplanted Il2rg~/'RagZ/~ 
c5^ ~ mice.
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Figure 3.13. Reconstitution of T, B and NK cell populations in the spleens and bone marrow of engrafted animals.
(A) Representative flow cytometry plots from the analysis of lymphocyte restoration in the spleen and bone marrow of Ittrg  
Rag2'/'c5'/' mice transplanted with '>c-retrovirally transduced U2rg lin' cells. CD4+ and CD8+ T cells and mature B220+IgM+ B 
cells present in the spleens of transplanted mice (first two rows). CD3+ T lymphocytes and NK1.1+ NK cells detected in the bone 
marrow of transplanted animals (bottom row). (B) Mice transplanted with SFFV-eGFP transduced cells failed to develop any T, 
NK or mature B cells. A small percentage eGFP+ cells were however detected in the spleens and bone marrow of two out o f four 
mice.
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3.3.5 Restoration of Thymopoiesis in Transplanted Il2rg'/~Rag2'/~c5~/' 
Mice
The recipient H2rg'/~Rag2~/'c5~/' strain are athymic under normal conditions due to the 
complete absence o f lymphopoiesis in these animals. Five months post-transplant 
however, thymi were clearly present in the majority o f reconstituted mice that had 
received *>c-retrovirally transduced donor cells, indicating restoration o f active 
thymopoiesis. Mice that had received donor cells transduced with the control vector, 
SFFV-eGFP, remained athymic, indicating that thymic development is likely due to 
restoration o f 'yc-signalling.
Staining of thymocytes with antibodies to T lymphocyte markers revealed similar 
percentages o f single positive (SP) and double positive (DP) T cells in wild-type 
C57/B16 mice and experimental mice reconstituted with either SIN or LTR-regulated 
retrovirally transduced cells (figure 3.14).
C57/BI6
Figure 3.14. Thym ic reconstitution in engrafted animals. Restoration o f 
thymopoiesis in U2rg'/'Rag2v'cS'/' mice transplanted with 'yc-retrovirally transduced 
H2rg/' lin' cells. Similar percentages o f DP and SP T lymphocytes are detected in 
the thymi o f experimental and wild-type C57/B16 mice. No thymi were present in 
mice transplanted with SFFV-eGFP transduced cells.
46 .3*
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3.3.5 Detection of Human yc Expression in the Bone Marrow of 
Transplanted Il2rg"/'Rag2'/'c5’/' Mice
To confirm expression o f the human yc transgene in reconstituted mice, Western blot 
analysis was performed on bone marrow cell lysates. Proteins were separated by SDS- 
PAGE, immunoblotted and probed with an anti-CD 132 antibody. Immunoblots were 
later re-probed with an antibody to P-actin to confirm the presence o f protein in all 
sample lanes. As shown in figure 3.15, protein bands detected by the anti-CD 132 
antibody were present in cell lysates from Il2rg~/'Rag2'/~c5'/~ mice transplanted with yc- 
retrovirally transduced lin* cells but not for animals that received SFFV-eGFP 
transduced cells; it must be noted however that the SFFV-eGFP protein sample was 
grossly underloaded, although a positive band is detected for the SRS II SF yc sample 
containing an equivalent low amount of protein. A dominant band o f approximately 68 
kDa was detected in all reconstituted mice, slightly larger than the 64 kDa isoform of 
yc previously detected in vitro (figure 3.2) possibly representing altered murine 
glycosylation patterns in vivo. Smaller bands were also detected by the anti-CD 132 
antibody, likely representing under-glycosylated precursor forms of the protein, as has 
been observed following Western blotting to detect yc expression on human neutrophils 
(Liu et al., 1994). These results indicate that for both the SIN vectors and the LTR- 
regulated vector, human yc is expressed at detectable levels in vivo in the bone marrow 
of reconstituted mice several months post-transplantation.
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Figure 3.15. Expression of human yc in the bone m arrow of transplanted
Il2 rg 'R a g T /~c5~/~ mice. Cell lysates from the bone marrow of transplanted Il2rg~ 
Rag2'/'c5 '' mice were separated by SDS-PAGE, immunoblotted and probed with an 
anti-CD 132 antibody. Bands probably representing glycosylated and under­
glycosylated forms of human yc are detected in the bone marrow of animals that 
received yc-retrovirally transduced cells. Control animals transplanted with SFFV- 
eGFP transduced cells had no detectable yc-positive bands indicating antibody 
specificity. The blot was also probed with an antibody to the 41 kDa p-actin protein 
(lower lane) to demonstrate protein loading in each lane. Results are shown for two 
representive mice for each of the MFG yc, SRS II EFS yc and SRS II SF yc groups.
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3.3.6 In Vitro Proliferation of Splenocytes from Transplanted 
Il2rg/~Rag2/ c5~/ Mice
To determine whether T lymphocytes present in the reconstituted ll2 rg /'Rag2'/'c5 '' 
mice expressed functional yc-containing receptor complexes, splenocytes were 
stimulated in vitro with the mitogen concanavalin A (Con A) alone or in the presence 
of the yc-dependent cytokine, IL-2. Splenocytes from MFG yc 3, SRS II SF yc 8 (found 
to have a low splenocyte count) and control SFFV-eGFP transplanted mice were not 
included in this assay due to insufficient cell numbers. Splenocyte proliferation was
'y
measured by H -thymidine incorporation and expressed as the mean stimulation index 
(stimulated average/unstimulated average) for each group. It is worth noting however 
that the basal proliferation levels for Il2rgf' mice and transplant recipients were 
significantly higher than for wild-type C57/B16 mice as also observed by Lo et al. (Lo 
et al., 1999). Consequently even though the absolute increase in proliferation was 
equivalent to that seen in C57/B16 animals for several experimental mice, the relative 
increase as expressed here is lower.
In all reconstituted Il2rg /'Rag2'/'c5'/' mice, T cells were capable o f proliferation in 
response to Con A at levels higher than those observed for splenocytes from Il2rg"  
donor mice (figure 3.16). These observations correlate with published data by Disanto 
et al. that thymocytes from l l2 r g ' mice fail to respond to Con A in vitro with or 
without IL-2 (DiSanto et al., 1995). In all but two o f the transplanted mice, IL-2 further 
stimulated the Con A mitogenic response, with significantly increased levels of 
proliferation observed for animals reconstituted with lin‘ cells transduced with either 
SIN vector (figure 3.16). These data demonstrate that SIN gammaretroviral human yc 
gene transfer in this model is able to restore expression o f functional IL-2 receptor 
complexes on murine T cells.
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Figure 3.16. Transplanted Il2rg'/'RagZ/'c5'/' mice exhibit mitogen-induced 
lymphocyte proliferation in vitro. Splenocytes from ll2rg 'Rag2'/'c5'/' transplant 
recipients and C57/B16 mice are able to proliferate in response to the mitogen, Con 
A. In all but two experimental mice, the proliferative response was increased in the 
presence o f IL-2, indicating the reconstitution of functional yc-containing interleukin 
receptors in these animals. The mean (+/-SD) stimulation indices for each 
experimental group are shown. (SD, standard deviation; *, P<0.05; **, P<0.01)
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3.3.7 Immunoglobulin levels in Transplanted IHrg'^Ragl '/'c5~/' Mice
To assess humoral immunity in reconstituted MFG yc and SRS II EFS yc mice (serum 
from reconstituted SRS II SF yc animals was unavailable for analysis) circulating 
plasma immunoglobulin levels were analysed by enzyme-linked immunosorbent assay 
(ELISA). Serum from Il2rg'f' donor mice was used as a control since the Il2rg~/'R ag2'' 
c5'f' recipient strain is alymphoid and hence unable to produce immunoglobulin, yc- 
deficient mice exhibit abnormal serum immunoglobulin levels reflecting the defective 
B cell development in these animals (Cao et al., 1995); in particular levels of IgGl and 
IgG2a are diminished in this model (figure 3.17). Following yc gene transfer however, 
levels of total IgG immunoglobulin (IgG) in the plasma of mice reconstituted with 
MFG yc or SRS II EFS yc retrovirally-transduced cells had increased as compared to 
levels in Il2rg f' donor mice (figure 3.17A). Furthermore, IgGl in the sera of these 
experimental mice were increased to levels comparable to those detected for wild-type 
C57/B16 animals (figure 3.17B). IgGl class-switching has been demonstrated to be 
dependent on IL-4 secreted by Th2 CD4+ T helper cells, hence these data in particular 
indicate restoration of both T lymphocyte function and yc-containing cytokine 
receptors in the reconstituted mice (Kuhn et al., 1991). Reconstitution of serum IgG2a 
appeared more efficient in the SRS II EFS yc mice, with IgG2a detectable in only one 
of the two MFG yc mice analysed (figure 3.17C). In this assay comparison to IgG2a 
levels in wild-type mice was not possible due to the antibody being unable to recognise 
the IgG2a allele present in C57/B16 animals.
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Figure 3.17. Serum immunoglobulin levels in transplanted Il2rg~/~Rag2'/~c5~/~ 
mice. (A) Total IgG, (B) IgGl or (C) IgG2a levels in the sera of reconstituted mice 
was assayed by ELISA. Levels o f IgG and IgGl in reconstituted MFG yc and SRS II 
EFS yc animals were found to be similar to those observed in normal C57/B16 mice. 
IgG2a was only detected in the sera of SRS II EFS yc reconstituted mice. Bars 
represent the mean values for each group. (*, PO .05; **, PO .O l; ***, P<0.001)
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3.3.8 Proviral Copy Number in Sorted Populations from 
T ransplanted Il2rg/~Rag2/~cS'/~ Mice
Lymphoid and myeloid populations from the spleen and thymus o f a representative 
Il2rg/'Rag2~/'c5~/' mouse transplanted with either MFG yc or SRS II SF yc transduced 
cells were sorted according to their cell surface markers. Genomic DNA was 
subsequently extracted and proviral copy number determined by quantitative real-time 
PCR using primers and Taqman probe specific for the human yc cDNA. Dilutions of 
the gammaretroviral plasmid, MFG yc, and a plasmid containing the murine tit in gene 
were used to produce standard curves within the assay against which copies of 
integrated provirus and cell number could be calculated respectively.
Provirus was detected in sorted splenic CD3+ T cells and IgM+ mature B cells from 
mice reconstituted with either MFG yc or SRS II SF yc transduced cells at low levels of 
less than one copy per cell, indicating the likelihood of untransduced Il2rg f donor lin' 
cells having also engrafted in these animals (figure 3.18A). Due to poor genomic DNA 
yield, proviral copy number in sorted myeloid C D llb  populations in the spleen were 
only determined for the SRS II SF yc reconstituted mice; proviral copy number was 
found to be extremely low in these myeloid populations representing the lack of 
selective engraftment potential of this lineage in the SCID-X1 setting. Provirus was 
also detected in sorted CD3+ and CD4+ T lymphocytes from the thymi o f SRS II SF yc 
reconstituted mice (figure 3.18B).
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Figure 3.18. Proviral copy number in sorted lymphoid and myeloid populations 
from transplanted Il2 rg /~RagT/~c5'/' mice. (A) Provirus was detected in sorted 
lymphoid populations from the spleens o f reconstituted mice. (B) Proviral copy 
number in sorted T lymphocyte populations from the thymus of an SRS II SF yc 
reconstituted mouse. Data shown represents one animal from each group.
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3.3.9 Proviral Copy Number in the Bone Marrow and Spleens of 
Transplanted Il2rg~/'Rag2~/~c5~/' Mice
Proviral copy number was also determined for unsorted cell populations from the 
spleens and bone marrow of experimental mice. Proviral copy number in the bone 
marrow was relatively low, less than 0.2 copies per cell for all experimental animals, 
indicating a high degree of chimerism between transduced and untransduced cells, 
likely as a result o f sub-lethal irradiation of recipient mice and the low multiplicity o f 
infection used (figure 3.19A). No large differences in proviral copy number were 
observed for mice that had received cells transduced with either the LTR-regulated 
vector or the SIN gammaretroviral vectors, although two mice in the SRS II SF yc 
group had the highest copy numbers recorded. Proviral copy number appeared to 
correlate with efficacy o f reconstitution, with the lowest copy number determined for 
the recipient MFG yc 3 (0.0001) which failed to reconstitute any lymphocytes in either 
tissue. Negligible yc-proviral copies were obtained for the bone marrow of control 
SFFV-eGFP mice.
Proviral copy number was determined to be slightly higher in the spleens of 
reconstituted mice for each group, with a range of 0.1-1.2 recorded for all animals that 
had restored lymphocyte populations (figure 3.19B). One experimental mouse from 
each SIN vector group was found to have a copy number greater than one, indicating 
the likelihood o f some cells in the spleens of these mice having more than one vector 
integration per cell. The higher copy numbers observed in the spleens o f experimental 
animals is likely due to the higher proportions of reconstituted lymphoid cells in this 
organ, interestingly the SRS II SF yc mouse with the highest copy number was found to 
have an enlarged spleen.
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Figure 3.19. Proviral copy number in the bone marrow and spleens of 
transplanted Il2 rg /~RagI/~c5~~ mice. Low proviral copy numbers were detected in 
the (A) bone marrow and (B) spleens o f reconstituted mice. Negligible yc-provirus 
was detected for control SFFV-eGFP transplanted animals
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3.3.10 Restoration of Lymphopoiesis in Secondary Transplant 
Recipients
To confirm that self-renewing haematopoietic progenitors were targeted during the 
original gene transfer protocol and hence demonstrate the longevity o f such a 
procedure, secondary transplants were performed. Ten million cells isolated from the 
bone marrow of reconstituted mice and wild-type C57/B16 mice were therefore 
transplanted into lethally irradiated Il2rg~/~Rag2~/~c5'/~ recipients of six to ten weeks of 
age. A single secondary transplant was performed from the SRS II SF yc, SRS II EFS 
yc and MFG yc primary ransplanted animals. Mice that had received secondary 
transplants were sacrificed for analysis approximately seven to eight months after 
transplantation; the recipient o f SRS II EFS yc reconstituted bone marrow was 
sacrificed only eight weeks post-transplant due to the onset of wasting and colitis-like 
symptoms. Spleens, thymi and bone marrow were harvested from each animal for 
analysis by flow cytometry and proviral copy number.
3.3.10.1 Flow Cytometric Analysis of the Spleens and Bone Marrow 
from Secondary Transplant Recipients
As for the initial reconstituted animals, splenocytes and bone marrow cells from the 
secondary transplant recipients were stained with antibodies for a variety of 
lymphocyte and myeloid cell surface markers and analysed by flow cytometry. In all 
secondary transplant recipients, except those that received bone marrow from SFFV- 
eGFP control mice, CD4+ and CD8+ T lymphocyte populations were restored in the 
spleen and bone marrow (figure 3.20). Reconstitution of the B cell compartment in 
these mice appeared less efficient, with mature B220+IgM+ B cells detectable only for 
SRS II SF yc and SRS II EFS yc secondary transplant recipients. The population of 
immature B220+ B lymphocytes detected in the MFG yc secondary transplant recipient 
was comparable to the B220+ populations observed in mice that received SFFV-eGFP 
bone marrow, thus it is likely that the origin o f these cells are untransduced donor lUrg  
A precursors. As with B lymphocyte reconstitution, restoration o f NK cells was most
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efficient in the SRS II EFS yc secondary transplant recipient, with NK1.1+ populations 
detectable in both the bone marrow and spleen. In all secondary transplant recipients 
the percentage of splenic myeloid CD1 lb + cells was noted to be increased as compared 
to mice transplanted with C57/B16 bone marrow. This trend was also observed in 
SFFV-eGFP secondary transplants however, thus it unlikely that these populations 
result from yc-transduced cells. No eGFP+ cells were detected in SFFV-eGFP 
transplant recipients, likely due to the lack o f selective engraftment potential of 
transduced cells in the primary transplanted mice being further reinforced in the 
secondary transplant recipients (figure 3.20B).
These results demonstrate the successful transduction and engraftment of 
haematopoietic progenitor cells with pluripotent potential by the SIN gammaretroviral 
vectors in the original transplant recipients, since bone marrow from these mice was 
able to restore T, B and NK cell populations in alymphoid secondary transplant 
recipients. It is possible that only transduced committed lymphoid precursors were 
originally transplanted in the MFG yc mouse from which the secondary transplant was 
performed as B lymphopoiesis was not restored.
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Figure 3.20. Reconstitution of lymphoid populations in the spleens of secondary transplant recipients. (A) Representative flow cytometry 
plots from the analysis of lymphocyte restoration in the spleens of secondary transplant recipients. Bone marrow from a wild-type C57/B16 
mouse was transplanted into Il2rg/R agI/'c5~/~ recipients to serve as controls. CD4+ and CD8+ T cells were detected in the spleens of all 
secondary transplant recipients, whilst mature B220+IgM+ B cells were only present in the spleens of mice that had received SRS II SF yc and 
SRS II EFS 'yc bone marrow (first two rows). NK cell reconstitution was most efficient in the SRS II EFS 'yc secondary transplant recipient (third 
row). An increase in the C D llb+ myeloid fraction was observed in the spleens of all secondary transplant recipients, (bottom row) (B) Mice 
transplanted with SFFV-eGFP bone marrow failed to develop any T, NK or mature B cells.
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3.3.10.2 Flow Cytometric Analysis of Thymocytes from Secondary 
Transplant Recipients
At the time o f sacrifice, small thymi were present in 'yc-secondary transplant recipients 
and C57/B16 transplanted mice, which were removed for analysis. The absence of 
detectable thymic organs in SFFV-eGFP secondary transplant recipients indicates that 
restored thymopoiesis in these mice is due to the engraftment o f />c-transduced 
progenitors. Thymocytes were stained with antibodies to T lymphocyte markers and 
subsequently analysed by flow cytometry (figure 3.21). Normal thymic staining, 
revealing a majority of double positive (DP) CD4+ CD8+ thymocytes differentiating 
into single positive (SP) T lymphocytes, was only observed for the SRS II EFS 'yc 
secondary transplant recipient. In all other transplanted mice only single CD4+ or CD8+ 
T cells could be detected, indicating cessation of active thymopoiesis at the time o f 
analysis. This halt in T cell development might have resulted from the engraftment of 
committed 'yc-corrected lymphoid progenitors in these mice that lack the capacity for 
self-renewal or transgene silencing in the engrafted transduced progenitors. The SRS II 
EFS “yc secondary transplant recipient, in which both DP and SP thymocytes were 
detected, was sacrificed only eight weeks post-transplant, approximately 5 months prior 
to remainder of the cohort. It is therefore possible that active thympoiesis in this animal 
may too have been finite.
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Figure 3.21. Flow cytometry of thymocytes from  secondary transp lan t 
recipients. DP and SP thymocytes were detected only in the thymi o f the SRS II 
EFS yc secondary transplant and C57/B16 transplanted mice.
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3.3.10.3 Proviral Copy Number Analysis in the Spleens and Bone 
Marrow of Secondary Transplant Recipients
Proviral copy number was determined by quantitative real-time PCR for both the 
spleens and bone marrow of secondary transplant recipients using the same primers and 
standards as for the analysis o f the initial transplanted mice. Integrated provirus was 
detected for all mice transplanted with bone marrow from 'yc-reconstituted primary 
animals, with proviral copy number detected at the same orders o f magnitude in the 
bone marrow o f both primary and secondary transplant recipients (proviral copy 
number in the bone marrow o f the SRS II EFS yc secondary transplant recipient was 
not estimated due to poor genomic DNA yield) (figure3.22A). Proviral copy numbers 
in the spleens o f the secondary transplant recipients were however found to be a log 
lower than estimated for the donor reconstituted mice (3.22B). These data likely reflect 
the decreased numbers o f splenic lymphocytes in the secondary transplant recipients 
due to poor B cell reconstitution. These results also confirm the likelihood that the 
increased CD1 lb + myeloid populations observed in the spleens o f the transplanted mice 
are not due to expansions o f  ^ -transduced cells.
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Figure 3.22. Proviral copy number in the spleens and bone marrow of 
secondary transplant recipients. Provirus was detected at low copy number in the 
(A) bone marrow and (B) spleens o f secondary transplant recipients. Copy numbers 
in the spleens o f the transplanted mice were found to be decreased as compared to 
the donor primary transplant recipients. Negligible Tc-provirus was detected for 
SFFV-eGFP secondary transplant recipients.
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3.3.11 Failure of T Cell Development in Older Engrafted Il2rgAR a g IA 
c 5~a  Mice
Transplantation o f a cohort o f older recipient Il2rg'Rag2~/~c5~/~ mice with SIN 
gammaretrovirally transduced cells failed to restore T lymphocyte populations in five 
out o f six mice. This trend correlates well with results from the human SCID-X1 gene 
therapy trial, in which two older treated patients failed to undergo lymphoid 
reconstitution following transplantation o f '■yc-retrovirally transduced HSCs (Thrasher et 
al., 2005).
3.3.11.1 Peripheral Blood Analysis of Transplanted Older Il2rg'AR a g I  
Ac$ A Mice
Twelve week old sub-lethally irradiated Il2rg /~Rag2~/~c5~/~ mice were transplanted with 
SIN gammaretrovirally transduced Il2rg~  lin' cells (recipient mice in all other cohorts 
were injected at six to ten weeks o f age) the protocol and gammaretroviral preparations 
used to transduce the donor HSCs were identical to those used previously to 
successfully reconstitute the younger recipient mice. Samples o f peripheral blood were 
taken for analysis three months post-transplant, stained for lymphocyte markers and 
analysed by flow cytometry for the reconstitution of circulating lymphoid cells.
In four o f five SRS II EFS 'yc recipients and in one SRS II SF 7 c mouse, CD3+ T cells 
were absent from the periphery at the time o f analysis. Circulating B220+ B 
lymphocytes were detected in all older recipient mice however, at levels comparable to 
wild-type mice indicating potential partial lymphoid reconstitution (figure 3.23). The 
remaining SRS II EFS yc transplanted mouse had both CD3+ and B220+ populations 
present in the peripheral blood (data not shown) and appeared to have undergone full 
lymphoid reconstitution as observed in younger recipient mice.
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Figure 3.23. T lymphocytes are absent from the periphery following 
transplantation of older Il2rg'ARagZAc5^' recipients. Peripheral blood from 
transplanted mice was stained with antibodies to T (CD3) and B (B220) cell markers 
three months post-infusion of transduced cells. Only B cells were present in the 
periphery o f five out of six older transplanted mice. An example flow cytometric 
plot o f one o f the SRS II EFS 'yc transplanted mice that failed to reconstitute 
circulating T lymphocytes is shown.
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3.3.11.2 Decreased Splenic Weight and Cellularity in Older 
Transplanted Il2rg ARag2 /~c5~A Mice
Transplanted mice were sacrificed five months post-injection for analysis o f lymphoid 
reconstitution. Spleens recovered from the five partially reconstituted mice were found 
to be significantly decreased in size and cellularity as compared to the majority o f 
spleens recovered from the younger transplanted animals which had recovered T and B 
lymphocytes (figure 3.24). These organs likely reflect the absence o f T lymphoid 
reconstitution in the five older transplanted recipients. The spleen recovered from the 
SRS II EFS yc recipient found to have circulating T and B cells was also increased in 
size and cellularity as compared to remainder o f the cohort.
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Figure 3.24. Splenic weight and cellularity is decreased in older transplanted
Il2rg/'RagT/'c5'/' mice. (A) Splenic weights and (B) cellularity are on average 
decreased in recipient mice transplanted at twelve weeks o f age due to the failure o f 
T lymphoid reconstitution. Bars represent the means for each group. (*, P<0.05)
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3.3.11.3 Flow Cytometric Analysis of Lymphocyte Reconstitution in 
the Spleens and Bone Marrow of Older Transplanted 
Il2rg/'RagT/'c5'/' Mice
Cells isolated from the spleens and bone marrow of the transplanted mice were stained 
with the same antibodies to lymphoid and myeloid cell surface markers as used 
previously and analysed by flow cytometry. In five o f the six older transplanted mice, T 
cells were undetectable in both the spleens and bone marrow confirming the results 
from the peripheral blood analysis (figure 3.25). Concurrent with these observations, 
thymi were undetectable in all five o f these mice. B220+ B lymphocytes were detected 
in both organs for all six transplanted older mice however. In the five partially 
reconstituted animals mature B220+IgM+ B cells were present, but at significantly 
lower levels than in wild-type C57/B16 animals or the immunologically reconstituted 
mice. NK cells were also detectable in the bone marrow of the older recipient mice 
indicating that in this murine model, reconstitution o f the T cell compartment appears 
to be directly related to age at transplantation. CD l ib  myeloid populations in all 
transplanted mice appeared normal (data not shown).
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Figure 3.25. Flow cytometric analysis of bone marrow cells from  older 
transplanted Il2rg/'Rag2v~c5'/~ mice. Bone marrow cells from transplanted mice 
were stained with antibodies to lymphocyte markers and analysed by flow 
cytometry. Five out o f six older recipient mice failed to reconstitute the T cell 
compartment five months post-transplantation. Data from two representative mice
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3.3.11.4 Failure of Immunoglobulin Isotype Switching in Older 
Transplanted Il2rg~/'Rag?/'c5~/' Mice
Serum immunoglobulin levels were analysed by ELISA as for the other experimental 
cohorts. Isotype switching was restored in only one out o f six older transplanted mice, 
the sole SRS II EFS yc transplanted animal that developed both T and B cells following 
gene therapy (figure 3.26). The levels o f immunoglobulin detected in this mouse were 
comparable to the levels seen in the younger transplanted mice and the differences are 
particularly striking for the results from the IgGl and IgG2a ELIS As (figure 3.26). For 
the five older transplanted Il2rg'/~Rag2'/'c5'/' mice in which only B cell development 
was recovered, isotype switching appeared impaired with negligible levels o f IgGl and 
IgG2a detectable in the circulating plasma. These results correlate with the flow 
cytometric data indicating an absence o f T helper cells in these mice.
Figure 3.26. Immunoglobulin levels in the sera of older transplanted IUrg^"
Rag2'/c5~A mice. (A) Total IgG, (B) IgGl or (C) IgG2a levels in the sera o f  the older 
transplant recipients was assayed by ELISA. Five out o f six older transplanted Il2rg 
/'Rag2'/c5~/~ mice were unable to undergo isotype switching. The results for the SRS 
II EFS yc older recipient that reconstituted both T and B lymphocytes are underlined 
in red. Data is compared to the serum levels from the SRS II EFS "yc reconstituted 
younger mice that were analysed within the same assay. Bars represent the mean 
values for each group. (*, P<0.05)
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3.3.11.5 Proviral Copy Number Analysis in the Spleens and Bone 
Marrow of Older Transplanted Il2rg/'Rag2'/'c5‘/~ Mice
Quantitative real-time PCR was used to estimate proviral copy number in the spleens 
and bone marrow of transplanted older recipient mice using the same primer sets and 
standards as previously. The highest copy number observed for both tissues was from 
the sole SRS II EFS yc older transplant recipient that reconstituted both T and B 
lymphocytes (figure 3.27A&B). These results confirm that the development o f both 
sets o f lymphoid populations in this mouse is directly linked to increased proviral copy 
number and thus that the lymphocytes are likely to have originated from vector 
transduced precursors.
On the whole, proviral copy number correlates with efficacy o f reconstitution, with the 
copy numbers detected in the spleens and bone marrow o f the partially reconstituted 
five older transplanted mice on average lower than observed for the younger transplant 
recipients with restored T and B lymphocyte development (figure 3.27C).
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Figure 3.27. Proviral copy number in the spleens and bone marrow of older 
transplanted Il2rg'/~Rag2~lc5~/~ mice. Proviral copy number in the (A) bone marrow 
and (B) spleens o f older transplanted Il2rg /~Rag2~lc5'/ mice. The results for the SRS 
II EFS 'yc older recipient that reconstituted both T and B lymphocytes are underlined 
in red. (C) Proviral copy number correlates with efficacy o f reconstitution with the 
average vector copies being higher in both tissues in mice (younger transplant 
recipients and the one older transplant recipient) that developed both T and B 
lymphocytes post-transplantation as opposed to the five older transplant recipients 
which reconstituted B cells only. Columns represent the means (+/-SD) o f each 
group. (SD, standard deviation; n, number o f mice)
148
Chapter Three
3.4 Conclusions
From the above data it is possible to conclude that the self-inactivating 
gammaretroviral SRS II vector series is able to efficiently transduce both immortalised 
and primary cells and express the human yc transgene on the cell surface. Both SRS II 
SF yc and SRS II EFS yc expressed the transgene to functional levels in murine yc- 
deficient haematopoietic precursors enabling in vitro lymphoid differentiation. 
Furthermore, the results demonstrate that transplantation of SIN vector transduced 
Il2rgf' lin" cells in alymphoid recipient mice enabled reconstitution of all lymphocyte 
lineages (for a summary of all in vivo experiments see Appendix 10). Immunity in these 
mice appeared restored; T cells were able to proliferate ex vivo in response to mitogens 
and at increased levels in the presence o f a yc-dependent cytokine. SRS II EFS yc 
reconstituted mice had increased levels of serum immunoglobulin and the presence of 
IgGl in the plasma demonstrated isotype switching in response to the yc-dependent 
cytokine IL-4.
The ex vivo lin' transduction protocol resulted in high transduction efficiencies whilst 
maintaining stem cell pluripotency, as secondary transplant recipients exhibited 
complete or partial immunological reconstitution. Copy numbers in the spleens and 
bone marrow of both primary and secondary transplant recipients were comparable for 
all vectors and found to be low. Furthermore, proviral copies in homogeneous sorted 
cell populations from several experimental mice were less than one, indicating only a 
single vector integration per cell in the engrafted gene-corrected HSCs and their 
progeny. Low proviral copy number is an important factor in terms o f safety of the 
gene therapy procedure, decreasing the likelihood of insertional mutagenesis by 
minimising the number of potentially hazardous integration events. The selective 
engraftment advantage of yc-corrected cells in the SCID-X1 model means that even in 
the setting of sub-lethal irradiation and low copy number phenotypic correction is 
acheived. This engraftment advantage was evident in reconstituted mice, since sorted 
myeloid C D llb + populations were found to harbour negligible proviral DNA as 
compared to sorted lymphoid lineages.
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Age at transplantation was found to be an important factor in terms o f restoration o f T 
cell immunity in the SCID-X1 murine model. Five out o f six animals in a cohort of 
Il2rg'/~Rag2'/~c5'/~ mice transplanted at 12 weeks o f age failed to reconstitute the T cell 
compartment, whilst B and NK cell populations were detected. These results correlate 
with the failure o f gene therapy for SCID-X1 in two older patients enrolled in the 
clinical trial (Thrasher et al., 2005). It is postulated that in these patients the capacity to 
initiate thympoiesis is likely to be time-dependent since the absence o f ongoing 
thymocyte and thymic epithelial cell interaction results in potentially irreversible 
disorganisation of thymic architecture and hypoplasia (Hale et al., 2004; Hollander et 
al., 1995; van et al., 2000). It is therefore likely that the T cell developmental failure in 
the older transplanted SCID mice is also attributable to irreversible disruption o f the 
thymic architecture due to the prolonged absence of ongoing thymopoiesis in these 
animals; particularly given that other lymphoid lineages were restored.
In conclusion, the self-inactivating design does not appear to impact on efficacy of 
transgene expression or immunological reconstitution following engraftment of 
retrovially transduced l t t r g 1 lin" cells in a SCID-X1 mouse model. Effective 
immunological reconstitution was observed for both viral (SFFV) and endogenous 
(EFS) promoter elements regulating human yc expression at comparable levels to those 
observed with the clinical LTR-regulated vector. Moreover, restoration o f humoral 
immunity appeared most efficient in mice reconstituted with SRS II EFS yc transduced 
cells as compared to the MFG yc group. However future cohorts will need to be set up 
to confirm these findings and to analyse immunoglobulin levels in SRS II SF yc 
reconstituted mice. These SIN gammaretroviral vectors therefore present potentially 
safer alternative vectors for gene therapy of SCID-X1 having been demonstrated to be 
equally effective in this pre-clinical model o f the disease. The less potent endogenous 
EFS promoter in particular provides a potentially less mutagenic alternative vector, 
being theoretically less likely to exert enhancer effects on nearby genes following 
proviral integration. Incorporation o f this promoter, comprised o f endogenous 
regulatory sequences, offers the further advantage that it is less likely cause an immune 
response, as opposed to viral promoters, that might result in transgene silencing (Qin et 
al., 1997).
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3.5 Final Conclusions
• The SRS II series o f gammaretroviral SIN vectors are able to efficiently 
transduce both haematopoietic and non-haematopoietic cell lines
• The SRS II vector series are able to restore the lymphoid differentiation 
potential of Il2rg'f' haematopoietic progenitor cells in vitro to similar levels as 
MFG yc
•  The SRS II series o f vectors were able to restore immunity in the SCID-X1 
mouse model following ex vivo gene therapy
• Pluripotent HSCs were targeted during the ex vivo lin" transduction protocol by 
the SIN gammaretroviral vectors
• Reconstitution of the T lymphoid compartment following gene therapy o f the 
SCID-X1 murine model is time-dependent
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Cloning and Analysis of the Human I L 2 R G
Promoter
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4.0 Aims
• To identify the conserved regulatory sequences upstream of the human IL2RG
gene and clone the promoter sequence into lentiviral vectors
• To analyse the tissue-specificity of the IL2RG  promoter in the context o f a
lentiviral vector regulating eGFP expression in a variety o f cell lines
• To analyse the tissue-specificity of the IL2RG promoter in vivo following
injection o f concentrated lentivirus into neonatal mice
4.1 Introduction
Whilst the SIN design confers a potential increase in vector safety by eliminating the 
potent dual viral promoter/enhancer LTR sequences, the choice of internal promoter 
remains an important factor when considering the mutagenic potential o f retroviral 
vectors for gene therapy. Firstly, transgene expression must be regulated to a level that 
enables phenotypic correction of the disorder to be treated whilst avoiding aberrant 
transgene expression that may contribute towards cellular transformation. This was not 
considered to be a potential risk with regards the treatment o f SCID-X1 however, since 
yc is unable to signal in the absence of other cytokine receptor components (Nakamura 
et al., 1994). A second consideration regarding the selection of an internal promoter is 
whether or not it is likely to exert enhancer effects on endogenous genes and thus 
trigger insertional mutagenesis. An ideal promoter for a gene therapy vector might 
therefore consist o f endogenous regulatory elements, thus enabling physiological 
expression of the transgene following proviral integration. This might be particularly 
significant in HSC targeted gene therapy resulting in transgene expression being 
regulated to appropriate levels during the different stages of development and hence 
decreasing the likelihood that aberrant expression might lead to oncogenic events. In 
particular, this approach might be feasible in the SCID-X1 setting whereby gene- 
marked progenitors exhibit a selective growth advantage. It was therefore decided to 
develop and test a self-inactivating lentiviral vector for SCID-X1 incorporating the 
endogenous IL2RG regulatory elements as an additional safety feature.
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4.2 Development of SIN Lentiviral Vectors Incorporating 
the IL2RG Promoter
4.2.1 Identification of IL2RG  Regulatory Sequences Conserved 
Between Human and Mouse
Promoter activity within the sequences 5’ to the IL2RG  gene was first described by 
Noguchi et al. (Noguchi et al., 1993a); a 600bp fragment 5 ’ to the transcription 
initiation site cloned upstream o f a luciferase reporter gene exhibited increased levels 
o f expression in Jurkat cells. Further characterisation of this region demonstrated 
minimal promoter activity within a fragment from 58 to 80 nucleotides upstream o f  the 
transcriptional start site incorporating a putative Ets binding site (figure 4.1) (Ohbo et 
al., 1995); the Ets family o f transcription factors are particularly implicated in the 
control o f expression of a large number o f genes in haematopoietic cells, especially 
during lymphoid development (Anderson et al., 1999). A later paper confirmed this site 
as critical for promoter activity, and also present in the murine Il2rg  promoter 
(Markiewicz et al., 1996). This work in addition characterised a -1053/+34 region and a 
series o f 5’ deletion constructs that exhibited promoter activity in cells o f 
haematopoietic origin only. Three other potential regulatory motifs, a second putative 
Ets binding site located 55 bp upstream o f the transcriptional start site, a GT-box and a 
TATA-like sequence at -88 were all characterised as non-essential for basal promoter 
activity (figure 4.1) (Markiewicz et al., 1996).
1 1 0 1  CTCTGTAAAG CCCTGGTTTA TAAGGTTCTT TCCACCGGAA GCTATGACAG
TATA like Ets
1 1 5 1  AGGAAACGTG T GGGTGGGGA GGGGTAGTGG GTGAGGGACC CAGGTTCCTG 
Ets GT Box
*  *  *
12  01  ACACAGACAG ACTACACCCA GGGAATGAAG AGCAAGCGCC A T G  
♦1
Figure 4.1. The minimal IL2RG  promoter region. The -104/+39 region 
encompassing the IL2RG  minimal promoter. The Ets binding site critical for 
promoter activity is shown in blue, all putative binding sites in black are non- 
essential for promoter activity. The three identified transcriptional start sites are 
marked with *, with the strong initiation start marked with +1. The ATG start codon 
is shown in red.
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To ensure that all putative significant regulatory sequences were identified prior to 
incorporation o f the promoter into lentiviral vectors, alignments between the region 5’ 
o f the human and murine yc genes were performed. The human and murine genes 
encoding yc exhibit 69% and 70% homology at the nucleotide and amino acid level 
respectively (Cao et al., 1993), it is therefore likely that important regulatory sequences 
upstream of these genes will be similarly conserved throughout evolution. Analyses 
were performed using a multiple sequence local alignment and visualisation tool 
(Mulan, http://mulan.dcode.org). The initial analysis aligned 20 kb o f  DNA directly 
upstream of the ATG start codons, identifying two areas o f significant homology 
represented on the dot plot as diagonal lines (figure 4.2A). The first representing a 
stretch o f DNA approximately 1.3 kb directly upstream of the yc genes and likely 
representing regulatory sequences comprising the IL2RG  promoter, including those 
already identified (Noguchi et al., 1993a; Ohbo et al., 1995; Markiewicz et al., 1996). 
The second area o f homology, located 7 kb downstream of the human and murine 'yc 
coding regions, represents an unrelated gene, MED 12, encoding a transcriptional 
coactivator (Mediator o f RNA polymerase II transcriptional subunit 12), and most 
likely its promoter elements, found in the reverse orientation within both genomes and 
also highly conserved. The area showing no significant homology between these two 
regions likely signifies that all non-redundant regulatory elements that comprise the 
endogenous 'yc promoters in both humans and mice are located proximal to the coding 
regions, within the first 1.3 kb directly upstream of the translational start sites.
To characterise the promoter region further, the 7 kb between the human IL2RG  and 
MED12 coding regions was analysed for both CpG content and the presence o f  Alu 
sequences (figure 4.2B). Approximately 1% of the human genome is comprised o f 
methylation-free sequences rich in CpG dinucleotides referred to as CpG islands (Bird, 
1986). CpG islands are associated with the promoter regions o f most housekeeping 
genes, however these sequences have also been identified within the 5 ’ flanking regions 
of tissue-specific genes such as human a-globin (Bird et al., 1987). Analysis o f the 7 kb 
intergenic sequence using the online CpG plot tool (www.ebi.ac.uk/emboss/cpgplot) 
predicted a single 247 bp CpG island, approximately 3.2 kb upstream o f IL2RG\ 
consequently the sequences thus far characterised as the IL2RG  promoter and those that 
retain cross-species homology are not CpG rich (figure 4.2B). Analysis o f  the
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corresponding region o f DNA from the murine genome failed to identify any putative 
CpG islands (data not shown). The equidistance o f the putative CpG island between the 
IL2RG  and MED12 coding regions indicates potential functionality in the regulation o f 
either or both genes, however, based on published evidence this sequence does not 
appear to be required for basal IL2RG  promoter function (Ohbo et al., 1995; 
Markiewicz et al., 1996).
A significant fraction o f DNA is comprised o f short interspersed repeats (SINEs) such 
as those o f the non-autonomous retroelement, Alu. The human genome contains over 
one million Alu sequences, the non-uniform distribution o f which implies a potential 
role in gene regulation since regions upstream of transcriptional start sites are enriched 
with Alu elements and these sequences contain putative transcription factor binding 
sites (Polak and Domany, 2006). Using the online RepeatMasker tool 
(www.repeatmasker.org), the 7 kb stretch o f DNA between the IL2RG  and MED 12 
genes was found to be enriched for these sequences, 41% of the DNA being comprised 
o f 11 Alu elements (figure 4.2B). O f these sequences, 44% are located within the 1.5- 
3.5 kb o f DNA closest to the IL2RG  promoter, however, as for the putative CpG island, 
these elements do not appear crucial for basal promoter activity since they lie upstream 
of the sequences homologous between the human and murine genomes and o f  the 
regions previously characterised as containing promoter activity (Ohbo et al., 1995; 
Markiewicz et al., 1996).
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A. Human Sequence
20k
1.5kb
B.
K.2RG
0 kb
P u ta tiv e  C pG  Is la n d s
2000 4000 
Bom  Number
Alu S e q u e n c e s
6000
MED12
7 kb
Figure 4.2. Homologous regions within 20 kb upstream of the human and 
murine 7 c genes. (A.) 20 kb o f DNA upstream of the human and murine 7 c 
translational start sites was aligned using Mulan. The results are visualised as a dot 
plot, whereby homologous regions are represented by diagonal lines. Two areas o f 
homology are observed; the first encompassing approximately 1.5kb upstream o f the 
7 c genes and likely representing the promoter regions and the second corresponding 
to an unrelated gene, MED12, in the reverse orientation to IL2RG  (*, ATG start 
codons). (B.) A putative CpG island is located approximately 3.2 kb upstream o f the 
IL2RG  start codon in the human genome. The 7 kb o f DNA between the human 
IL2RG and MEDJ2 coding regions is rich in Alu sequences.
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In order to analyse the region upstream o f the human and murine IL2RG  genes in more 
detail, a second alignment was performed contrasting only 2 kb o f sequence upstream 
of the translational start sites. This second analysis identified two regions o f close 
homology 1.2 kb immediately upstream of the ATG start codons, and a third, smaller 
region found to be homologous to the reverse complement in the DNA possibly 
signifying a repeat sequence (figure 4.3A). In particular this alignment revealed two 
highly conserved regions o f 94% and 92% homology within 91 bp upstream o f  the 
previously characterised transcriptional start site (Noguchi et al., 1993a). These almost 
identical sequences correlate with findings that this region incorporates the minimal 
IL2RG  promoter in humans (Ohbo et al., 1995; Markiewicz et al., 1996), and most 
likely also in mice. The latter region also encodes the Ets binding site demonstrated to 
be crucial for promoter activity (figure 4.3A) (Markiewicz et al., 1996). To date, 
experiments to characterise the IL2RG  promoter have used constructs encompassing 
between 669 and 1089 bp o f sequence upstream o f translational start site (Ohbo et al., 
1995; Markiewicz et al., 1996), however this alignment reveals a further 98 bp o f 
sequence 5’ to the 'yc gene that shows significant homology to the corresponding region 
in the murine genome and hence implies a potential regulatory role. Analysis o f 
conserved transcription factor binding sites between the two species was performed 
using the MultiTF tool (http://multitf.dcode.org) (figure 4.3B). Several putative binding 
sites were identified within the regions of homology along the 2kb upstream o f the 'yc 
genes. Within the 98 bp o f sequence thus far omitted in IL2RG  promoter studies, five 
conserved potential transcription factor binding sites were identified, o f which one, the 
putative MZF1 site, is implicated in early haematopoiesis (Gaboli et al., 2001). 
Furthermore, in the 40 bp directly upstream of this stretch o f DNA within the area 
homologous to the reverse complement in the murine sequence, a further five potential 
transcription factor binding sites were identified. These binding sites also imply a 
regulatory role for this third region o f homology; in particular an Ets2 binding site is 
conserved, which, together with Etsl is thought to be expressed during T cell 
development (Anderson et al., 1999). It was therefore decided to clone the entire 1.24 
kb region upstream of the IL2RG  gene translational start site (-1164/+36 relative to the 
transcriptional start site) into lentiviral vectors representing potentially all o f the 
endogenous sequence regulating 'yc expression in humans.
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Figure 4.3. The homology between the 2 kb upstream of the hum an and m urine 
yc genes. (A) Alignment o f the 2 kb of DNA immediately upstream o f the human 
and murine yc coding regions reveals two regions o f close homology directly 
upstream of the ATG start codons, and a third region homologous to the murine 
reverse complement. (B) Putative transcription factor binding sites conserved within 
the homologous regions were identified using MultiTF. The critical Ets binding site 
in the basal promoter (recognised here as two potential overlapping sites) is 
underlined in red. The additional binding sites incorporated into the 1.24 kb IL2RG 
promoter for use in lentiviral vectors are bracketed. (*, ATG start codons).
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4.2.2 Cloning of the Human IL2RG Promoter
To construct a lentiviral vector containing 'yc regulated by its endogenous promoter the 
SFFV LTR was excised from SIN LV SF 'yc (figure 1.7) by digestion with Xhol and 
BamHl and the IL2RG promoter was amplified by PCR using Pfu (a proof-reading 
DNA polymerase) from human genomic DNA using primers containing sites for these 
endonucleases at their 5’ ends (figure 4.4A). Due to difficulties encountered in 
attempting to clone into the Xhol site, following digestion with this enzyme the vector 
was treated with Klenow to fill in the 5’ overhang and create a blunt end. The SFFV 
LTR was subsequently excised from the vector backbone by BamHl digestion. 
Following amplification of the IL2RG promoter, the 1.24 kb product was digested with 
BamHl only, PCR using Pfu DNA polymerase yields DNA fragments with blunt ends, 
and successfully ligated into the lentiviral vector to create SINLV tcP 'yc (figure 4.4B).
A second construct incorporating the IL2RG promoter regulating an eGFP expression 
cassette was created for use as a control vector and for analysis o f promoter tissue 
specificity. IL2RG was amplified from human genomic DNA using primers that created 
EcoRl and BamHl recognition sites at the 5’ and 3’ ends o f the PCR product 
respectively. Digestion of SINLV SF eGFP (figure 1.7) with these enzymes enabled 
excision of the SFFV LTR and subsequent ligation to the similarly digested IL2RG  
promoter fragment to create SINLV 'ycP eGFP (figure 4.4B). Sequencing o f the IL2RG  
promoter from both lentiviral vectors was performed (data not shown).
1650bp ■
1000bp
SINLV r c P r cPPT
U5 R U3
SINLV ycP eGFP
US R U3
IL2RGP IL2RG W PK t
cPPT
IL2RGP eGFP WPRE
AU3 R U5
403 R 05
Figure 4.4. Lentiviral constructs incorporating the IL2RG  prom oter. (A) PCR of
the 1.24 kb IL2RG promoter region from human genomic DNA. (B) Lentiviral 
constructs containing the cloned IL2RG promoter.
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4.3 Analysis of the Tissue-Specificity of the IL2RG 
Promoter/w Vitro
To assess the tissue-specificity o f the IL2RG  promoter in vitro a variety o f 
haematopoietic and non-haematopoietic cell lines were transduced with VSV-G 
pseudotyped SINLV 'ycP eGFP or SINLV SF eGFP and analysed for transgene 
expression. The eGFP transgene enables convenient direct identification o f transduced 
cells by both fluorescence microscopy and flow cytometry negating the requirement o f 
antibody staining.
Each cell line was transduced using three different MOIs (0.1, 1 and 10) in triplicate. 
The haematopoietic cell lines used included the Tc-deficient T lymphoid cell line ED- 
7R, SCID-X1 LCL (immortalised B cells) and the myeloid monocytic cell line U937. 
The non-haematopoietic cell lines consisted o f the fibroblastoid cell line HT1080, an 
embryonic kidney cell line (293T), the C2C12 muscle cell line and the HepG2 liver 
carcinoma cell line. All cell lines used, except for C2C12, are originally derived from 
human cells.
4.3.1 Analysis of Transduced Cell lines by Fluorescence Microscopy
Cells were analysed for eGFP expression by light microscopy forty-eight hours post­
transduction, at which time the cloned 1.24 kb human IL2RG  promoter appeared to be 
regulating cell line-specific expression (figure 4.5). GFP+ cells were detected for all o f 
the SINLV SF eGFP transduced cell lines by this method, however no GFP+ cells were 
observed for the C2C12 muscle cell line or the 293T embryonic kidney cell line 
transduced with SINLV *ycP eGFP. In all other cell lines transduced with SINLV *ycP 
eGFP, faint GFP+ cells were visible by microscopy, however the low levels o f GFP 
observed mean that these cells are difficult to distinguish following photographic 
capture (figure 4.5). The SINLV SF eGFP transduced cells appeared brighter under the 
fluorescence microscope than those transduced with the IL2RG  promoter vector
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demonstrating the potency o f the viral promoter. For both viruses the highest levels o f 
eGFP expression were observed in transduced ED-7R and U937 cells, both o f 
haematopoietic origin.
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Mock SINLV SF eGFP SINLV y r P  eGFP
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C2C12
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U937
Figure 4.5. Analysis of GFP expression in transduced cell lines by light 
microscopy. A variety o f haematopoietic and non-haematopoietic cell lines were 
transduced with SINLV SF eGFP or SINLV *ycP eGFP and analysed by light 
microscopy for eGFP expression after forty-eight hours. No eGFP expression was 
observed for 293T or C2C12 cells transduced with SINLV *ycP eGFP, whilst GFP+ 
cells were detected for all cell lines transduced with SINLV SF eGFP. Photos are 
representative of three transductions o f each cell line at an MOI o f 10.
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4.3.2 Flow Cytometric Analysis of Transduced Cell Lines
Cells were analysed for eGFP expression by flow cytometry seventy-two hours post­
transduction. GFP+ cells were detected in all cell lines transduced with either vector and 
at each o f the MOIs used, with equivalent transduction efficiencies observed for each 
MOI between lentiviruses (figures 4.6A and 4.7A).
The mean expression levels in the transduced populations for each cell line were 
compared for both vectors (figures 4.6B and 4.7B). In correlation with the results 
observed by light microscopy, higher levels of eGFP expression in all o f the 
haematopoietic and non-haematopoietic cell lines tested were seen for the viral SFFV 
promoter. SINLV SF eGFP was found to regulate the highest levels o f transgene 
expression in the embryonic kidney cell line 293T; conversely the IL2RG  promoter 
appeared least active in this cell line and, in correlation with observations by light 
microscopy, exhibited the highest levels o f GFP expression in ED-7R cells.
The finding that the SINLV 'ycP eGFP vector was able to express eGFP in all the non- 
haematopoietic cell lines tested indicate that the IL2RG  promoter is not entirely 
haematopoietic-restricted in vitro in contrast to published observations (Markiewicz et 
al., 1996).
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Figure 4.6. Analysis of GFP expression in transduced haematopoietic cell lines 
by flow cytometry. Cells were analysed for eGFP expression seventy-two hours 
post-transduction by flow cytometry. (A) Representative plots o f eGFP expression in 
cell lines transduced at an MOI of 1. (B) Mean (+/-SD) eGFP expression levels in 
each cell line at each MOI for both vectors. The IL2RG promoter is less potent than 
the viral SFFV promoter, both promoters are most active in ED-7R cells. (SD, 
standard deviation)
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Figure 4.7. Analysis of GFP expression in transduced non-haem atopoietic cell 
lines by flow cytometry. Cells were analysed for eGFP expression seventy-two 
hours post-transduction by flow cytometry. (A) Representative plots o f eGFP 
expression in cell lines transduced at an MOI o f 1. (B) Mean (+/-SD) eGFP 
expression levels in each cell line at each MOI for both vectors. The IL2RG  
promoter is able to regulate low levels o f expression in non-haematopoietic cell 
lines. (SD, standard deviation)
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4.3.3 Comparison of IL2RG  Promoter Activity in Haematopoietic and 
Non-Haematopoietic Cell Lines
GFP expression following transduction of each cell line with SINLV ycP eGFP relative 
to the expression detected in the SINLV SF eGFP transduced cells was compared 
(figure 4.8). Analysis of the data in this way reveals that relative to the viral SFFV 
promoter, the IL2RG regulatory sequences exhibit the highest activity in the B and T 
lymphoid cell lines (SCID-X1 LCL and ED-7R) respectively. These results are 
expected since endogenous yc would normally be expressed in T and B lymphocytes 
and demonstrate that the IL2RG promoter, although active in the non-haematopoietic 
cell lines tested, does confer a degree of tissue-specificity in vitro (Leonard, 1996). 
Relatively high promoter activity was also observed in two non-haematopoietic cell 
lines, HT1080 and HepG2. For the latter this may be explained by the presence of high 
levels of Ets transcription factors (Ko et al., 1999), binding sites for which have been 
characterised as critical for 1L2RG promoter activity (Markiewicz et al., 1996; Ohbo et 
al., 1995).
Figure 4.8. GFP expression in SINLV ycP eGFP transduced cell lines relative to 
expression from the SFFV promoter. The relative GFP expression in all cell lines 
transduced with SINLV ycP eGFP relative to expression in SINLV SF eGFP 
transduced cells is compared. The IL2RG promoter exhibits the highest relative 
activity in the two lymphoid cell lines, SCID-X1 LCL and ED-7R. Results shown 
represent the means o f three transductions with each virus at an MOI o f 1.
CL
O<D
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167
Chapter Four
4.4 Analysis of Tissue Specificity of the IL2RG Promoter In 
Vivo -  Intraveneous Injection of Lentiviral vectors into 
Neonatal Mice
Due to the aberrant phenotype of some immortalised cell lines, the SINLV ycP eGFP 
vector was also tested in an in vivo setting. Direct injection o f concentrated lentiviral 
supernatant into the superficial temporal vein of one-day old neonatal outbred mice has 
been shown to permit transduction of a variety of different organs and cell types in vivo 
(VandenDriessche et al., 2002; Kobayashi et al., 2005; Carbonaro et al., 2006) (Dr S 
Waddington personal communication). Analysis of GFP localisation one month post­
injection therefore enables characterisation of tissue-specificity conferred by a 
promoter in an in vivo setting.
Equal volumes of VSV-G pseudotyped SINLV ycP eGFP or SINLV SF eGFP 
matched-titre supernatant was intravenously injected into the superficial temporal vein 
of one-day old neonatal mice (injections performed by Simon Waddington). A total of 
three neonates were injected per vector. One month post-injection, mice were sacrificed 
and analysed for GFP expression by fluorescence microscopy and flow cytometry.
4.4.1 Fluorescence Microscopic Analysis of Lentivirally Injected Mice
Whole organs from the injected mice were analysed for GFP+ cells by fluorescence 
microscopy. Mice injected with SINLV SF eGFP had detectable GFP expression in 
both lymphoid and non-lymphoid tissues, with particularly strong expression detected 
in the livers from all three mice and widespread expression observed in the spleens 
(figure 4.9A). GFP expression in all three mice injected with SINLV ycP eGFP 
however appeared restricted to the spleens only, with no detectable GFP+ cells in the 
liver. Furthermore, GFP expression in the spleens of these mice appeared localised to 
the periphery of the white pulp in each animal, potentially within the marginal zone 
known to contain mainly B cells and macrophages (figure 4.9B) (Nolte et al., 2004).
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Figure 4.9. GFP expression in the livers and spleens from mice neonatally- 
injected with SINLV SF eGFP or SINLV tc P  eGFP. (A) Fluorescence 
microscopic analysis of whole livers and spleens from mice one-month post- 
neonatal injection of lentiviral supernatant (30x magnification). Mice injected with 
SINLV SF eGFP had detectable GFP expression in the livers and spleens, whilst 
mice injected with SINLV ycP eGFP had GFP+ cells detectable in the splenic white 
pulp only. (B) Higher magnification o f GFP expression in the spleens o f mice 
injected with SINLV *ycP eGFP (90x magnification). The GFP+ cells are mainly 
located in the periphery of the white pulp. Photographs are representative o f three 
mice for each vector. The control represents an uninjected mouse. (Photographs 
taken by Dr S Waddington)
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4.4.2 Flow Cytometric Analysis of GFP Expression in the Spleens of 
Lentivirally Injected Mice
The spleens from the injected mice were stained for a variety o f lymphoid and myeloid 
markers and analysed by flow cytometry in order to characterise the GFP+ populations 
observed by fluorescence microscopy (figure 4.9). For mice injected with either virus, 
GFP+ T, B and CD1 lb+ myeloid populations were detected in the spleen (figure 4.10A) 
with no GFP+ cells detected in the bone marrow or thymi (data not shown). For the 
mice injected with SINLV ^cP eGFP lentivirus the highest proportions o f  GFP+ 
splenocytes appeared to be B2201o B lymphocytes or C D llb + myeloid cells with no 
such bias observed for the SFFV promoter (figure 4.1 OB). These results are concurrent 
with the fluorescence microscopic analysis since both B220+ B cells and C D llb + 
macrophages are found in the marginal zone o f the splenic white pulp and both cell 
types express yc (Leonard, 1996; Andersson et al., 1997).
These results imply tissue-specificity o f the cloned IL2RG promoter in vivo and 
highlight the differences that can be obtained between in vitro analyses in cell lines and 
experiments utilising in vivo models.
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Figure 4.10. Flow cytometric analysis of splenocytes from mice neonatally- 
injected with SINLV SF eGFP or SINLV ycP eGFP. (A) Splenocytes from the 
injected mice were stained with lymphoid and myeloid cell surface markers and 
analysed by flow cytometry. GFP+ B and T lymphocytes and CD1 lb + myeloid cells 
were observed in all mice. Representative plots from one mouse in each group are 
shown. (B) The mean (+/-SD) proportions of GFP+ cells that co-stained with the cell 
surface markers. Mice injected with SINLV *ycP eGFP had high proportions o f 
B2201o and CD1 lb+ GFP+ cells in the spleen. (SD, standard deviation)
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4.5 Conclusions
Analysis of regulatory sequences upstream of the human and murine genes for yc 
identified a previously uncharacterised region of DNA that showed significant 
evolutionary conservation and led to the construction of lentiviral vectors incorporating 
a 1.24 kb segment 5’ of the human IL2RG gene that might potentially enable 
physiological transgene expression.
To analyse tissue-specificity of the cloned IL2RG promoter region in vitro, a variety of 
haematopoietic and non-haematopoietic cell lines were transduced with SINLV ycP 
eGFP or SINLV SF eGFP for comparison. GFP+ cells were detectable by light 
microscopy forty-eight hours post-transduction in all haematopoietic cell lines and in 
all but two of the non-haematopoietic cell lines tested for SINLV ycP eGFP. All cell 
lines transduced with SINLV SF eGFP had detectable GFP+ cells at this stage however, 
with noticeably brighter expression regulated by the SFFV promoter. Seventy-two 
hours post-transduction transgene expression was detected by flow cytometry in all cell 
lines transduced with either SINLV ycP eGFP or SINLV SF eGFP, with much higher 
levels of GFP observed in all cell lines tested for the latter vector. Analysis of IL2RG 
promoter activity relative to that from the SFFV promoter revealed the highest levels of 
transgene expression in the T and B lymphoid cell lines, derived from cells in which yc 
is normally expressed. Although monocytes have been documented to express yc and 
respond to yc-dependent cytokines (Alderson et al., 1991; Bonder et al., 1999), much 
lower relative expression was observed in the U937 monocytic cell line. This result 
may reflect either that yc is not ubiquitously expressed in this cell type, a study 
investigating yc expression in monocytes from SCID-X1 patients suggests that yc is not 
essential for monocyte development or function (Ariga et al., 2002), or differences 
between the phenotype o f wild-type and immortalised cells. Despite published results 
that the IL2RG promoter is haematopoietic-specific in vitro (Markiewicz et al., 1996), 
transgene expression was detected in all non-haematopoietic cell lines transduced with 
SINLV ycP eGFP lentivirus, with the highest expression seen in the fibroblastoid cell 
line HT1080 and the liver carcinoma cell line HepG2. The promoter activity detected in 
HepG2 cells might be explained by the high levels of Ets-1 and Ets-2 transcription 
factors expressed in this cell line (Ko et al., 1999), since a crucial Ets binding site has
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been identified within the basal IL2RG promoter (Markiewicz et al., 1996; Ohbo et al., 
1995). The differences observed between this in vitro assay and published work using a 
plasmid transfection system may be attributed to the use o f a lentiviral vector to 
characterise promoter activity in this instance. Lentiviral vectors integrate into the host 
genome and therefore may be affected by neighbouring regulatory elements resulting in 
potentially enhanced or decreased expression levels, effects that episomally-maintained 
plasmid DNA would not be subjected to. Whilst the vectors incorporate the self- 
inactivating design, it has been reported that the inactivated LTR retains a degree of 
promoter activity, thus it is possible that transgene expression regulated by the viral 
enhancer elements has been detected in cell lines in which the IL2RG  promoter is 
inactive (Logan et al., 2004; Hanawa et al., 2005). It must also be noted that all o f the 
non-haematopoietic cell lines tested differ from those used in a previous study to 
characterise this promoter (Markiewicz et al., 1996).
To analyse tissue-specificity of the IL2RG promoter in an in vivo setting one-day old 
neonatal mice were injected with concentrated lentiviral supernatant in a method 
demonstrated to target a wide variety of cell types (VandenDriessche et al., 2002; 
Kobayashi et al., 2005; Carbonaro et al., 2006). Analysis of the injected animals one 
month post-injection revealed IL2RG promoter activity to be restricted to the spleen 
and localised to the periphery of the white pulp, whilst transgene expression was 
widespread in the spleens and livers of animals injected with SINLV SF eGFP 
lentivirus. These data highlight the tissue-specificity of the IL2RG  promoter in vivo 
since integrated SINLV ycP eGFP provirus was detectable in both organs by PCR (data 
not shown) and injection of lentiviral supernatant via this method into neonatal mice 
has been demonstrated to primarily target the liver (VandenDriessche et al., 2002; 
Kobayashi et al., 2005; Carbonaro et al., 2006). Flow cytometric analysis of 
splenocytes from the injected mice characterised the highest proportions o f GFP+ cells 
in the SINLV ycP eGFP mice to stain positive for B220 B lymphocyte or CD l ib  
myeloid cell surface markers. These populations are found in high number in the 
splenic marginal zone located in the periphery of the white pulp and would explain the 
localisation of transgene positive cells observed by fluorescence microscopy (Nolte et 
al., 2004). The high proportion of GFP+ B cells also correlates with the results observed 
from the in vitro analyses in which the highest relative activity from the IL2RG
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promoter was observed in SCID-X1 LCLs. It is therefore possible to conclude that the 
IL2RG promoter exhibits tissue-specificity in vivo, with promoter activity restricted to 
cells of haematopoietic origin only in the model used. This promoter might therefore be 
suitable for use in a gene therapy vector for SCID-X1, increasing vector safety by 
restricting transgene expression to the required cell types only. These results also 
highlight the importance o f in vivo experiments in the assessment o f regulatory 
sequences, in particular due the aberrant phenotypes o f immortalised and cancer cell 
lines, since promoter activity was detected in a liver carcinoma cell line following in 
vitro transduction, whilst no transgene expression whatsoever was observed in the 
livers of three injected mice.
4.6 Final Conclusions
• High homology is observed between 1.24 kb of sequence upstream of the 
human and murine yc genes
• In the context of a lentiviral vector, the human 1.24 kb IL2RG  promoter region 
exhibits activity in both haematopoietic and non-haematopoietic cell lines
• In vivo, expression from the IL2RG promoter is restricted to cells of 
haematopoietic origin in the periphery of the splenic white pulp
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Self-Inactivating Lentiviral Vectors for SCID-X1
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5.0 Aims
• To assess the performance of the SIN lentiviral vectors incorporating the SFFV, 
EFS and IL2RG promoters in vitro
• To assess the ability of the SIN lentiviral vector series to restore immunity in 
the SCID-X1 murine model following ex vivo gene therapy
5.1 Introduction
The integration phase of the lentivirus life cycle differs from that o f the 
gammaretroviruses in that the pre-integration complex (PIC) may be transported into 
the nucleus by the nuclear import machinery of the target cell (Bukrinsky et al., 1992). 
Following infection, reverse transcription of the lentiviral RNA genome occurs in the 
cytoplasm of the host cell and the resultant double-stranded DNA subsequently 
assembles with proteins to form the PIC. In wild-type lentiviruses these include matrix, 
integrase and vpr proteins, all of which have been implicated in nuclear import 
(Sherman and Greene, 2002). In addition, a triple-stranded DNA ‘flap’ structure 
created by the initiation of reverse transcription at the cPPT acts as a nuclear import 
signal for the PIC (Zennou et al., 2000). In the context of lentiviral vectors for gene 
therapy, the central polypurine tract (cPPT) sequence has been shown to be required for 
improved transduction of both human primary cells (including HSCs) and rat neurons, 
whilst the role of vpr in nuclear translocation is thought to be redundant since the viral 
accessory proteins were omitted during the production of these vectors (Follenzi et al., 
2000; Zennou et al., 2001).
Vectors derived from lentiviruses such as HIV-1 therefore offer the advantage that they 
are able to transduce non-dividing cells. This ability may be of significant benefit in 
HSC gene therapy given that the cycling of progenitor cells required for ex vivo 
transduction with gammaretroviral vectors may result in loss o f self-renewal and 
engraftment capabilities. A series of second generation self-inactivating lentiviral
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vectors derived from HIV-1 (Zufferey et al., 1998) have therefore been developed for 
the treatment of SCID-X1 incorporating identical SFFV and EFS promoter elements to 
those present in the SRS II series of gammaretroviral vectors (figure 1.7). These 
vectors, together with the SINLV ycP yc vector incorporating the IL2RG  promoter, 
were therefore assessed both in vitro and in vivo for their potential as gene therapy 
vectors for the treatment of SCID-X1.
5.2 In Vitro Analysis of SIN Lentiviral Vectors
5.2.1 Transduction of Fibroblast and SCID-X1 Lymphoid Cell lines
In order to test the SINLV ycP yc vector and the lentiviral vectors incorporating the 
SFFV and EFS promoters, VSV-G pseudotyped lentiviral supernatant was produced by 
transient transfection of 293T cells and concentrated by ultracentrifugation. The murine 
fibroblast cell line SC-1 and the two aforementioned human SCID-X1 cell lines, ED- 
711 and SCID-X1 LCL, were consequently transduced with equivalent vector doses to 
analyse performance of the SIN lentiviral vector series in vitro. Transgene cell surface 
expression following lentiviral transduction was assessed by flow cytometry 
subsequent to staining with an antibody to human yc (anti-CD 132-PE).
The SIN lentiviral vector series was found to efficiently transduce the murine fibroblast 
cell line and express yc transgene to detectable levels on the cell surface (figure 5.1). 
Markiewicz et al. reported tissue specificity of the human IL2RG  promoter using a 
luciferase reporter system with little or no luciferase activity detected in non- 
haematopoietic cell lines including fibroblasts (Markiewicz et al., 1996). In the context 
of a lentiviral vector however, the IL2RG promoter appears active in all three o f the cell 
lines tested, with yc expression detected in fibroblasts and lymphoid cell lines 
transduced with SINLV ycP yc but not in mock-transduced cells (figure 5.1). SINLV 
SF yc and SINLV EFS yc were also demonstrated capable of restoring yc expression in 
lymphoid SCID-X1 cell lines.
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In all three of the cell lines tested, the highest expression levels were observed for the 
viral SFFV promoter (figure 5.IB) correlating with in vitro data gained from SIN 
gammaretroviral vector analysis (see figures 3.1 and 3.2). Whilst the levels o f yc 
expression were consistently lower for SINLV EFS yc, the difference in expression 
levels as compared to SINLV SF yc appeared much smaller in the lymphoid SCID-X1 
cell lines, correlating with published data that the elongation factor la  promoter is 
suitable for use in haematopoietic cells (Salmon et al., 2000). The lowest expression 
levels in the SC-1 and ED-7R cell lines were observed for the IL2RG  promoter vector, 
however expression of yc in the SCID-X1 LCLs following transduction with this vector 
was comparable to the levels detected for the other lentiviral vectors. These data 
confirm that the 1.24 kb sequence upstream of the endogenous IL2RG  gene exhibits 
promoter activity in the lymphoid and fibroblastoid cells tested and that the SINLV ycP 
yc lentiviral vector is capable o f restoration of yc on the cell surface o f SCID-X1 B and 
T cell lines. The levels of yc expression observed following transduction o f fibroblast 
and T lymphoid cell lines with this vector were lower than seen for SINLV SF yc and 
SINLV EFS yc at an equivalent MOI; however a degree o f tissue specificity was 
conferred by SINLV ycP yc.
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Figure 5.1. Lentiviral transduction of fibroblast and lymphoid SCID-X1 cell 
lines. (A) Flow cytometric analysis of SC-1 (fibroblast), ED-7R and SCID-X1 LCL 
(lymphoid) cells transduced with the SIN lentiviral vector series at an MOI o f 1. (B) 
The mean fluorescent intensity (MFI) of each transduced cell line was compared for 
both vectors, the highest expression levels being observed for SINLV SF yc.
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5.2.2 Western Blot Analysis of Human yc Expression in Transduced 
SC-1 Cells
To further confirm transgene expression by the SIN lentiviral vectors, transduced SC-1 
cells were analysed by Western blot. Equivalent multiplicities of infection were used 
for all lentiviral vectors (MOI 5) except SINLV ycP yc, for which an MOI o f 1 was 
used due to poor lentiviral titre. Protein lysates were separated by SDS-PAGE, 
immunoblotted and probed with an antibody to human yc. As observed by flow 
cytometry, higher levels of yc expression are detected following transduction with the 
SINLV SF yc vector (figure 5.2). The lowest levels o f yc expression are detected for 
SINLV ycP yc, reflecting the lower dose o f lentivirus used and the lower potency of 
this promoter in this cell line; this result however confirms the flow cytometric data 
that the IL2RG  promoter is active in these murine fibroblastoid cells. Concurrent with 
Western blot analysis of gammaretrovirally transduced cells, three bands are detected 
by the anti-yc antibody likely representing glycosylated (64 kDa band) and 
underglycosylated (the two smaller bands) protein isoforms. A single, smaller cross­
reactive band of approximately 49 kDa is visible following analysis o f lysate from cells 
transduced with control vector encoding enhanced green fluorescent protein under the 
control of the SFFV promoter (SINLV SF eGFP).
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Figure 5.2. W estern blot analysis of SC-1 cells transduced with the SIN 
lentiviral vectors. SC-1 fibroblast cells were transduced with the SIN lentiviral 
vector series at an MOI of 5 (an MOI of 1 was used for SINLV ycP yc); Western 
blot analysis of cell lysates confirmed that the IL2RG promoter is active in SC-1 
cells and that the highest levels of transgene expression are detected in cells 
transduced with SINLV SF yc. To confirm antibody specificity and as a vector 
control, SC-1 cells were also transduced with SINLV SF eGFP. The blot was also 
probed with an antibody to the 41 kDa p-actin protein (lower lane) to demonstrate 
equivalent loading in each lane.
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5.2.3 Reconstitution of Functional IL-2 Receptor Complexes 
Following Lentiviral Transduction of ED-7R Cells
The common cytokine receptor y-chain is shared by the receptors for IL-2, 4, 7, 9, 15 
and 21, which signal through association with the JAK family of tyrosine kinases. In 
particular yc associates with JAK3 following ligand binding, which causes subsequent 
phosphorylation of the transcription factor STAT5. Having previously demonstrated 
that the self-inactivating lentiviral vectors are able to efficiently transduce the human T 
cell line ED-7R, an assay was performed to assess functionality o f the expressed yc 
transgene. ED-7R cells are derived from a human T cell leukaemia line (ED40515*) 
naturally deficient in yc however they express all other components o f the IL-2 receptor 
(IL2R) (Ishii et al., 1994); lentivirally-transduced cells were therefore analysed for the 
presence of restored functional IL2R by incubation with IL-2 molecules and subsequent 
analysis o f downstream signalling by staining with an antibody specific for the 
phosphorylated STAT5 transcription factor (pSTAT5). A yc positive T-cell line, ED- 
7R-yc, was used as a positive control.
Following incubation with IL-2, phosphorylated STAT5 is detectable for each of the 
SIN lentivirally-transduced ED-7R cells at levels comparable to the yc-expressing 
control ED-7R-yc cells (figure 5.3) indicating that the yc transgene expressed by the 
lentiviral vectors is able to restore functional IL-2 receptor complexes in this cell line. 
No aberrant downstream JAK-STAT signalling was observed in the transduced cells in 
the absence o f IL-2. Mock transduced ED-7R cells incubated with the cytokine had no 
detectable pSTAT5.
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Figure 5.3. The restoration of functional IL-2 receptors on lentivirally 
transduced ED-7R cells. Lentivirally transduced yc-deficient ED-7R cells (MOI 5) 
were incubated with IL-2 and assessed for downstream signalling by intracellular 
staining with an anti-pSTAT5 antibody. pSTAT5 was detected by flow cytometry in 
cells transduced with either SINLV SF yc, SINLV EFS yc or SINLV ycP yc but not 
in mock transduced ED-7R cells, indicating that the yc transgene expressed by each 
of the promoters within the SIN lentiviral vectors is functional.
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5.2.4 In Vitro B cell differentiation of Il2rg'A HSCs Transduced with 
the SIN Lentiviral Vectors
To assess the ability of the SIN lentiviral vectors to transduce and form functional yc- 
containing receptor complexes on primary murine progenitor cells the OP9 system was 
used. As for the analysis of the self-inactivating gammaretroviral vectors, lin' 
haematopoietic progenitors isolated from yc-deficient mice were transduced ex vivo. 
The protocol used for the VSV-G pseudotyped lentiviral vectors however involved only 
a single round of transduction, in which the lin* cells were incubated overnight with 
concentrated lentiviral supernatant at an MOI of 25 in serum-free media in the presence 
of cytokines. Following transduction the lin’ cells were seeded onto OP9 stromal layers 
and co-cultured for a total o f thirteen days in the presence o f IL-7 and Flt-3. The co­
cultures were analysed by light microscopy and flow cytometry subsequent to staining 
with antibodies to differentiated lymphocyte cell surface markers.
Following six days of co-culture on OP9-eGFP stromal layers, cobblestone colonies 
formed from primitive progenitor populations were visible for both the lentivirally- 
transduced and mock transduced //2rgv' lin’ cells (figure 5.4A). A large amount of cell 
death was apparent for the SINLV SF yc transduced cells however, potentially 
indicating toxicity of the lentiviral preparation used to transduce the cells. On day six, 
the haematopoietic cells were removed from the stromal layers, stained with antibodies 
to B (CD 19) and NK (NK1.1) cell markers and analysed by flow cytometry (figure 
5.4B). Wild-type C57/B16 cells were found to have undergone B cell differentiation 
with the majority o f cells being CD19+. The lentivirally and mock transduced cells 
however appeared to be differentiating at a slower rate, with between 15 and 31 % of 
cells staining positive for the NK cell marker NK1.1 and only a smaller percentage of 
cells found to be CD19+. As observed by light microscopy, only a small proportion of 
the cells transduced with SINLV SF yc remained viable and could thus be analysed by 
flow cytometry.
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Figure 5.4. Analysis of OP9-eGFP co-cultures on days five and six.
(A) Cobblestone colonies representing early progenitor cell populations are visible 
after five days co-culture o f transduced lin' cells on the 0P9-GFP stromal cell line.
(B) Cells were stained with antibodies to NK cell marker NK1.1 and B cell marker 
CD 19 and analysed by flow cytometry on day six. A large population o f CD19+ 
early B lymphocytes are observed for C57/B16 wild-type cells, with smaller CD19+ 
populations present for the Il2rg'A cells transduced with the SIN lentiviral vectors.
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Ten days after seeding the progenitors onto the OP9-eGFP stromal layers large 
numbers o f round haematopoietic cells were observed for the SINLV EFS yc 
transduced Il2rg'A lin' cells and the wild-type C57/B16 cells (figure 5.5A). A smaller 
proportion o f differentiated cells were observed in the mock treated well and even 
fewer for the SINLV 'ycP yc transduced cells at this stage. The cells transduced with 
SINLV SF 'yc were discarded at this point as they were no longer viable.
By day thirteen the mock and SINLV ycP yc transduced cells had all died; whilst this 
was expected for the mock transduced cells, demonstrating the necessity o f yc to 
support further differentiation and proliferation in this in vitro system, the results are 
surprising for the SINLV 'ycP 'yc vector. Thus far the vector has been demonstrated 
capable o f transducing both fibroblast and lymphoid cells in vitro, and SINLV tcP  'yc 
transduced ED-7R cells reconstituted ^c-dependent signalling to almost identical levels 
as for the other lentiviral vectors.
The differentiated haematopoietic cells originating from the SINLV EFS 'yc transduced 
or wild-type progenitors were separated from the stromal layers, stained with 
antibodies to B cell markers CD 19 and B220 and again analysed by flow cytometry. By 
this stage of the experiment over 97% of the SINLV EFS 'yc transduced Il2rg~  cells 
had differentiated into CD19+B220+ B lymphocytes, indicating that the progenitors 
were successfully transduced by the lentiviral vector and that the human 7 c transgene is 
expressed to sufficient and functional levels in these cells to allow lymphoid 
differentiation and proliferation (figure 5.5B). Similarly, over 99% o f cells from the 
C57/B16 progenitors were characterised as CD19+B220+. It is unclear as to why the 
SINLV SF 7 c transduced progenitors died at such an early stage o f the experiment, in 
particular since the mock transduced cells remained healthy and viable for a longer 
period of time and that thus far this vector has performed in a similar fashion to SINLV 
EFS yc. These results represent a single experiment using the OP9 system due to time 
constraints within the project; hence repetition o f this work using a different lentiviral 
preparation would confirm whether the results observed are due to toxicity o f the 
preparation or due to an inherent property o f the vector itself.
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Figure 5.5. Analysis of OP9-eGFP co-cultures on days ten and thirteen.
(A) After ten days co-culture large numbers of round haematopoietic cells are 
observed resting on top o f the stromal OP9 layers for the wild-type and SINLV EFS 
'yc transduced cells. The SINLV 'ycP 'yc transduced cells however appeared to be 
arrested from undergoing further differentiation or proliferation. (B.) Cells were 
stained for B cell surface markers CD 19 and B220 on day thirteen and analysed by 
flow cytometry. Over 97% o f wild-type and SINLV EFS 'yc transduced I t tr g '' HSCs 
cells had differentiated into CD19+B220+ B lymphocytes by this stage.
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5.2.5 In Vitro T cell differentiation of Il2rg A HSCs Transduced with 
the SIN Lentiviral Vectors
To assess the propensity for the SIN lentivirally transduced Il2rgf' lin' cells to undergo 
T cell differentiation, a proportion o f the progenitors were also seeded on OP9-DL1 
stromal layers. As observed for the OP9-eGFP co-cultures, cobblestone colonies were 
visible for all conditions on day 5 (data not shown). The cells used to seed both the 
OP9-eGFP and the OP9-DL1 stromal layers originated from the same initial 
transduction and hence, as expected, poor viability o f the SINLV SF 'yc transduced cells 
was also observed at this stage.
On day six, haematopoietic cells from each co-culture were stained with antibodies to 
thymocyte markers CD44 and CD25 and analysed by flow cytometry. By this stage o f 
the experiment the SINLV EFS yc and the surviving SINLV SF yc transduced lin' 
progenitors appeared to be undergoing differentiation at the same rate as the C57/B16 
wild-type cells, with approximately 90% of the population at the CD44+CD25‘ stage o f 
T cell development and the remainder having proceeded to the CD44+CD25+ DN2 
stage. Concurrent with analysis by light microscopy, very few o f the SINLV SF 'yc 
transduced cells remained viable for analysis (figure 5.6). These results contrast those 
obtained from the analysis o f SIN gammaretrovirally transduced progenitors, which at 
the same stage o f the experiment appeared to be undergoing T cell differentiation at a 
faster rate than the C57/B16 wild-type cells (see figure 3.6B). These data may be 
indicative o f the shorter transduction protocol required for lentiviral vectors resulting in 
decreased differentiation o f the lin' progenitors. The majority o f the mock transduced 
cells appeared arrested at the DN1 stage indicating a requirement for ^c-mediated 
signalling for further T cell development. The SINLV 'ycP 'yc transduced cells also 
appeared arrested at the D N 1 stage correlating with the results observed from the OP9- 
eGFP co-cultures.
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Figure 5.6. Analysis of OP9-DL1 co-cultures on day six. After six days co-culture 
on OP9-DL1 stromal layers, haematopoietic cells were stained with antibodies to 
early T cell markers (CD44 and CD25) and analysed by flow cytometry. Both the 
C57/B16 and SINLV EFS "yc transduced cells were found to be differentiating from 
the DN1 to the DN2 stage o f thymocyte development, whilst the mock and SINLV 
"ycP 'yc transduced cells appeared arrested at DN1.
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Similarly to the results observed for the OP9-eGFP co-culture, after ten days incubation 
the wild-type and SINLV EFS yc transduced wells had large numbers o f round 
differentiated haematopoietic cells visible resting on top of the OP9-DL1 stromal layers 
(figure 5.7A). Fewer cells were observed in the mock and SINLV ycP yc transduced 
wells, whilst the SINLV SF yc transduced cells were no longer viable at this time-point. 
By day thirteen however, all o f the mock and SINLV 'ycP yc transduced cells were 
found to have died. Analysis by flow cytometry at this stage o f the experiment revealed 
the majority o f the C57/B16 and SINLV EFS yc transduced cells to be the CD44+CD25+ 
DN2 stage o f thymocyte development with populations also detectable at the D N 1 and 
DN3 stages (figure 5.7B). These results demonstrate that SINLV EFS yc transduced 
Il2rg~A lin' progenitors are able to undergo T cell differentiation at a similar rate to 
wild-type progenitor cells and thus that this vector is capable o f tranducing primitive 
murine progenitor cells and expressing human yc to functional levels.
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Figure 5.7. Analysis of OP9-DL1 co-cultures on days ten and thirteen. (A) After 
ten days co-culture, large numbers of round haematopoietic cells are visible resting 
on top o f the stromal layers in the C57/B16 and SINLV EFS yc transduced wells. (B) 
Following thirteen days o f co-culture the wild-type C57/B16 and SINLV EFS yc 
transduced cells appeared to be differentiating further towards DN4. No viable cells 
remained for all other conditions.
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5.3 In VivoAnlaysis of SIN Lentiviral Vectors
5.3.1 Transduction of Murine Lin' Progenitor Cells
The ability o f lentiviral vectors to be transported across the nuclear membrane means 
that pre-stimulation of lin' progenitors prior to transduction, as required for 
gammaretroviral vectors, is unnecessary. A shorter two-day protocol for the ex vivo 
transduction of H2rg'A lin' cells was therefore employed, as outlined in figure 5.8. 
Briefly, bone marrow was harvested from the femurs and tibias of I l2 r g ' mice and lin' 
progenitor cells isolated by negative selection. A single round of transduction using an 
MOI o f 25 was then performed overnight with concentrated lentiviral supernatant 
added to serum-free media and cytokines. As for the in vitro assays, VSV-G 
pseudotyped lentivirus was used. On day two the transduced cells were harvested and 
injected intravenously into the tail veins o f sublethally-irradiated Il2rg /'Rag2'/'c5'/' 
mice. Transplanted animals were maintained in pathogen-free environments for 
approximately four months to allow engraftment and repopulation, the mice were 
subsequently sacrificed and analysed for immune reconstitution.
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Figure 5.8. E x vivo lin' transduction protocol. A schematic o f the SIN lentiviral ex 
vivo transduction protocol; lin' cells isolated from Il2rg mice were transduced 
overnight with VSV-G pseudotyped lentivirus and subsequently injected into sub- 
lethally irradiated Il2rg / Rag2Tc5'/~ mice.
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5.3.2 Lentiviral Lin' Transduction Levels
A cohort o f mice injected with Il2 rgA lin' cells transduced with SINLV SF yc , SINLV 
TcP yc, SINLV 'ycP eGFP or with mock-transduced Il2rg~ progenitors was set up. A 
different preparation o f SINLV SF yc than was used for the in vitro OP9 co-culture 
assay was used for this study. To assess pre-transplant lentiviral transduction levels, a 
proportion o f transduced lin' cells were also seeded in semi-solid medium 
supplemented with murine cytokines. Following two weeks incubation at 37°C, 
colonies formed from the transduced progenitor cells were isolated and genomic DNA 
harvested for analysis. Colonies were assessed for the presence o f integrated vector by 
polymerase chain reaction (PCR) using primers directed to the yc transgene for SINLV 
SF yc transduced lin' cells, whilst the cells transduced with the IL2RG  promoter vectors 
were analysed using primers to the IL2RG  regulatory sequences. Analysis o f the PCR 
products by agarose gel electrophoresis enabled calculation o f the proportion of 
transduced progenitor cells that were injected into the recipient mice. Lin' cells 
transduced with the SINLV tcP  eGFP vector were also analysed by flow cytometry to 
estimate transduction levels by assessing the proportion o f eGFP-expressing cells 
present within the population.
Whilst equivalent doses o f lentivirus were used to transduce the Ittrg^ ' progenitors 
differing transduction efficiencies were observed between vectors, with 100% o f the 
colonies picked from the SINLV SF yc transduced lin' cells found to have integrated 
pro virus (figure 5.9 A). A total o f twenty-eight colonies were picked for each vector, it 
is therefore possible that had a larger number been analysed, transgene negative 
colonies may have been detected and thus the true transduction efficiency might be 
slightly lower than calculated. The lowest transduction efficiency was observed for 
SINLV tcP  yc, with only 41% of the colonies picked found to contain integrated 
provirus; the same titration method was used for both lentiviral preparations, hence it 
was surprising that such low transduction efficiency was achieved for this vector. 
Repetition of the PCR using primers to the yc transgene yielded a similar result (data 
not shown) hence the data does not reflect a discrepancy between the efficiencies o f the 
two primer sets used. Flow cytometric analysis o f the SINLV *ycP eGFP transduced 
progenitors revealed approximately 60% of cells to be eGFP+, indicating that this
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promoter is active in early murine progenitor cells (figure 5.9B); analysis o f the 
colonies derived from these cells by PCR gave a transduction o f 70%, potentially 
reflecting a degree o f transgene silencing in 10% of the population or a discrepancy 
between the two assays (figure 5.9A).
SINLV rcP eGFP
Figure 5.9. Lin' transduction efficiency. (A) Pre-transplant CFU transduction 
efficiencies of the lentiviral cohort o f transplanted animals. (B) The transduction 
efficiency of SINLV y^cP eGFP transduced lin' cells was also assayed by flow 
cytometric analysis.
194
Chapter Five
5.3.3 Detection of Circulating Lymphoid Cells in the Peripheral Blood 
of Il2rg'/~Rag2'/'c5'/' Mice Transplanted with Lentivirally 
Transduced Cells
Eight weeks post-transplant samples o f peripheral blood from repopulated mice were 
analysed for circulating T and B lymphocytes by flow cytometry. In three out o f four 
mice that had received lin' cells transduced with SINLV SF 'yc, CD3+ T cells and B220+ 
B lymphocytes were detected at this early stage at levels similar to those observed in 
wild-type C57/B16 mice (figure 5.10A). Only B cells were found to be present in the 
peripheral blood o f the fourth animal however. All three mice that were injected with 
SINLV 'ycP 'yc transduced lin' cells failed to reconstitute circulating T lymphocytes, 
with only small populations o f  B2201o B cells detected as also seen in mice that had 
received mock-transduced or SFFV-eGFP transduced cells. Despite the high 
transduction levels achieved for SINLV 'ycP eGFP, the four mice that received cells 
transduced with this vector had no detectable eGFP+ cell populations in the peripheral 
blood (figure 5.1 OB). These data indicate either that the transduced progenitors failed to 
engraft in the transplanted mice, that the promoter was silenced in vivo or that it is 
inactive in the differentiated myeloid and B2201o B cell lineages in these animals.
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Figure 5.10* Peripheral blood analysis of transplanted Il2rg /~Rag2~/c5v~ mice.
(A) Peripheral blood mononuclear cells from repopulated mice were stained with 
antibodies to CD3 (T cell marker) and B220 (B cell marker) and analysed by flow 
cytometry. Circulating T and B lymphocytes were detected in Il2rg 'Rag2'/c5'/ mice 
eight weeks post-transplantation of SINLV SF yc transduced U2rg'/~ lin" cells. Mice 
that had received cells transduced with SINLV yc? yc or mock-transduced cells 
failed to reconstitute circulating lymphocytes. (B) No detectable eGFP+ or 
lymphocyte cell populations were present in the SINLV yc? eGFP mice.
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5.3.4 Splenic Weights of Il2rg~/'Rag2'/~c5'/~ Mice Transplanted with 
Lentivirally Transduced Cells
Approximately four months post-transplant the repopulated mice were sacrificed for 
analysis o f immune reconstitution. Prior to this time-point one of the mice transplanted 
with SINLV SF yc transduced cells was found to have died from colitis-like 
symptoms, leaving only three in this group available for further analysis.
The spleens from wild-type and experimental mice were removed and weighed before 
further analysis. Spleens from untreated Il2rg /~Rag2~/'c5'~ mice are normally 
hypocellular due to the absence o f lymphocyte populations, hence an increase in 
splenic weight post-transplantation with gene-corrected cells might signify the presence 
o f recovered lymphoid cells. In contrast to the gammaretrovirally treated mice, the 
spleens from animals that had received lentivirally transduced lin' cells were uniformly 
smaller and lower in weight than observed for wild-type animals (figure 5.11). 
Surprisingly, the spleens removed from the SINLV SF yc mice, that had detectable 
circulating lymphocytes eight weeks post-injection, were similar in weight to the 
spleens from the SINLV ycP eGFP or mock-treated animals. The mice that had 
received cells transduced with SINLV ycP yc were found to have the largest spleens, 
which were noted to be significantly heavier than those from the SINLV ycP eGFP 
mice, even though no detectable lymphocyte populations were present in the peripheral 
blood o f these animals. No cases o f splenomegally were observed in any of the 
experimental animals.
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Figure 5.11. The splenic weights of Il2rg/'Rag2~lc5'/' mice transplanted with 
lentivirally transduced lin' cells. The splenic weights from all transplanted mice 
were observed to be lower than for wild-type C57/B16 animals. The heaviest spleens 
were those removed from SINLV ycP yc mice, found to be significantly increased in 
weight as compared to SINLV ycP eGFP animals despite lymphocytes being absent 
from the periphery. (*, P<0.05)
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5.3.5 Flow Cytometric Analysis of Lymphoid Populations in the 
Spleen and Bone Marrow of Il2rg'/'Rag2~/~c5~/' Mice 
Transplanted with Lentivirally Transduced Cells
Cells isolated from the spleens and bone marrow of transplanted mice were stained 
with antibodies to lymphoid and myeloid populations and analysed by flow cytometry. 
In correlation with the results from the peripheral blood analysis, two out of three 
SINLV SF yc mice had detectable T, B and NK cell populations in the spleens and 
bone marrow (figure 5.12A). The third mouse failed to reconstitute the T cell 
compartment; however mature B220+IgM+ B cells and NK cell populations were 
detected in both tissues (data not shown). The partial immunological reconstitution 
observed in this animal might be due to less successful intravenous injection resulting 
in a lower dose o f lentivirally-transduced cells as compared to the remainder of the 
cohort. All three mice transplanted with SINLV ycP yc transduced lin' cells failed to 
undergo immune reconstitution, with similar staining observed in the two ll2 rg 'R ag2 "  
c5"  mice transplanted with mock-transduced cells (figure 5.12A). T and NK cells 
remained absent in these animals, however approximately 30% of cells in the spleen 
were found to have an immature B2201o phenotype. These results likely reflect the 
ability o f Il2rg~ ~ lin' cells to undergo partial B cell development in the absence of yc 
signalling (DiSanto et al., 1995; Cao et al., 1995).
Concurrent with the peripheral blood analysis, all four mice transplanted with SINLV 
ycP eGFP transduced cells had no detectable eGFP+ populations in either tissue (figure 
5.12B). As observed for the mock-transduced and SINLV ycP yc mice, T and NK cells 
failed to develop in these animals due to the absence o f yc-mediated signalling, 
however a proportion of B220+ cells were detected.
An increase in the proportion o f myeloid C D llb + cells in both the spleen and bone 
marrow was observed for all transplanted mice as compared to wild-type animals. It is 
therefore likely that this increase is due to the ex vivo manipulation o f the murine HSCs 
and/or the repopulation setting in this experiment as opposed to relating to the yc 
transgene itself.
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Figure 5.12. Flow cytometric analysis of lymphoid reconstitution in the spleens and bone marrow of engrafted animals. (A)
Representative flow cytometry plots from the analysis of lymphocyte restoration in the spleen and bone marrow of IUrg^RagT/c5 f mice 
transplanted with ')c-lentivirally or mock transduced lUrg1' lin" cells. CD4+ and CD8+ T cells and mature B220+IgM+ B cells are present only 
in the spleens of SINLV SF yc mice (first two rows). Similarly, CD3+ T lymphocytes and NK1.1+ NK cells are also only detected in the bone 
marrow of these animals (third row). CD1 lb+ myeloid populations in the bone marrow are increased following repopulation (fourth row). (B) 
Mice transplanted with SINLV ycP eGFP transduced cells had no detectable eGFP+ populations and failed to develop any T, NK or mature B 
cells.
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5.3.6 Thymic Development in Il2rg/~RagI/~c5'/' Mice Transplanted 
with Lentivirally Transduced Cells
Following transplantation o f gammaretrovirally-transduced lin" cells I l2 r g R a g 2 /' c 5 ' 
were found to have developed small thymi, normally absent in this strain due to a lack 
o f T cell differentiation (Goldman et al., 1998). Four months post-transplantation o f 
lentivirally-transduced cells however, small thymic-like organs were detected in the 
two SINLV SF yc mice that had recovered T lymphocyte populations in the spleen, 
bone marrow and periphery. Thymi were absent in all other transplanted mice, further 
demonstrating the lack o f T cell development in these animals. The thymi were 
removed and analysed for the presence o f T lymphocytes by staining with antibodies 
to CD4 and CD8 cell surface markers.
For both animals, very few double positive (DP) thymocytes and relatively low 
numbers o f single positive CD4 or CD8 T cells were detected by flow cytometric 
analysis o f cells from the recovered organs (figure 5.13). One possible explanation is 
that the intact thymi were in fact missed during the dissection o f these animals since 
these organs are typically very small and hard to detect in reconstituted mice. 
Alternatively, thymopoiesis may have halted in these animals at the time o f sacrifice 
due to an absence o f T lymphoid progenitor cells, indicating that committed 
progenitors and not pluripotent stem cells with a capacity for self-renewal were 
targeted during the ex vivo transduction. Repetition o f the experiment might allow 
definitive conclusions to be drawn with regards to thymic development following gene 
therapy using lentiviral vectors.
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Figure 5.13. Flow cytometric analysis of thymocytes from I l2 r g 'R a g 2 'lc 5 mice 
transplanted with lentivirally transduced lin' cells. Thymi removed from the two 
SINLV SF *yc mice that had undergone T cell development and from a wild-type 
C57/B16 mouse were stained with antibodies to CD4 and CD8 and analysed by flow 
cytometry. Very few DP cells were detected for the transplanted mice.
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5.3.7 Detection of Human yc Expression in Il2rg 'Rag2'/'c5'/~ Mice 
Transplanted with SINLV SF yc Transduced Cells
Cells harvested from the bone marrow of transplanted mice were analysed by Western 
blotting for detection of yc transgene expression. A band of approximately 68-70 kDa 
was detected in all lanes, including those from SINLV ycP eGFP and mock-transduced 
control mice, indicating a degree of non-specific staining with the antibody used 
(figure 5.14). A dominant band of approximately 58 kDa was observed for the SINLV 
SF yc mice only however, confirming expression of the yc transgene in these animals. 
No such bands were observed in the lanes representing two mice transplanted with 
SINLV ycP yc transduced cells, indicating a lack of transgene expression in the bone 
marrow of these animals and thus explaining the failure of T and B cell differentiation.
39 kDa
Figure 5.14. yc expression in the bone marrow of Il2rg~/~Rag2'lc5v' mice 
transplanted with lentivirally transduced lin' cells. Protein isolated from the bone 
marrow of transplanted mice was analysed by Western blotting using an antibody to 
human yc. A band of approximately 58 kDa, likely representing human yc, was 
detected for two SINLV SF yc mice only. The blot was also probed with an antibody 
to P-actin (41 kDa) to confirm protein loading (bottom lane).
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5.3.8 Immunoglobulin Levels in Il2rg~/'Rag2~/~c5~/' Mice Transplanted 
with Lentivirally Transduced Cells
Samples o f sera taken from the transplanted mice at the time of sacrifice were analysed 
by ELISA to assess immunoglobulin levels and thus reconstitution o f humoral 
immunity (figure 5.15). Levels o f IgG in the sera o f mice transplanted with SINLV ycP 
yc, SINLV ycP eGFP or mock transduced cells were found to be uniformly low, 
reflecting the absence of mature B cells in these animals. Levels of isotype subclasses 
IgGl and IgG2a also remained diminished in these mice post-transplantation, 
reflecting the failure o f immunological reconstitution in these animals. Although two 
of the three SINLV SF yc mice analysed had recovered T and B cell populations in the 
bone marrow and spleen, humoral immunity remained impaired in these animals at the 
time o f sacrifice. Levels o f IgG in the sera o f these animals were detected at similar 
levels to donor Il2rg"  mice; furthermore the differentiated T cells appeared impaired 
with regards to isotype-switching, since levels o f IgGl and IgG2a were comparable to 
those detected for mock transduced and SINLV ycP eGFP mice. The results for the 
SINLV SF yc mice are therefore surprising given that humoral immunity appeared 
restored in mice transplanted with lin* cells transduced with retroviral vectors 
expressing the identical transgene.
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Figure 5.15. Serum immunoglobulin levels in Il2rg~/~Rag2'lc5'/~ mice 
transplanted with lentivirally transduced lin* cells. Serum immunoglobulin levels 
in transplanted and control mice were analysed by ELISA. Humoral immunity 
remained impaired in all transplanted animals.
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5.3.9 Proviral Copy Number in the Spleens and Bone marrow of 
l l 2 r g ' R a g I c Mice Transplanted with Lentivirally 
Transduced Cells
Genomic DNA extracted from splenocytes and bone marrow cells from transplanted 
mice was analysed for integrated provirus by real-time quantitative PCR. Primers and 
probes to the yc cDNA and mouse titin housekeeping gene were used as previously. 
Provirus was detected in the spleens o f all mice that had received SINLV SF yc 
transduced //2rg"/_ lin' cells, with copy number reflecting efficacy of reconstitution 
(figure 5.16). The lowest proviral copy number was observed for SINLV SF yc 3, the 
sole animal in the group that failed to develop T lymphocytes. This mouse also had 
negligible provirus detected in the bone marrow, reflecting the low proportion of 
mature B cells detected by flow cytometric analysis o f this tissue (data not shown) and 
the likelihood that few transduced pluripotent progenitor cells with self-renewal 
capacity engrafted post-transplantation. The highest proviral copy number was for 
SINLV SF yc 1, correlating with the highest proportion o f both T and mature B cells 
detected by flow cytometric analysis o f the spleens and bone marrow and indicating 
that these cell populations developed from lentivirally-transduced, engrafted progenitor 
cells. Low levels o f integrated provirus were only detected for one o f the mice 
transplanted with SINLV ycP yc in both tissues. Since this animal failed to reconstitute 
T cells or mature B lymphocytes, these data likely signify that although transduced 
cells engrafted post-transplant, the IL2RG  promoter might have been silenced. The 
SINLV ycP eGFP mice and those that had received mock-transduced cells were found 
to contain negligible proviral copies, demonstrating the specificity o f the primer sets 
used.
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Figure 5.16. Proviral copy number in the spleens and bone marrow of 112rg^’ 
Rag2'/c5^~ mice transplanted with lentivirally transduced lin' cells. Proviral copy 
number detected in the (A) bone marrow and (B) spleens o f transplanted mice. 
Integrated provirus was detected for all mice transplanted with SINLV SF yc 
transduced cells and SINLV ycP yc 2.
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5.4 Conclusions
In vitro analyses of SINLV ycP yc together with SIN lentiviral vectors incorporating 
SFFV and EFS promoters demonstrated these that vectors were capable o f transducing 
both lymphoid and fibroblast cell lines and expressing human yc on the cell surface to 
detectable levels. Expression o f the yc transgene in the murine fibroblastoid cells was 
further confirmed by Western blot analysis, verifying that the IL2RG  promoter is 
active in this cell line. This data conflicts with a previous report that the IL2RG 
regulatory sequences exhibit little or no promoter activity in non-haematopoietic cell 
lines (Markiewicz et al., 1996). Functionality o f yc expressed from each of the 
lentiviral vectors was confirmed following transduction o f a yc-deficient human T cell 
line, enabling reconstitution o f functional yc-containing IL-2 receptor complexes and 
subsequent downstream signalling.
The OP9 system was used to assess the potential o f the SIN lentiviral vectors to 
transduce primary murine progenitor cells and express yc to functional levels that 
enable lymphoid differentiation in vitro. The lentiviral vector SINLV EFS yc 
performed in a similar manner to the SRS II series of gammaretroviral vectors in this 
system (see chapter 3.2.3) with transduced cells undergoing T and B cell development 
at similar rates as the wild-type C57/B16 progenitors. Lin' cells transduced with 
SINLV SF yc however exhibited poor viability, potentially attributed to toxicity of the 
lentiviral preparation used and hence few results were gained from this assay. 
Following transduction with SINLV ycP yc, ll2 rg f' progenitors were found to behave 
in much the same way as mock transduced cells, with little or no lymphoid 
differentiation seen in vitro leading to loss o f viability by day thirteen. Several reasons 
might explain why the SINLV ycP yc vector does not function in this system -  firstly, 
the cloned IL2RG  promoter region might not function in primary murine 
haematopoietic progenitors; although all sequences upstream of the human IL2RG 
gene that displayed significant homology to the corresponding region in the murine 
genome were incoporated into the vector, it is possible that a regulatory m otif critical 
for expression in primitive cell populations was omitted. Secondly the initial 
transduction o f the Il2rg f' progenitors may have been unsuccessful, although the same 
preparation has been shown to successfully transduce cell lines in vitro. Finally, as the
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IL2RG  promoter is neither a strong viral promoter nor that o f a housekeeping gene, it 
might be more prone to silencing following integration either due to positional effects 
or downregulation by cellular factors. Further work to characterise the IL2RG  
promoter using a vector encoding eGFP may lead to more definite conclusions being 
drawn.
Analysis o f the SIN lentiviral vectors in vivo confirms the hypothesis that the failure o f 
the OP9 experiment using SINLV SF yc transduced Il2rg'f' progenitors was probably 
due to toxicity associated with the particular lentiviral preparation used. A different 
preparation o f this lentiviral vector was demonstrated capable o f efficiently 
transducing murine lin' cells using an overnight protocol (without prior stimulation of 
the progenitors) and expressing human yc to levels that enabled detection o f circulating 
T and B lymphocyte populations in the peripheral blood of three out o f four animals 
just eight weeks post-transplantation (for a summary o f the in vivo experiments see 
Appendix 11). Furthermore, five months post-gene therapy T, B and NK cell 
populations were restored in the spleens and bone marrow of these mice. Despite the 
high transduction levels and presence of recovered lymphocyte populations, spleens 
from the transplanted mice remained hypocellular and thus T cell proliferation could 
not be assessed. Furthermore, it is debatable whether or not thymi were present in 
these animals since normal thymocyte staining was not observed. Failure of transduced 
HSCs with self-renewal capacity to engraft post-injection may have resulted in 
degeneration o f the thymi due to an absence o f seeding by T cell progenitors. Humoral 
immunity, as assessed by serum immunoglobulin levels, also remained impaired in 
these mice with levels of IgG in the plasma comparable to levels detected in Il2rg f' 
donor mice and no evidence o f isotype switching observed. Integrated provirus was 
detected in splenocytes and bone marrow cells from the reconstituted mice and yc 
expression also detected in the latter by Western blot analysis; hence it is unclear why 
the spleens in these mice remained hypocellular and immunoglobulin isotype 
switching remained defective.
One o f the three SINLV SF yc mice was found to have recovered only the B cell 
compartment post-transplantation. It is likely that this animal received a lower dose of 
transduced progenitors than the other transplanted mice due to unsuccessful injection 
and thus received fewer yc-corrected, pluripotent lin' cells.
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Analysis o f the self-inactivating lentiviral vectors incorporating the cloned IL2RG 
promoter region correlates with the results observed following co-culture o f transduced 
ll2 rg f' lin’ cells on the OP9 stromal layers. Despite lin' transduction levels of 
approximately 40%, recipient mice failed to develop T or mature B lymphocytes post­
transplantation o f SINLV ycP yc transduced cells. These data indicate that either the 
human 1L2RG promoter is inactive in murine haematopoietic progenitors, that the 
transduced progenitors failed to engraft post-injection or that the promoter was 
silenced in vivo. The first hypothesis was disproved by the presence o f eGFP+ cells 
detected by flow cytometric analysis of the SINLV ycP eGFP transduced lin' cells; 
however no eGFP+ cells were detected eight weeks post-transplantation of these cells. 
Although eGFP+ cells would have no proliferative advantage in this setting, two out of 
four mice that had received cells transduced with a gammaretroviral vector encoding 
eGFP had detectable transgene positive cells in the peripheral blood post-transplant. It 
therefore seems likely that whilst the IL2RG  promoter appears active in murine lin' 
progenitors, the promoter is somehow silenced, potentially during differentiation, 
resulting in a failure o f progenitor cells to respond to cytokine signals either in vitro or 
in vivo. In the case o f the SINLV ycP yc transduced progenitors, promoter silencing at 
an early stage might also lead to loss of selective proliferative advantage which might 
explain why negligible proviral copies were detected in the spleens and bone marrow 
from two o f the transplanted mice. The detection o f low levels o f integrated provirus in 
the spleen and bone marrow of the third SINLV ycP yc mouse also supports the theory 
that the human IL2RG  promoter is inactive since this mouse failed to develop T cells, 
yc-deficient human cells transduced with SINLV ycP yc were able to signal in response 
to IL-2 in vitro, thus differences between the human and murine regulatory sequences 
may result in the promoter being inactivated. This hypothesis could be tested by co­
culture o f human Il2rg"  CD34+ cells transduced with SINLV ycP yc on the OP9 
stromal layers. It is also possible however that the lin' transduction levels for the 
SINLV ycP yc in vivo experiments were below the threshold required for lymphoid 
reconstitution, since repopulation experiments with all other vectors (both lentiviral 
and gammaretroviral) were performed with transduction levels o f over 70%.
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5.5 Final Conclusions
• The SIN lentiviral vector series incorporating the SFFV, EFS and IL2RG
promoters are able to transduce both lymphoid and fibroblastoid cells in vitro 
and restore functional IL-2 receptor complexes on a SCID-X1 T cell line
• The SINLV EFS yc vector restored the lymphoid differentiation potential of
Il2rg '’ haematopoietic progenitor cells in vitro
• ll2rg'f' lin' cells transduced with SINLV ycP yc failed to undergo lymphoid 
development in vitro or reconstitute the murine SCID-X1 defect in vivo
• The SINLV SF yc vector was able to restore T, B and NK cell populations in
the SCID-X1 murine model following ex vivo gene therapy
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Discussion
Chapter Six
Gene therapy for SCID-X1 has proven an effective treatment in two separate clinical 
trials (Hacein-Bey-Abina et al., 2003a; Hacein-Bey-Abina et al., 2002; Gaspar et al., 
2004). Out o f a total o f twenty-one treated infants, nineteen have successfully restored 
cellular and humoral immunity, enabling them to return to normal social environments 
and cope with environmental pathogens (Gaspar et al., 2004; Hacein-Bey-Abina et al., 
2003a; Hacein-Bey-Abina et al., 2002; Ginn et al., 2005). Given the morbidity and 
mortality associated with haploidentical stem cell transplantation and the recurrent 
failure to restore humoral immunity following these transplants, gene therapy for this 
condition offers an effective alternative treatment with superior immunological 
reconstitution. The recent development of lymphoproliferative diseases in three 
patients enrolled in the French SCID-X1 gene therapy trial however, has underlined 
the potential risks o f such a treatment and reinforced the necessity o f continued 
research into vector design and safety (Hacein-Bey-Abina et al., 2003b; Hacein-Bey- 
Abina et al., 2003c; AFSSAPS, 2005).
Insertional mutagenesis is an inherent risk associated with integrating retroviral vectors 
used in gene therapy, highlighted by the severe adverse events observed in the French 
SCID-X1 trial (Hacein-Bey-Abina et al., 2003b; Hacein-Bey-Abina et al., 2003c). 
Insertional activation o f growth-promoting genes has since also been reported in a 
gene therapy trial for X-linked chronic granulomatous disease (X-CGD), however in 
this instance, the in vivo expansion of the insertionally activated cell clones is thought 
to have attributed to therapeutic benefit o f the two affected patients (Ott et al., 2006). 
Whilst retroviral integration was initially considered an essentially random process, the 
completion o f the human genome sequence has led to the identification of integration 
site preferences o f lentiviral and gammaretroviral vectors. Studies in immortalised cell 
lines and in cells derived from transduced simian HSCs in vivo, determined the 
preferential integration o f MLV-based gammaretroviral vectors near transcriptional 
start sites, whilst lentiviral vector integrants (derived from either HIV-1 or simian 
immunodeficiency virus) were located predominantly within transcriptional units 
(Schroder et al., 2002; Wu et al., 2003; Mitchell et al., 2004; Hematti et al., 2004). 
These studies indicate that the integration preferences o f retroviral vectors may be 
independent o f cell-type; however the targeted coding regions may be dependent on 
the set o f genes expressed in the particular transduced cell type.
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One advance in vector technology is the self-inactivating (SIN) design (Yu et al., 
1986); the duplication o f the LTR promoter-enhancer elements in retroviral vectors 
following reverse transcription may increase the risk o f insertional mutagenesis, 
therefore enhanced safety may be achieved by a SIN deletion within the U3 region of 
the 3’ LTR, leading to inactivation o f both LTR sequences following entry into the 
host cell. Evaluation o f these vectors in an in vitro toxicity assay demonstrated their 
capacity to immortalise murine haematopoietic cells, by insertional activation of 
growth-promoting genes, to be significantly reduced as compared to their LTR- 
regulated counterparts (Modlich et al., 2006). Expression o f the transgene in SIN 
vectors is therefore regulated by an internal promoter, the selection of which confers a 
further degree o f safety to this vector design, since a less-potent or even tissue-specific 
promoter may be incorporated into the vector backbone, thus further decreasing the 
likelihood o f insertional mutagenesis and potentially restricting transgene expression 
to relevant tissues only.
The SRS II series o f self-inactivating gammaretroviral vectors for SCID-X1 were 
developed to incorporate advances in vector technology and include the deletion of all 
known promoter-enhancer sequences within the U3 region o f the 3’ LTR (Kraunus et 
al., 2004). Whilst the LTR-regulated vector used in SCID-X1 clinical trials retained 
portions of MLV gag-pol coding sequence to enable splicing and thus enhanced 
transgene expression, the SIN vectors are devoid o f any gammaretroviral coding 
regions so that the probability o f recombination events leading to replication 
competent retrovirus (RCR) production is decreased. Additional features o f these 
vectors include a Rous sarcoma virus (RSV) promoter in the 5’ LTR and the 
incorporation o f a Woodchuck hepatitis virus post-transcriptional regulatory element 
(WPRE) to increase vector titre (Schambach et al., 2006d; Schambach et al., 2006a). 
The internal promoters, consisting o f either the U3 region o f the murine Spleen focus 
forming virus (SFFV) or the short form of the human elongation factor la  promoter 
(EFS), are located immediately upstream of the yc transgene and were selected due to 
their high activity levels in haematopoietic cells, including human CD34+ progenitors 
(Demaison et al., 2002; Baum et al., 1995; Tumas et al., 1996; Salmon et al., 2000; 
Dardalhon et al., 2001).
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In this study the SRS II series of gammaretroviral vectors encoding the human IL2RG  
cDNA, were assessed both in vitro and in vivo and compared to the LTR-regulated 
vector, MFG yc, used in both the French and UK clinical gene therapy trials for SCID- 
XI (chapter three). Both SRS II SF yc and SRS II EFS yc, incorporating the SFFV and 
EFS internal promoters respectively, were demonstrated capable of transducing both 
fibroblastoid and SCID-X1 lymphoid cell lines and efficiently expressing the human yc 
transgene to detectable levels on the cell surface. Furthermore, the SIN 
gammaretroviral vectors were able to restore the T and B lymphoid differentiation 
potential o f U2rgf' murine lin' progenitors in vitro post-transduction, and to equivalent 
levels to those achieved with the clinical vector, MFG yc. Immunological 
reconstitution o f the SCID-X1 murine model following engraftment of yc-deficient 
HSCs transduced with LTR-regulated gammaretroviral vectors encoding the human 
IL2RG  cDNA has been previously described (Lo et al., 1999; Aviles Mendoza et al., 
2001). Therefore, to assess the feasibility o f gene therapy o f SCID-X1 using the SRS II 
series of self-inactivating gammaretroviral vectors, in vivo reconstitution experiments 
using the SCID-X1 murine model were performed. T and NK cell reconstitution post­
gene therapy with either of the SIN gammaretroviral vectors encoding yc was achieved 
to the same levels as for MFG yc. Furthermore, restoration o f humoral immunity in 
transplanted animals appeared more efficient for SRS II EFS yc than for the LTR- 
regulated vector. The selective proliferative advantage o f transduced, yc-corrected 
HSCs in the SCID-X1 setting was evident by the negligible proviral copies detected in 
sorted myeloid populations from reconstituted mice, as compared to the low proviral 
copy numbers detected in sorted lymphoid populations. Maintaining low proviral copy 
number is desirable with regards to safety of the gene therapy procedure by minimising 
the number o f potentially hazardous integration events. That cellular and humoral 
reconstitution was observed in these animals following gene therapy with low proviral 
copy number (less than one in sorted lymphocytes) and in the setting o f only sub-lethal 
irradiation, indicates that phenotypic correction of the disease is achievable by gene 
therapy with a low vector dose. Immunological reconstitution observed in secondary 
transplant recipients demonstrated that pluripotent haematopoietic stem cells were 
successfully targeted by the SIN vectors during the initial transduction protocol and 
that both the SFFV and EFS promoters remained active over an extended period of 
time in vivo (approximately seven months for the EFS promoter and approximately
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twelve months for the SFFV promoter). A requirement for SCID-X1 gene therapy is 
that the promoter remains active over the duration o f the patient’s lifespan and not 
provoke an immunological response in vivo that may result in transgene silencing, 
such has been observed for vectors incorporating the Cytomegalovirus (CMV) 
promoter (Qin et al., 1997). These results demonstrate that the SIN vector design in the 
context o f a potent viral or endogenous promoter, whilst potentially increasing vector 
safety, does not impact on efficacy of immune reconstitution following gene therapy o f 
the SCID-X1 murine model.
Failure o f gene therapy in two older treated SCID-X1 patients has been reported 
(Thrasher et al., 2005), indicating a potential time-dependence on the capacity to re­
initiate thympoiesis. Results gained from reconstitution experiments in older recipient 
mice support this theory (chapter three). Five out o f six recipient Il2rg /~Rag2~'c5'/' 
mice transplanted at twelve weeks o f age failed to reconstitute the T cell compartment, 
whilst B and NK cell populations were detected in both the spleens and bone marrow. 
In contrast, only one out of twenty-one recipient mice transplanted at between six to 
ten weeks o f age failed to develop T cells post-gene therapy. Analysis o f the older 
transplanted mice in which T lymphopoiesis failed to develop revealed an absence of 
detectable thymic organs. The integrity of the thymic microenvironment is dependent 
upon the presence of developing thymocytes such that the absence of ongoing 
thymopoiesis results in potentially irreversible disorganisation o f the thymic 
architecture (van et al., 2000; Hollander et al., 1995). It is therefore likely that in the 
older treated SCID-X1 patients and the older transplanted Il2rg'/'Rag2' 'c5'/' mice, T 
cell development failed post-gene therapy due to the prior breakdown of the thymic 
microenvironment.
Lentiviruses rely on active transport o f the pre-integration complex though the host 
cell nuclear membrane and thus vectors derived from these viruses offer the advantage 
of being able to transduce non-dividing cells (Sherman and Greene, 2002). This 
property is particularly desirable for the transduction of quiescent haematopoietic stem 
cells, enabling shorter ex vivo transduction protocols without the requirement for pre­
stimulation and thus potentially avoiding loss o f progenitor pluripotency and/or 
engraftment capabilities. These vectors have consequently been widely used in gene
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transfer studies (Vigna and Naldini, 2000) and the development o f second and third 
generation vectors, in which the accessory genes are abolished and the required coding 
genes are provided in trans during vector production, have increased the safety of such 
vectors (Dull et al., 1998; Zufferey et al., 1998).
A series o f lentiviral vectors derived from HIV-1 were developed for the treatment of 
SCID-X1. As for the gammaretroviral series of vectors, the lentiviruses incorporate the 
self-inactivating design and either the SFFV or EFS internal promoters for regulation 
of yc transgene expression. Transduction of a SCID-X1 T lymphoid cell line with these 
vectors enabled restoration of functional yc-containing IL-2 receptor complexes and 
the SINLV EFS yc vector, incorporating the EFS promoter, restored the lymphoid 
differentiation potential o f murine yc-deficient lin' progenitor cells in vitro post­
transduction (chapter five). Results for the SINLV SF yc vector, incorporating the 
SFFV promoter, were not obtained for the latter assay since the vector preparation 
used appeared toxic to the primary murine cells, a problem associated with VSV-G 
pseudotyped vector supernatants. High transduction levels o f murine H2rg'f' lin' cells 
were observed following an overnight transduction protocol with the SINLV SF yc 
vector and the transduced progenitors successfully reconstituted T and B lymphoid 
lineages in three out of four transplanted mice (chapter five). Gene therapy using the 
SINLV SF yc vector appeared less efficient than for the gammaretroviral vectors; the 
spleens from the SINLV SF yc reconstituted mice remained hypocellular five months 
post-transplantation and immunoglobulin isotype switching remained impaired. 
Furthermore, both single and double-positive T cells were undetectable in the 
recovered thymi from these animals, potentially due to degeneration o f these organs as 
a result o f an absence o f seeding by T cell progenitors. This might have occurred had 
transduced pluripotent haematopoietic stem cells failed to engraft post-transplantation. 
It was postulated that the overnight transduction protocol used in this experiment, as 
compared to the five-day protocol required for gammaretroviral transduction, might 
result in an increased pool o f transduced, pluripotent progenitors prior to injection into 
the recipient mice; hence these results are unexpected. There are several possible 
explanations for these data however; firstly, it is possible that the gammaretrovirally- 
treated mice received an increased number o f transduced, pluripotent progenitors due 
to the prolonged transduction protocol, involving forty-eight hours pre-stimulation,
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having expanded this primitive cell population. Consequently, the proportion of 
lentivirally transduced progenitors in the setting o f only sub-lethal irradiation may 
have been insufficient for the equivalent, prolonged phenotypic correction seen with 
SRS II SF yc and SRS II EFS yc. It is also possible that the lentiviral supernatant used 
in this experiment triggered the differentiation o f the murine lin' cells during the ex 
vivo transduction protocol, so that an increased proportion o f committed lymphoid 
precursors engrafted in the recipient mice. The lentiviral vector used in this experiment 
was pseudotyped with the VSV-G envelope and concentrated by ultracentrifugation, 
hence it is possible that cellular debris and components o f the media used to culture the 
transfected 293T cells for viral production were also present in the lentiviral 
preparation. It must be noted however that prior to ultracentrifugation, lentiviral 
supernatants were filtered through 0.22pm sterile filters, hence any contaminating 
particles would be extremely small in diameter.
The use o f tissue-specific promoters in the context o f SIN retroviral vectors may act as 
an additional safety feature by restricting transgene expression in vivo to the required 
tissues for therapeutic benefit only and hence avoid aberrant expression that may 
potentially result in cellular transformation. This is particularly desirable with regards 
to cancer gene therapy whereby the expression o f toxic gene products in healthy 
tissues must be prevented. Much research has therefore focussed on the development 
of viral vectors incorporating tissue-specific regulatory elements and progress has 
included the use of the a 1-antitrypsin promoter and the human Wiskott Aldrich 
Syndrome protein (WASP) promoter for liver and haematopoietic-specific expression 
respectively (Kramer et al., 2003; Dupre et al., 2006). For gene therapy o f SCID-X1, 
restriction of human yc expression to cells o f haematopoietic origin only might confer 
a further degree o f safety to a SIN retroviral vector. The human IL2RG  evolutionarily- 
conserved regulatory sequences were consequently identified and incorporated into 
SIN lentiviral vectors upstream of yc or eGFP transgenes (chapter four). A further 
desirable property o f utilising such a promoter is physiological transgene expression in 
vivo, particularly in the context o f HSC gene therapy, ensuring regulation of yc 
expression to the appropriate levels during differentiation.
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Previous studies have characterised the region immediately upstream of the human and 
murine IL2RG  genes to contain promoter activity and demonstrated haematopoietic- 
specificity o f these sequences when regulating luciferase expression in transfected cell 
lines (Noguchi et al., 1993a; Ohbo et al., 1995; Markiewicz et al., 1996; Cao et al., 
1993). Analysis o f the 1.24 kb of sequence immediately upstream o f the human IL2RG 
translational start site in the context of a lentiviral vector regulating eGFP transgene 
expression (SINLV ycP eGFP) yielded contradictory results in vitro (chapter four). 
Transgene expression was detected by flow cytometry in all haematopoietic and non- 
haematopoietic cell lines transduced with SINLV ycP eGFP, however analysis of 
transgene expression relative to that from the SFFV promoter in each o f the cell lines 
tested revealed the highest relative IL2RG  promoter activity in the T and B lymphoid 
cell lines. The discrepancy between these results and those from published studies may 
reflect the differences between plasmid and lentivirus-based assays; whilst plasmids 
are maintained episomally, integrated lentiviral vectors may be subjected to enhanced 
or decreased expression levels due to neighbouring endogenous regulatory sequences. 
Furthermore, despite the vectors used in this study being o f the self-inactivating 
design, it has been reported that SIN LTR sequences retain a degree o f promoter 
activity and thus the transgene expression observed in the non-haematopoietic cell 
lines transduced with SINLV ycP eGFP may have been regulated by non-specific viral 
promoter-enhancer elements within the LTR (Logan et al., 2004; Hanawa et al., 2005). 
Injection o f SINLV ycP eGFP into neonatal mice however demonstrated tissue- 
specificity o f the IL2RG promoter in vivo; transgene expression in three SINLV ycP 
eGFP injected mice was restricted to the spleens in all animals, despite detection of 
proviral DNA in both the livers and spleens by PCR (data not shown) and published 
observations that the liver is primarily targeted by lentivirus injected using this 
technique (VandenDriessche et al., 2002; Kobayashi et al., 2005). These results 
underline the importance of in vivo models for comprehensive assessment of 
regulatory sequences (chapter four).
The lentiviral vector incorporating the IL2RG  promoter upstream of the yc transgene 
(SINLV ycP yc) efficiently transduced a SCID-X1 T lymphoid cell line and 
reconstituted functional IL-2 receptor complexes on the cell surface (chapter five). In 
contrast to SINLV EFS yc however, SINLV ycP yc transduced murine H2rg'f' lin' cells
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retained their inability to undergo T or B lymphoid differentiation in vitro and behaved 
in the much the same way as the mock-transduced Il2rg f~ progenitors. Analysis of this 
vector in vivo revealed a similar result; despite lin- transduction levels o f 
approximately 40%, the SINLV ycP yc transduced progenitors failed to restore 
lymphopoiesis in the murine model o f SCID-X1 and proviral DNA was undetectable 
in the bone marrow and spleens of two out o f three transplanted animals. The 
absence/low levels o f integrated provirus in the SINLV ycP yc mice implies the lack or 
low levels o f engraftment and proliferation of transduced lin' cells post-injection, thus 
explaining the failure o f immune reconstitution post-gene therapy. These results are 
difficult to interpret since data from SINLV ycP eGFP transduced U2rg~ lin' cells 
confirms that the promoter is active in these murine progenitors. Furthermore, analysis 
o f promoter specificity following injection o f SINLV ycP eGFP into neonatal mice 
demonstrated promoter activity in splenocytes in vivo (figure 4.9). It is therefore likely 
that the IL2RG  promoter incorporated into the lentiviral vector is silenced in vivo, 
potentially at an early stage o f differentiation, leading to the loss o f proliferative 
advantage conferred upon yc-expressing cells in this model. Furthermore, had only low 
numbers o f pluripotent HSCs with self-renewal capacity been initially transduced 
using the overnight transduction protocol (as hypothesised for SINLV SF yc 
reconstitution experiments) any engrafted committed lymphoid progenitors would 
have been lost over time, thus explaining the lack of detectable proviral sequence in 
two out three mice. It is possible that silencing may have occurred due to differences in 
the human and murine IL2RG regulatory sequences, a hypothesis that would be 
confirmed by transduction and in vitro differentiation of human SCID-X1 CD34+ cells. 
It must also be noted however that failure o f immune reconstitution in these mice may 
have been simply due to the SINLV ycP yc transduction levels being lower than 
required for phenotypic correction in this model, particularly in the setting o f sub- 
lethal irradiation.
One abstacle to successful long-term correction of inherited disorders by gene therapy 
is transcriptional silencing o f retroviral vectors, in particular following the transduction 
o f primitive cell types such as HSC (Challita and Kohn, 1994). Retrovirus vector 
transgene silencing has been associated with cytosine methylation of CpG 
dinucleotides and consequent histone deacetylation leading to chromatin condensation
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(Pannell and Ellis, 2001) as observed in a clinical gene therapy trial for CGD in which 
silencing of the therapeutic transgene is coupled with methylation of the SFFV LTR 
promoter sequences (M.Grez personal communication). To counteract silencing, 
modified retroviral vectors, such as the SRS II series o f SIN gammaretroviral vectors 
used in this study, containing deletions or mutations o f viral silencing elements have 
been developed; in addition progress has been made with the inclusion of insulator 
elements, such as the hyper-sensitive site 4 (HS4) o f the chicken p-globin locus, into 
gene therapy vectors (Recillas-Targa et al., 2004). These elements are being exploited 
to reduce gene expression variability seen with integrated vectors due to chromosomal 
position effects (Puthenveetil et al., 2004); moreover, the enhancer blocking activity o f 
insulator elements may protect endogenous genes from insertional activation (Burgess- 
Beusse et al., 2002). More recently, we have shown that the “ubiquitously-acting 
chromatin opening element” (UCOE) from the human HNRPA2B1-CBX3 genes 
(Antoniou et al., 2003; Williams et al., 2005) is able to provide reproducible, 
therapeutically relevant and stable transgene expression from within a lentiviral vector 
context and therefore shows great promise as part o f future developments to provide 
efficacious and safe gene therapy (Zhang et al., 2007).
Another strategy to improve upon vector safety is the incorporation o f suicide genes 
such as thymidine kinase that permits the elimination of transduced cells in the event 
o f neoplastic transformation. In a murine model of insertional mutagenesis, this 
approach was recently demonstrated effective in eliminating leukaemia (Blumenthal et 
al., 2007). Progress in the mapping of integration site preferences allows identification 
o f viral vectors that might potentially be less likely to cause insertional mutagenesis, 
such as those derived from avian sarcoma leukosis virus (ASLV) and human foamy 
virus, which demonstrate little bias for integration within transcriptionally active 
regions (Narezkina et al., 2004; Mitchell et al., 2004; Trobridge et al., 2006; Nowrouzi 
et al., 2006). A desirable property of a gene therapy vector would be the ability to 
integrate into a precise location within the human genome, thus mediating efficient 
transgene expression without perturbing neighbouring genes. The use o f bacteriophage 
integrases such as phi C31, chimeric transposases and the AAV Rep protein are 
addressing this issue (Ishikawa et al., 2006; Liu et al., 2006; Maragathavally et al.,
220
Chapter Six
2006), however more research is needed before these systems might be suitable for 
clinical application.
The results gained from this study indicate that self-inactivating gammaretroviral 
vectors for the treatment of SCID-X1 are able to reconstitute the immune defect in the 
SCID-X1 murine model to equivalent levels as the LTR-regulated vector used in 
clinical trials for gene therapy of this disease. Furthermore, improved humoral 
immunity in the murine model was observed following gene therapy with the SRS II 
EFS yc vector incorporating a human house-keeping gene promoter. SIN lentiviral 
vectors encoding the human yc transgene were found to efficiently correct defective 
yc-dependent signalling in vitro following transduction of a human SCID-X1 T cell 
line, however in vivo immune reconstitution o f the SCID-X1 murine model with 
SINLV SF yc appeared less effective than for the SIN gammaretroviral vectors. On the 
basis of these experiments, and data obtained in Professor Christopher Baum’s 
laboratory in which a SIN gammaretroviral vector incorporating the EFS promoter was 
significantly less mutagenic than an equivalent vector containing an internal SFFV 
promoter (unpublished observations), it has been proposed that the SRS II EFS yc 
vector replace MFG yc in the clinical trial o f gene therapy for SCID-X1 at Great 
Ormond Street Hospital. Long-term in vivo safety studies have therefore been initiated, 
as well as pilot scale production of good manufacturing practice (GMP) GALV 
pseudotyped vector. The self-inactivating design of this vector, together with the less 
potent, endogenous EFS promoter, will potentially decrease the likelihood of 
insertional mutagenesis following transplantation of gene-corrected cells in vivo whilst 
maintaining the therapeutic efficacy thus far seen in this clinical trial.
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tfindlll (91 3 9 )
\
5’ LTR MoLV
AmpR
Eco RI (4808)
MFG gc
9142 bp
gamma chain
Eco RI (3139)
Bam HI (3388)
3' LTR MoMLV
Appendix 1. MFG 7 c gam m aretroviral vector map.
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AmpR MPSV U3
A  RUS
SFFV-eGFP
6158 bp
Xhol (3908)
RU5 
SFFV U3
Hindlll (3283)
Bam HI (3277) 
Eco RI (3271)
eGFP
Eco RI (2365)
wPRE
Bam HI (2999)
Appendix 2. SFFV-eGFP gam m aretroviral vector map.
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X*38
RSV promoter 
RU5
pSRS 11 SF gc
6046 bp
0  Hmdlll (1741)
*7 io I(3 7 9 6 ) M
3 L T R
Eco r i  (3629) / r \  gamma c
//indlll (3540) Eco RI (2644)
Eco RI (3528) j  Bam HI (2903)
PRE* jEcoRI (2921)
IXhol (1312) SFFV
Appendix 3. SRS II SF 7c gammaretroviral vector map.
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RSV Promoter
Clal (1316) 
EFS
IL2RG
Eco RI (2456) 
Bam HI (2715)
Eco RI (2733)
pSRS 11 EFS gc
5858 bp
Xhol (3608)
3'SIN LTR
Eco RI (3441)
//indlll (3352) 
Eco RI (3340)
Appendix 4. SRS I I  EFS 7c gammaretroviral vector map.
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HindHI (6554) 
3’ LTR
Eco RI (6341)
PRE*
AmpR
SINLV SF gc
7682 bp
Eco RI (5490) 
gammac
Bam HI (4606)
Clal (4592)
Hindlll (4585)
SFFV
Xhol(4156) 
Clal (4 1 3 9 )
Hindlll (2213) 
Hindlll (2526)
Hindlll (3079) 
HIV-1 5' LTR
Hindlll (3663)
Appendix 5. SINLV SF 7 c lentiviral vector map.
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y LTR
\
Ncol (6110)
Hindlll (5754)
Eco RI (5541)
Pstl (5372)
Eco RI (5273)
Ncol (5213) 
gammac 
Pstl (4853)
Pstl (4451)
Bam HI (4389)
EFS Promoter 
Clal (4139)
Hindlll (3663)
AmpR
SINLV EFS gc
6882 bp
\
I
Hindlll (2213)
//indlll (2526)
Hindlll (3079) 
HIV-1 5' LTR
Appendix 6 . SINLV EFS 7 c lentiviral vector map.
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Clal (9776) 
WPRE
Clal (9048) 
eGFP 
Bam HI (8254)
3* LTR SFFV 
Eco RI (7746)
Clal (7729) 
cPPT 
3'-splice site
RRE
gag (ORF-disrupted) 
5'-splice site
LTR HIV-1
Xhol (1)
SINLV SF eGFP
9789 bp
LTR-HIVdelU3
AmpR
rep ori
*
SV40
gpt (OFR-frame shift)
Appendix 7. SINLV SF eGFP lentiviral vector map.
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A.
HIV-1
Hindlll (jt
Hindlll (6854) 
Hindlll (6541)
WPRE
Eco RI (2987)
3’ LTR
Hindlll (3200)
B.
Xhol
ctcgagctatccccctctccatcttggtaaatttagttacttcctcttctgtgctcacatactttgtaetatctctacatttatgctata
ggacttgttacactatgttgtattacttgtttatgtcttccccacttttctgtgagtgtctagaaatatgaggatgtcttgttggtctattt
ccagaacataagcacagtgcctggcacatattaaaaacgtaataaatgtttgctgaataaatagtttctgtaagtggcttctcca
atcacctctgtgttttcggggaaggtaaaactggcaacaggatgaagaatggattagagagcagagggcctttagaaaggg
aggccagttgatggagtctagatagaatcatgactagagctaatgaaagactgatttagcagagtggctgtggtaatggaaa
ggaggaaaccgttgggagaaacaccacagaagcagagtgggttatattctctgggtgagagagggggagaaattgaagct
gattctgaggtttcaagtctgggtgactgagagggtgacgataccattgactgaggtggggaaggcaggaagagaagcag
agttgggggaagatgggaagcttgaagctagtattgttgttcctccatttctagaatatttttgtattataagtcacacttcctcgcc
agtctcaacagggacccagctcaggcagcagctaagggtgggtattctggtttggattagatcagaggaaagacagctgtat
atgtgcccacaggagccaagacggtattttccatcctcccaaaacagtagagctttgacagagatttaagggtgaccaagtca
aggaagaggcatggcatagaacggtgatgtcgggggtgggggttcagaacttccattatagaaggtaatgatttagaggag
aaggtggttgagaatggtgctagtggtagtgaacagatccttcccaggatctaggtgggctgaggatttttgagtctgtgacac
tattgtatatccagctttagtttctgtttaccaccttacagcagcacctaatctcctagaggacttagcccgtgtcacacagcacat
atttgccacaccctctgtaaagccctggtttataaggttctttccaccggaagctatgacagaggaaacgtgtgggtggggag
gggtagtgggtgagggacccaggttcctgacacagacagactacacccagggaatgaagagcaagcgccggatcc
BamHl
Appendix 8 . (A) SINLV 7 CP 7 c lentiviral vector map. (B) Sequence of cloned 
IL2RG promoter.
X hol(8484)
Clal (8467) Xhol (5)
Hindlll (612)
hlL2RG prom
Bam HI (1252)
gammac
Eco RI (2136)
SINLV gcP gc
8487 bp
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A.
EFS promoter
Hindlll (9889) 
Eco RI (9282)
Hindlll (9270)
C/al (9265) 
cPPT 
3'-splice site 
Hindlll (8737)
RRE 
Hindlll (8153) 
gag (ORF-disrupted)
5'-splice site 
Hindlll (7597)
LTR HIV-1
\
Bam HI (1)
SINLV gcP eGFP
10528 bp
Hindlll (776)
Hindlll (788)
Clal (795)
wpre
CZal (1523) 
LTR-HIVdelU3
Hindlll (1757)rtmaii
AmpR
V
\ * repori
gpt (OFR-frame shift) SV40
B.
Hindlll (4991 )
EcoR l
gaattcctatccccctctccatcttggtaaatttagttacttcctcttctgtgctcacatactttgtagtatctctacatttatgctatag
gacttgttacactatgttgtattacttgtttatgtcttccccacttttctgtgagtgtctagaaatatgaggatgtcttgttggtctatttc
cagaacataagcacagtgcctggcacatattaaaaacgtaataaatgtttgctgaataaatagtttctgtaagtggcttctccaat
cacctctgtgttttcggggaaggtaaaactggcaacaggatgaagaatggattagagagcagagggcctttagaaagggag
gccagttgatggagtctagatagaatcatgactagagctaatgaaagactgatttagcagagtggctgtggtaatggaaagg
aggaaaccgttgggagaaacaccacagaagcagagtgggttatattctctgggtgagagagggggagaaattgaagctga
ttctgaggtttcaagtctgggtgactgagagggtgacgataccattgactgaggtggggaaggcaggaagagaagcagagt
tgggggaagatgggaagcttgaagctagtattgttgttcctccatttctagaatatttttgtattataagtcacacttcctcgccagt
ctcaacagggacccagctcaggcagcagctaagggtgggtattctggtttggattagatcagaggaaagacagctgtatatg
tgcccacaggagccaagacggtattttccatcctcccaaaacagtagagctttgacagagatttaagggtgaccaagtcaag
gaagaggcatggcatagaacggtgatgtcgggggtgggggttcagaacttccattatagaaggtaatgatttagaggagaa
ggtggttgagaatggtgctagtggtagtgaacagatccttcccaggatctaggtgggctgaggatttttgagtctgtgacacta
ttgtatatccagctttagtttctgtttaccaccttacagcagcacctaatctcctagaggacttagcccgtgtcacacagcacatat
ttgccacaccctctgtaaagccctggtttataaggttctttccaccggaagctatgacagaggaaacgtgtgggtggggagg
ggtagtgggtgagggacccaggttcctgacacagacagactacacccagggaatgaagagcaagcgccggatcc
Bam H l
Appendix 9. (A) SINLV 7 CP eGFP lentiviral vector map. (B) Sequence of cloned 
IL2RG  prom oter.
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Group No. Reconstitution of 
PB
Reconstitution of 
Spleen and BM
Reconstitution 
of Thymus
Splenic
Weight
(mg)
Observations
MFGrc 1. + + + 64
2. ♦ + + (no DP) 141 8
3. - - 51.0
4 + ♦ +<no DP) 905
5 + + + 160
6 + + ♦ 330
Enlarged spleen
7. + + ♦ 120
SRS 11 SF yc 1. + ♦ + 390 9 Enlarged spleen
2 + + + 42.6 Wastng. smal spleen
3. + + + 108.4
4 + + + 103.6
5. B cells only B & NK cells CD3 only nd
7. ♦ + + (no DP) 280 Enlarged spleenWastng anaerwc spleen
8 + + + 100
9 + + + (no DP) 80
SRS 11 EFIetyc 1. ♦ + + 1 3 8 9
2. + + + 150
3. + (few CD3s) B & NK cells v. few SP & CD3 50
4. B cells only B  & NK cells CD3 only 60
5. B cells only B & NK cells CD3 only 40
6. B cells only B & NK cells GD3 only 50 NK expansion in BM
7. + + athymic 70 .Wasting, co*is?
8 + + athymic 130 Wasting, cotts’
9 ♦ + + 110
10. ♦ + + 160
11. + + + 250
SFFV-oGFP 1. - - - 47 8
2 - - - 253
3. - • - 376
4 • - - 30.9
2° SRS 11 SF fc 1. nd + SP only 40
2° SRS 11 EFIorc 1. nd ♦ + 4 0 Sacrificed at 9*fcs
2° MFG yc 1. nd T. NK & B220IO SP only nd
Appendix 10. Summary of mice reconstituted with gam m aretrovirally 
transduced cells.
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Group No. Reconstitution of 
PB
Reconstitution of 
Spleen and BM
Reconstitution of 
Thymus
Splenic
Weight
(mg)
Observations
SINLV SF yc 1. ♦ ♦ SP only 90
2. ♦ ♦ SP only 60 Sick, anaemic spleenSick, anaemic spleen
3. B cells only Bs & NKs in spleen • 50
4. ♦ - • bed before analysis
SINLV ycP yc 1. B220+ 70
2. B220+ 100
3. B220+ 96
SINLV ycP eGFP 1. B220*. small eGFP* in BM 40
2 B220+ 60
3. B220+ 60
4 B220+ 50
MOCK 1. B220+ 40
2. B220IO B220+ • 70
Appendix 11. Sum m ary of mice reconstituted with lentivirally transduced cells.
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